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ground. Causative mutations explain 
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erogeneous. Several risk genes are 
known but their underlying biological 
mechanisms in AD pathogenesis re-
main generally unspecified. This thesis 
aims at exploring the molecular mech-
anisms of seladin-1 and δ-opioid recep-
tor that have been postulated to geneti-
cally and/or functionally play a role 
in AD. Genes and pathways studied in 
this thesis may prove to be potential 
targets as novel biomarkers in early 
diagnosis, and the results obtained may 
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therapeutic approaches in AD.
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ABSTRACT
Alzheimer’s disease (AD) is a complex and heterogeneous disorder with an evident genetic
background. So far, mutations in three genes have been implicated in the familial,
autosomal dominant form of AD with an early age of onset (< 65 years). These genes are
APP encoding amyloid precursor protein and PSEN1 and PSEN2 encoding presenilin-1 or
presenilin-2 proteins, respectively. On the other hand, a naturally occurring polymorphism,
the 4 allele in the apolipoprotein E gene, (APOE4), represents the major genetic risk
factor for the development of both early- (EOAD) and late-onset (LOAD) forms of AD.
Causative mutations in APP and PSEN genes explain less than 1% of all AD cases, while the
vast majority of cases represent LOAD with a complex genetic inheritance. LOAD is
considered to be caused by a combination of genetic, acquired, and environmental risk
factors. Since the early nineties, nearly 700 individual susceptibility genes with low risk
effects have been proposed as being to be associated with AD in various ethnic populations.
Nonetheless, the underlying biological mechanisms of many of the risk genes in AD
pathogenesis remain to be determined. This thesis aimed at exploring the molecular
mechanisms of specific genes that have been postulated to genetically and/or functionally
play a role in the pathogenesis of AD. The effects of these genes on the key pathways and
processes relevant for AD pathogenesis, such as generation and accumulation of -amyloid
(A), were investigated in different in vitro and in vivo models.
In this thesis, the risk effects of the common risk gene polymorphisms were assessed in the
Eastern Finnish sample cohort consisting of ~1300 AD patients and controls as well as in the
familial AD sample set originating from USA. In addition, the role of different factors
believed to be involved in AD pathogenesis, namely seladin-1, -opioid receptor (OR) and
-site APP cleaving enzyme 1 (BACE1), were examined in cultured human neuronal and
non-neuronal cells as well as in the rat thalamus under conditions partially mimicking the
cellular environment of the AD brain.
In study I, single nucleotide polymorphisms (SNPs) in the candidate genes were selected
for genotyping on the basis of the meta-analyses retrieved from the publically accessible
AlzGene database. This study revealed SNPs in the tumor necrosis factor  (TNF) and
interleukin 1B (IL1B) genes, which genetically associated with AD in the Finnish
case-control cohort and which also affected cerebrospinal fluid biomarker levels in AD
patients.
Study II revealed that under in vitro stress conditions, reduced seladin-1/DHCR24
expression resulted in enhanced GGA3 depletion in neuronal cells. GGA3 is a
well-characterized BACE1 trafficking protein, which regulates the lysosomal degradation of
BACE1. GGA3 depletion subsequently led to augmented post-translational stabilization of
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BACE1 and increased -amyloidogenic processing of APP. This is an important mechanistic
finding since the expression of seladin-1 has been consistently shown to be down-regulated
in brain regions affected in AD.
Study III elucidated the genetic and functional role of OR in AD pathogenesis. Previous
data had shown that the agonist-induced activation of OR increased the activity of - and
-secretases, which are responsible for A generation. It was observed that the cysteine
variant in the codon 27 of OR (OR-Cys27) differentially affected APP processing through
altered endocytic trafficking in non-neuronal and neuronal cells as compared to the
phenylalanine variant (OR-Phe27). Furthermore, genetic assessment of the OPRD1 gene
encoding for OR in two different AD sample cohorts indicated that the heterozygosity of
OR-Phe27Cys variation may increase the risk of AD. As intervention approaches focusing
on the formation and trafficking of the OR/- and -secretase complex have been
suggested as novel strategies against AD, it is possible that patients with the OR-Cys27
variant may respond to OR antagonist treatments differentially when compared to the
OR-Phe27 homozygotes.
In study IV, a non-selective calcium channel blocker and -secretase inhibitor, bepridil, was
used to treat ischemic rats after transient middle cerebral artery occlusion (MCAO). In these
MCAO rats, A and calcium accumulate in the ipsilateral thalamus. Thus, MCAO
represents a feasible in vivo model with which to study whether bepridil can modify A
and calcium pathology. Daily treatment of MCAO rats for 27 days with bepridil (50 mg/kg
p.o.) starting two days after the operation decreased A40 and A42 and calcium levels in
the ipsilateral thalamus as compared to vehicle-treated MCAO rats. Furthermore, seladin-1
mRNA levels were significantly decreased by an average of 40% in the ipsilateral thalamus
of vehicle-treated, but not in the bebridil-treated MCAO rats. Significant inverse
correlations between seladin-1 mRNA and calcium levels as well as with the levels of
seladin-1 and insoluble A42 in the ipsilateral thalamus after MCAO were observed.
Collectively, these findings suggest that in rats bepridil mitigates A and calcium
pathology and that seladin-1 is an indicator of neuronal survival.
AD-related genes and pathways studied in this thesis may prove to be potential molecular
targets and used as novel biomarkers for risk assessments, early diagnosis, and monitoring
disease progression. Furthermore, the results obtained in this thesis may be applied in the
development of novel intervention approaches to interrupt the progression of AD. Finally,
the genetic results emphasize the importance of knowing the genetic profile of a person
when introducing new potential pharmacological approaches in the therapeutics of AD.
National Library of Medical Classification: WT 155, QU 470, QU 500, QU 55.7
Medical Subject Headings: Alzheimer Disease/etiology; Genes; Genetics; Genotype; Polymorphism, Genetic;
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TIIVISTELMÄ
Alzheimerin tauti (AT) on geneettisesti monimuotoinen sairaus. Tällä hetkellä tunnetaan
kolme geeniä (amyloidiprekursoriproteiini (APP) -geeni sekä preseniliini 1 ja 2 (PSEN1 ja
PSEN2) –geenit), joissa tapahtuvat mutaatiot aiheuttavat varhaisella iällä (< 65-vuotiaana)
alkavan perinnöllisen AT:n. Lisäksi kromosomissa 19 sijaitsevan apolipoproteiini E
epsilon 4 (APOE4) alleelin on todettu merkittävissä määrin lisäävän riskiä sairastua
AT:iin. Tautia aiheuttavat geenimutaatiot selittävät kuitenkin vain pienen osan varhaisiän
AT-tapauksista, ja näin ollen suurin osa AT-tapauksista onkin myöhäisiän tautimuotoa,
jonka taustalla on sekä geneettisiä että ympäristöön liittyviä riskitekijöitä. Viimeisten
kahdenkymmenen vuoden aikana on löydetty satoja uusia ehdokasgeenejä, joiden on
raportoitu joko altistavan tai suojaavan AT:lta lukuisissa eri etnisissä väestöryhmissä. AT:n
patogeneesin kannalta keskeisiä ovat APP:n pilkkoutumisessa tapahtuvat muutokset, jotka
vaikuttavat amyloidi- (A)-peptidin tuotantoon ja kertymiseen aivokudoksessa. Tästä
huolimatta taudin perimmäisiä syntymekanismeja ei vielä ole täysin pystytty selvittämään
ja siksi riskigeenien toiminnallinen tutkimus on ehdottoman tärkeää etsittäessä keinoja
taudin ennaltaehkäisemiseksi. Tämän väitöskirjan tarkoituksena oli selvittää jo tunnettujen
geenimuutosten riskivaikutuksia suomalaisilla AT-potilailla. Tämän lisäksi tavoitteena oli
tutkia AT:n patogeneesiin liittyvien tekijöiden geneettisiä sekä molekyyli- ja solutason
vaikutusmekanismeja erilaisissa solu- ja eläinmalleissa.
Riskigeenimuutosten vaikutuksia itäsuomalaisessa tautipopulaatiossa tutkittiin käyttämällä
SNP-pohjaista assosiaatioanalyysiä, jossa riskigeenialueiden valinta perustui julkiseen
AlzGene tietokantaan. Itäsuomalainen tapaus-verrokkiaineisto koostui noin ~1300
myöhäisiän AT:a sairastavasta potilaasta ja kontrollihenkilöistä. Geneettisissä
jatkotutkimuksissa käytettiin yhdysvaltalaista Alzheimer-perheaineistoa varmentamaan
saatuja löydöksiä. Tämän lisäksi tutkittiin mm. seladiini-1:n, -opioidireseptorin (-OR)
sekä -sekretaasiproteaasin (BACE1) molekulaarisia vaikutusmekanismeja AT:lle
keskeisissä solutason tapahtumissa käyttäen erilaisia solu- ja eläinmalleja.
Ensimmäisessä osatyössä AlzGene -tietokantaan pohjautuvien kandidaattigeenien SNP-
pohjainen kartoitus osoitti, että muutokset TNF- (tumor necrosis factor ) sekä IL1B-
(interleukin 1B) geeneissä vaikuttivat AT:n riskiin itäsuomalaisessa
tapaus-verrokkiaineistossa. Kyseiset geenimuutokset vaikuttivat merkittävästi AT-
potilaiden selkäydinnesteen merkkiaineiden, kuten A42:n ja tau-proteiinin tasoihin.
Toisessa osatyössä osoitettiin, että seladiini-1-proteiinin tasojen lasku
SH-SY5Y-neuroblastoomasoluissa apoptoottisen stressin yhteydessä aiheutti
GGA3-proteiinin lisääntyneen pilkkoutumisen, mikä puolestaan johti BACE1:n post-
translationaaliseen stabiloitumiseen endosomeihin. Aikaisemmissa tutkimuksissa on
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osoitettu, että GGA3 toimii BACE1:n kuljetusproteiinina, joka säätelee BACE1:n
lysosomaalista hajotusta. Kyseisissä olosuhteissa BACE1:n stabiloitumisen puolestaan
osoitettiin lisäävän A-peptidin tuotantoa. Tämä on merkittävä mekanistinen havainto
AT:n patogeneesin kannalta, sillä seladiini-1:n tasojen on useissa aiemmissa tutkimuksissa
raportoitu alentuneen juuri niillä aivoalueilla, jotka eniten altistuvat AT:n tyypillisille
patologisille muutoksille.
Kolmannessa osatyössä selvitettiin OR:n merkitystä AT:n patogeneesissä. Aikaisemmin on
näytetty, että OR:n agonistivälitteinen aktivaatio lisää - ja -sekretaasien aktiivisuutta
lisäten näin A-peptidin muodostusta. Tutkimuksessamme havaittiin, että kodonissa 27
esiintyvä OR:n kysteiinivarianttimuoto (OR-Cys27) lisäsi APP:n prosessointia
muuttamalla sen endosytoottista kuljetusta sekä ei-neuronaalisissa että neuronaalisissa
soluissa verrattuna reseptorin fenyylialaniinimuotoon (OR-Phe27). Lisäksi OR:a
koodaavan geenin OPRD1:n SNP-pohjainen assosiaatioanalyysi kahdessa eri
AT-potilasaineistossa osoitti, että OR:n kysteiini- ja fenyylialaniinivarianttien
heterotsygoottimuoto (OR-Phe27Cys) saattaa lisätä AT:n riskiä. OR-antagonistihoitoja on
esitetty potentiaaliseksi AT:n terapiavaihtoehdoksi. Tämän väitöskirjatutkimuksen mukaan
on mahdollista, että AT-potilaat, jotka kantavat heterotsygootisti OR-Phe27Cys
variaatiota, reagoivat OR-antagonistihoitoihin APP prosessoinnin ja A-tuotannon osalta
eri tavalla verrattuna OR-Phe27-homotsygootteihin.
Viimeisessä osatyössä tutkittiin ei-selektiivisen kalsiumkanavasalpaajan, bepridilin, roolia
koe-eläinmallissa, jossa rotan toiseen aivopuoliskoon aiheutettiin kohdennettu aivoiskemia
(MCAO). Aikaisemmat tutkimukset ovat osoittaneet, että MCAO aiheuttaa rotilla
-peptidin ja kalsiumin tasojen merkittävän lisääntymisen talamuksen alueella tarjoten
näin mahdollisuuden tutkia AT:n patogeneesissä keskeisten tekijöiden roolia. Koska
bepridilin on todettu myös inhiboivan APP:n -sekretaasivälitteistä pilkkoutumista,
tutkimuksessa pyrittiin selvittämään voidaanko A- ja kalsiumpatologiaan vaikuttaa
bepridil-käsittelyllä MCAO:n jälkeen. Rottia lääkittiin 27 vuorokauden ajan annoksella 50
mg/kg alkaen kaksi päivää MCAO-leikkausoperaation jälkeen. Tutkimuksessa havaittiin,
että bepridil-käsittely laski MCAO-rottien kohonneita A40- ja A42- sekä kalsiumtasoja
talamuksessa verrattuna kontrollieläimiin. Tämän lisäksi havaittiin, että seladiini-1:n
lähetti-RNA-tasot talamuksessa olivat merkittävästi laskeneet kontrollirotilla, kun taas
bepridil-lääkityillä rotilla seladiini-1:n lähetti-RNA-tasoissa ei nähty merkittäviä
muutoksia. MCAO-rottien talamuksen seladiini-1:n ja kalsiumtasojen välillä havaittiin
lisäksi merkittävä käänteinen korrelaatio, samoin kuin seladiini-1:n ja liukenemattoman
42:n tasojen välillä. Tämän tutkimuksen havainnot osoittavat, että bepridil voi vaikuttaa
rottien aivojen A- ja kalsiumpatologiaan ja että seladiini-1:n ilmentymistasot heijastelevat
mahdollisesti hermosolujen selviytymistä tilanteessa, jossa nähdään AT:lle tyypillisiä
patologisia muutoksia.
Tässä väitöskirjassa tutkitut geenit sekä molekyyli- ja solutason mekanismit liittyen AT:n
patogeneesiin tarjoavat potentiaalisia kohteita uusien biomarkkereiden kehittämiseen, joita
voidaan hyödyntää AT:n riskikartoituksessa sekä varhaisemmassa diagnostiikassa. Lisäksi
saadut tulokset voivat edesauttaa uusien AT:n terapiavaihtoehtojen kehittämistä.  Tässä
yhteydessä potilaiden geneettisen profiilin tuntemisella on tämän väitöstutkimuksen
valossa merkittävä osa.
Luokitus: WT 155, QU 470, QU 500, QU 55.7
Yleinen Suomalainen asiasanasto: Alzheimerin tauti; molekyylilääketiede; patogeneesi; geenit; genetiikka;
genotyyppi; riskitekijät; proteiinit; reseptorit; aivo-selkäydinneste; merkkiaineet
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1 Introduction
Alzheimer’s disease (AD) is an irreversible progressive neurodegenerative brain disease
affecting learning and memory. It is the most common form of dementia among the elderly
and the fourth leading cause of death in Western countries. In Finland, the prevalence of
dementia is approximately 2% in individuals aged 65–67 years, increasing to 35% at the age
older than 85 (Viramo and Sulkava, 2010). Around 13 000 new patients with dementia are
annually diagnosed, and of these patients approximately 65-70% are estimated to suffer
from AD (Viramo and Sulkava, 2010; Pirttila et al., 2010). A recent report suggested that the
prevalence of dementia will double every 20 years worldwide, reaching an alarming 120
million by 2050 (World Alzheimer’s Report 2010).
The histopathological hallmarks of AD include widespread neuronal degeneration, neuritic
plaques (NPs) containing -amyloid (A) and neurofibrillary tangles (NFTs) (Selkoe 2001;
Iqbal et al., 2009). Amyloid plaques are primarily composed of aggregates of A while NFTs
are intracellular aggregates of hyperphosphorylated tau protein. These aggregates are
distributed throughout the brain of patients with AD, particularly in the neocortex (Braak
and Braak, 1991) and are believed to trigger a series of neurodegenerative processes. A
number of other mechanisms appear to contribute to the neurodegenerative process as
well, including alterations in calcium homeostasis in the endoplasmic reticulum, which
contribute to neuronal apoptosis and excitotoxicity. Mitochondrial dysfunction may also be
linked to neurodegenerative diseases through a variety of different pathways, including
free-radical generation, impaired calcium buffering, and the mitochondrial permeability
transition (Beal, 1999). Synapse loss is an early ubiquitous feature in AD and there is a
strong correlation between the extent of synapse loss and the severity of dementia (Selkoe,
2001; Shankar and Walsh, 2009). Synaptic dysfunction is caused by diffusible oligomeric
assemblies of the A protein, and there is mounting evidence to suggest that these maky
evoke a subtle alteration of hippocampal synaptic efficacy prior to frank neuronal
degeneration (Selkoe, 2002).
AD can be roughly grouped into two forms, the familial and sporadic form. In the
early-onset familial form, mutations in the amyloid precursor protein (APP), presenilin-1
(PSEN1), and presenilin-2 (PSEN2) genes are responsible for rare autosomal dominant form
of the disease, which usually appears before the age of 65 years (Goate et al., 1991;
Sherrington et al., 1995; Levy-Lahad et al., 1995; Rogaev et al., 1995). These causative familial
early-onset AD (EOAD) mutations, however, explain less than 1% of all early-onset AD
cases. Thus, the vast majority of EOAD patients cannot be explained by such simple
genetics. The sporadic late-onset form of AD (LOAD) is considered to be caused by a
combination of genetic, acquired, and environmental risk factors, although it is believed
that up to 60-80% of this form of AD results from complex genetic inheritance (Gatz et al.,
2006). Moreover, environmental and epigenetic factors likely make an important
contribution in determining an individual’s risk. However, the precise nature and
mechanisms underlying this nongenetic component remain largely elusive, in part because
it is difficult to assess these factors experimentally (Traynor and Singleton, 2010). In the
search of genetic causes of LOAD, apolipoprotein E (APOE) was introduced approximately
two decades ago as a major risk factor for complex forms of AD (Strittmatter et al., 1993;
Saunders et al., 1993; Raber et al., 2004). Subsequently, APOE has represented the major risk
gene for LOAD, showing a strong association to AD in several independent replication
2studies in a number of different ethnic populations (Bertram et al., 2007). Importantly,
APOE4 allele has been associated with an increased risk of developing both EOAD and
LOAD (Tanzi and Bertram, 2005).
Mutations in the PSEN1, PSEN2 or APP genes as well as genetic alterations in some
sporadic AD susceptibility genes result in an increase in the production of A1-42, the
42-amino acid long A peptide (Suzuki et al., 1994; Lemere et al., 1996; Borchelt et al., 1996;
Scheuner et al., 1996; Ertekin-Taner et al., 2001). In addition, genetic variation in some genes
may influence either A clearance or aggregation (Murakami et al., 2003; Tsubuki et al.,
2003). The identification of the familial EOAD genes has significantly improved our
understanding of the pathogenetic mechanisms underlying neurodegeneration in AD. The
knowledge of the identified pathogenic mechanisms has been widely utilized in developing
in vitro and in vivo AD models for investigating the role of LOAD genes in disease
pathogenesis.
Altered APP processing leading to increased production of A is a commonly accepted key
feature in the pathogenesis of AD. APP processing is initiated by either -secretase
(non-amyloidogenic pathway) or -secretase (amyloidogenic pathway) to generate APP
C-terminal fragments (CTFs). These CTFs are then cleaved by -secretase, leading to the
formation of p3 (from CTF) or A (from CTF) peptides (Tanzi and Bertram, 2005). The
-secretase mediated cleavage of the CTF generates A peptides of different lengths, but
the A1-42 (42 amino acids), the A1-40 (40 amino acids) (Thinakaran and Koo, 2008) as
well as A1-43 (43 amino acids) (Saito et al., 2011) forms are the most prevalent. Changes in
the above-mentioned APP processing steps alter the production of A. In the context of AD,
however, it should be noted that the events controlling the degradation of A through the
A-degrading enzymes (Insulin-degrading enzyme (IDE), neprilysin (NEP),
endothelin-converting enzyme 1 (ECE1), and ECE2) are equally as important as those
involved in the production of A (Miners et al., 2008). Nonetheless, decreasing the activity
of - or -secretase have been shown to inhibit the production of A peptides. Therefore,
identification of proteins or compounds that influence the activity of these secretases is a
major goal in AD research as it might yield potential new therapies.
Ever since the APOE was identified, the LOAD candidate gene approach has spurred a
large number of genetic association studies assessing other loci of potential relevance based
on functional, mostly A-centered, hypotheses. These studies have resulted in the
identification of a number of AD susceptibility genes, including A2M (encoding
-2-macroglobulin) (Blacker et al., 1998; Saunders et al., 2003), BChE (the K-variant of
butyrylcholinesterase; Lehmann et al., 1997), and LRP (Low density lipoprotein
receptor-related protein; Lendon et al., 1997) genes, as well as more recently LDLR (Low
density lipoprotein receptor; Lamsa et al., 2008), CALHM1 (Calcium homeostasis modulator
1; Bertram et al., 2008), CLU (Clusterin; Harold et al., 2009; Lambert et al., 2009), PICALM
(Phosphatidylinositol-binding clathrin assembly protein; Harold et al., 2009), and CR1
(Complement component (3b/4b) receptor 1; Lambert et al., 2009) genes. The consistency,
however, have been poor in different cohorts. In fact, out of the nearly 700 candidate AD
genes investigated over the past 30 years, only a few have shown significant risk effects
when data from all available studies are combined (Bertram and Tanzi, 2008). Still,
identification of new potential candidate genes is important, because functional studies on
these genes can help to better understand the molecular and cell biological events
influencing AD pathogenesis. This functional approach provides essential information
about the biological mechanisms underlying the disease pathogenesis and progression,
offering the opportunity to learn from and, eventually, overcome AD.
3Despite the growing number of risk genes identified, only a few of the studies have
employed functional approaches to determine the biological consequences of the genetic
alteration. It is evident that the candidate genes may influence certain key events in AD,
such as A production and degradation. Therefore, in the initial functional assessments, it
is reasonable to focus on how the observed variations in the identified candidate genes
affect the already known factors involved in AD pathogenic mechanisms, such as the
secretases (e.g. -secretase), A-degrading enzymes, or disrupted calcium homeostasis.
This thesis focuses on screening some of the most prominent AD candidate genes and
assessing their disease association among Eastern Finnish case-control cohort. Furthermore,
it aims to investigate the functional influences of some of the key factors – such as delta
opioid receptor (OR), seladin-1 and BACE1 – hypothezised to play a role on cellular events
relevant for AD pathogenesis.
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2.1 CLINICAL AND NEUROPATHOLOGICAL CHARACTERISTICS IN
ALZHEIMER’S DISEASE
2.1.1 Clinical aspects and diagnostic criteria of AD
The clinical features in AD are very heterogeneous. Typically, the earliest clinical sign is an
impairment of recent memory function and attention, followed by a failure in language
skills, visual–spatial orientation, abstract thinking, and judgement. As the disease
progresses, alterations of personality start to accompany these defects (Förstl and Kurz,
1999; Bouchard and Rossor, 2001; Cummings, 2003). The diagnosis of AD is based on the
neuroimaging and biomarker quantification, and the patient’s clinical status. Mental status
questionnaires are useful in providing a global quantification of the deficits and a means of
characterizing the stage of the patient’s cognitive decline as well as other
dementia-associated abnormalities. The Mini-Mental State Examination (MMSE) (Folstein et
al., 1975) is the most widely used mental status questionnaire (Cummings, 2003). It includes
30 questions assessing orientation, learning, attention, serial subtraction/attention, recall,
naming, repetition, comprehension, reading, writing, and copying a complex figure.
However, it is generally insensitive to the cognitive abnormalities present in the earliest
phases of AD, and also loses applicability in the final phases of the disease (Cummings,
2003). Another example of a cognition measuring test is the Alzheimer’s Disease Assesment
Scale (ADAS) (Rosen et al., 1984). In order to characterize the patient’s cognitive, functional
and behavioural aspects of the disorder more extensively, global assessment scales for
diagnosis and stage of severity are employed. These kinds of global assessment measures
include The Clinical Dementia Rating (CDR) (Hughes et al., 1982; Berg, 1988), and The
Global Deterioration Scale (GDS) (Reisberg et al., 1982). CDR measures the performance in
six domains: memory, orientation, judgement and problem-solving, community affairs,
home and hobbies, and personal care. It was last revised in 1993 (Morris, 1993; Sahadevan
et al., 2001). A comprehensive evaluation may involve both cognitive tests and global
assessment. By performing all of the three latter tests – MMSE, GDS, and CDR –, one may
categorize AD into three different stages according to respective scores: mild (MMSE 18-26,
GDS 3-4, CDR 0.5-1), moderate (MMSE 10-22, GDS 4-6, CDR 1-2), and severe (MMSE 0-12,
GDS 6-7, CDR 2-3) (Pirttila and Erkinjuntti, 2002).
Prior to the appearance of significant clinical symptoms, the neuropathological changes in
AD are thought to begin primarily in the entorhinal and transentorhinal cortex,
hippocampus, and then to progress to the association cortices of the temporal, parietal and
frontal lobes (Braak and Braak, 1991). In particularly, the hippocampal formation is thought
to be a major location of the memory impairment seen in AD (de Leon et al., 1999). The
primary sensory and motor cortices and most subcortical structures are relatively well
spared (Figure 1). Consistent with these widespread neuropathologic changes, the primary
clinical manifestation of AD is a progressive dementia syndrome that usually begins in later
life. Braak and Braak’s model (1991) devides AD into six subcategories: Transentorhinal (I-
II), limbic (II-IV), and neocortical (V-VI) stages (Figure 1). The progression of the clinical
symptoms runs in tandem within these stages (Pirttila and Erkinjuntti, 2002). In the final
stages (V-VI), typically about 8-10 years after the initial diagnosis of AD, patients are
completely bedridden and unable to communicate effectively. Perpetual confusion,
5incontinence, and an inability to execute even the most basic cognitive functions are the
hallmarks of this final stage of AD (Table 1) (Sweatt, 2003). The diagnosis of the disease is
confirmed when there are frequent NPs using the criteria developed by the Consortium to
Establish a Registry for AD (CERAD) (Mirra et al., 1991), and NFTs in the medial
temporal-lobe structures graded by the Braak and Braak approach as stage V-VI (Braak and
Braak, 1991).
Table 1. Different stages of AD progression.
 AD stage Areas first affected Symptoms
 I, II Trans-entorhinal region
Entorhinal cortex
Hippocampal CA1 area
Can be clinically silent: Subtle loss of episodic memory and
difficulty in excecuting complex progressive tasks; anecdotal
repetition; some spatial disorientation
 III, IV Entirety of hippocampus Early-stage AD: loss of episodic memory; difficulty in spatial
reasoning and recognition, difficulty in coherent speech and
planning
 V, VI Neocortex Fully developed AD: pronounced decline in cognition; frank
dementia, can include psychosis or depression; ultimately a
complete inability to communicate or care for themselves
Adapted from Sweatt, 2003.
6Figure 1. Evolution of neurofibrillary tangle (NFT) pathology as originally conceived by Braak
and Braak (1991). Before the first clinical symptoms appear, neurofibrillary changes begin to
accumulate in the entorhinal and transentorhinal cortex (Transentorhinal stage; I and II) and
may appear surprisingly early in life (e.g., in the individual’s thirties or forties). Mild clinical
symptoms are believed to coincide with increasing appearance of NFTs in the medial temporal
lobe and surrounding association cortices (Limbic stage; III and IV), followed by clinically
apparent Alzheimer’s disease and the severe involvement of medial temporal and cortical
association areas (Neocortical stage; V and VI). (From Bondi et al., 2008)
Pathologically, the severity of the characteristic findings in AD differs considerably among
individual patients and this diversity complicates accurate diagnosis. Thus, clinical
definitions and diagnostic criteria are needed to advance research in AD, improve the
treatment of AD, and identify non-AD causes of dementia. There are three widely used
criteria based approach in the diagnosis of AD: the International Classification of Diseases,
10th revision (ICD-10), the Diagnostic and Statistical Manual of Mental Disorders, 4th edition
(DSM-IV), and the National Institute of Neurological and Communicative Disorders and
Stroke-Alzheimer’s Disease Related Disorders Association (NINCDS-ADRDA) Work
Group criteria (McKhann et al., 1984; Cummings and Khachaturian, 2001; Cummings, 2004).
The characteristics used in each approach are presented in Table 2. The NINCDS-ADRDA
criterion takes a different approach than the other two by dividing the disease states into
definite, probable and possible AD. The definite criteria require that the patient meets both
probable clinical criteria and has histopathological evidence of AD obtained by biopsy or
autopsy.
7Since NINCDS-ADRDA and DSM-IV criteria have long been the prevailing diagnostic
standards in research, some revisions have been proposed. Distinctive and reliable
biomarkers of AD are now available through structural magnetic resonance imaging (MRI),
molecular neuroimaging with positron emission tomography (PET), and cerebrospinal
fluid analyses. This progress provides an additional support for revised diagnostic criteria
for AD (Bouwman et al., 2010). The criteria have been devised to capture both the earliest
stages before full-blown dementia as well as the full spectrum of the illness, and they are
centered on a clinical core of early and significant episodic memory impairment. According
to the new putative guidelines, there must be at least one or more abnormal biomarker(s)
among structural neuroimaging with MRI, molecular neuroimaging with PET, or
cerebrospinal fluid analysis of A or tau proteins, to support the diagnosis suggested by the
cognitive tests (Dubois et al., 2007).
8Table 2. Main characteristics and comparison of three commonly used criteria for the diagnosis
of Alzheimer’s disease.
Criteria Main characteristics
ICD-10 Deterioration in both memory and thinking, which is sufficient to impair personal
activities of daily living.
The registration, storage, and retrieval of new information are impaired.
Deficits in thinking and reasoning in addition to the memory disturbances.
Presence of insidious onset, slow deterioration of cognition.
Absence of clinical or laboratory evidence of systemic illness or brain disease
that can induce dementia.
Absence of sudden onset. Both early (< 65-years) and late-onset subtypes
recognized as well as atypical and mixed types.
DSM-IV Multiple cognitive deficits including memory impairment.
At least one of the following: aphasia, apraxia, agnosia, or disturbance in
executive functioning.
Social and occupational impairment. Other neurological disorders, systemic
conditions or substance abuse excluded.
Absence of other major psychiatric disorder (e.g. schizophrenia).
Deficits not limited to delirious period. Subtypes of both early (< 65-years) and
late-onset forms of AD recognized.
NINCDS-ADRDA Probable, possible, and definite AD recognized.
 Probable Dementia established by clinical examination and documented by mental status
questionnaire.
Dementia confirmed by neuropsychological testing.
Deficits in two or more areas of cognition.
Progressive worsening of memory and other cognitive functions.
No disturbances of consciousness.
Onset between ages 40 and 90.
Absence of systemic disorders or other brain diseases capable of producing a
dementia syndrome.
 Possible Presence of a systemic disorder or other brain disease capable of producing
dementia but not thought to be a cause of the dementia.
Gradually progressive decline in a single intellectual function in the absence of
any other identifiable cause (e.g. memory loss or aphasia).
 Definite Clinical criteria for probable AD and histopathological evidence of AD (autopsy or
biopsy).
Adapted from Cummings and Khachaturian, 2001.
One of the main features of AD is the age of onset, according to which the disease may be
divided into three categories (Terry et al., 1983; Ertekin-Tanner, 2007). First, the most
common form is the LOAD accounting for approximately 90% of all AD cases and
occurring usually at the age of 65 years or more. Age is the most common risk factor of AD.
This is supported by the fact that the prevalence of AD is below 1% in individuals aged 60
9to 64 years, but it shows an almost exponential increase with age and in people aged 85
years or older, the prevalence is around 30% (Pirttila and Erkinjuntti, 2002; Hebert, 2003). In
longitudinal studies exploring inheritance of AD subjects and their offspring, it is evident
that both LOAD and EOAD have a transmissible pattern. However, the genetic component
in LOAD is likely to have a more complex form of inheritance compared to that of EOAD
with minor evidence of autosomal dominant transmission component (Ertekin-Taner,
2007). Despite the fact that LOAD is often referred to as “sporadic AD”, it is important to
understand that up to 60 to 80% of this form of AD is claimed to be genetically determined
(Gatz et al., 2006). Second, EOAD can be divided into two different subgroups: those
patients with no Mendelian inheritance status, and the ones with clear transmissible
component. EOAD is exceedingly rare. Its prevalence is estimated to range between 6 to 7%
of all AD cases, and autosomal dominant form of EOAD accounts for 13% of all EOAD
cases. The mutations in APP, PSEN1 or PSEN2 can explain up to 71% of the autosomal
dominant transmission pattern in EOAD. These genes account for about 0.5% of all AD
cases (Ertekin-Tanner, 2007; Lehtovirta, 2002). However, one must understand that this
traditional categorization of AD into LOAD and EOAD (including the familial EOAD
subgroup with rare APP, PSEN1, and PSEN2 genes) is overly simplistic. There are cases of
EOAD without evidence for Mendelian transmission. Conversely, LOAD is frequently
observed with a strong familial clustering, sometimes resembling a Mendelian pattern
(Bertram et al., 2010).
2.1.2 Neuropathology in AD
Neuroimaging studies and subsequent post-mortem correlations have shown that AD
features a loss of neurons and synapses in the cerebral cortex and certain subcortical
regions. This loss results in gross atrophy of the affected regions, including degeneration in
the temporal and parietal lobes, and parts of the frontal cortex and cingulate gyrus (Wenk,
2003). The brain tissue, especially the cortex, becomes atrophied and a visual examination
reveals the microscopic appearance of diffuse NPs and NFTs (Braak and Braak, 1991; Bondi
et al., 2008). In addition, degeneration in the basal forebrain results in a major reduction in
the levels of acetylcholine, a central neurotransmitter (Whitehouse et al., 1982). Loss of
white matter, congophilic (cerebral) amyloid angiopathy (CAA), inflammation and
oxidative damage are also present in AD brain (Querfurth and LaFerla, 2010).
NPs have a central core consisting of A peptide, which is surrounded by astrocytes,
microglia, and dystrophic neurites containing paired helical filaments (Cummings and
Back, 1998; Cummings, 2003). Plaque densities are typically at their highest in the temporal
and occipital lobes in the AD brain (Cummings, 2003). NFTs are intra-axonal deposits
consisting of paired helical filaments of abnormally hyperphosphorylated, microtubule-
associated tau protein (Grundke-Iqbal et al., 1986). These filaments disrupt normal
intracellular transport and result in cell death (Cummings, 2003). The toxicity of
hyperphosphorylated tau is based on its ability to inhibit microtubule assembly and disrupt
microtubules. Furthermore, hyperphosphorylated tau is able to sequester also normal tau
to the tau aggregates (Alonso et al., 1994). Both plaques and tangles are considered to be the
leading causes of neurotoxicity. A oligomers and plaques are potent synaptotoxins:
synapses and axons are known to degenerate when surrounded by filamentous,
star-shaped plaques (Selkoe, 2002; Haass and Selkoe, 2007; Walsh and Selkoe, 2007).
In addition to the two classical histopathological features, the brains of patients with AD
also feature a reduction in synaptic density and loss of neurons in the hippocampal neurons
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(Cummings and Back, 1998). Hence, AD may also be considered as a disorder characterized
by synaptic failure. In the early stages of AD, there can be up to a ~35% decrease in the
density of synapses in the cortex, and a ~15 to 35% decrease in the number of synapses per
cortical neuron, as estimated in by brain biopsy (Selkoe, 2002). At the advanced stages of
the disease, this loss of synapses has been reported to correlate better with cognitive decline
than the numbers of plaques or tangles, degree of neuronal loss, or extent of cortical gliosis
(DeKosky and Scheff, 1990; Terry et al., 1991; Selkoe, 2002).
The majority of AD patients suffer from vascular lesions, such as cerebral amyloid
angiopathy (CAA; affecting more than 90% of patients with AD) (Greenberg et al., 2004),
and exhibit capillary abnormalities, disruption of the blood-brain-barrier (BBB), and large-
vessel atheroma (Roher et al., 2004). CAA is characterized by amyloid depositions in the
cerebral vasculature leading to fibroid necrosis of the vessel wall and formation of
microaneurysms. These predispose the vessels to rupture or leakage, thus causing
haemorrhage in the brain (Vasilevko et al., 2010). Approximately 60 to 90% of patients are
affected by ischemic disease mainly due the vascular lesions. Conversely, one third of
putative cases of vascular dementia display coincidental pathological features of AD
(Querfurth and LaFerla, 2010). Additionally, individuals with familial EOAD mutations in
PSEN1, Down Syndrome (DS) patients, and carriers of APOE 4 allele have increased A
deposition in the cerebral vasculature (Yamada et al., 1997; Yamada, 2004; Belza and Urich,
1986; Chalmers et al., 2003). Furthermore, polymorphisms in PSEN1 and NEP genes, which
are important in the context of AD, have also shown an association with CAA (Yamada et
al., 1997; 2003).
Neuronal loss in the nuclei responsible for the maintenance of different neurotransmitter
systems results in a reduction in the levels of several major neurotransmitters, including
acetylcholine (ACh) (Hardy et al., 1985; Cummings and Back, 1998). Several postmortem
studies have reported a loss of cholinergic neurons in the basal forebrain (Cullen and
Halliday, 1998; Geula et al., 2008; Lehericy et al., 1993; Vogels et al., 1990) and a decline in
cortical choline-acetyltransferase (ChAT) and cholinesterase (ChE) activity (Gil-Bea et al.,
2005; McGeer et al., 1984; Ruberg et al., 1990) in patients with AD compared to
nondemented control subjects. Moreover, the reduction of ChAT activity in the cortex has
been shown to correlate with the density of plaques (Perry et al., 1978) as well as with the
loss of cholinergic neurons in AD (Joynt and Shoulson, 1985). The cholinergic system
appears to play a role in memory and cognition. The loss of cholinergic neurotransmission
in the cerebral cortex caused by degeneration of these nerve cells in the basal forebrain
might be responsible for the significant decline in the cognitive abilities so common among
subjects with AD (Bartus et al., 1982; Coyle et al., 1983). Thus, this has become the basis for a
symptom-based treatment currently available for AD: inhibition of cholinesterase (ChE),
the enzyme responsible for breaking down acetylcholine in the synapse. Today, three ChE
inhibitors, donepezil, rivastigmine, and galantamine, are used to delay the onset of the
symptoms, but so far no treatment exists, which could cure AD or even stop the disease
progression.
Other than findings from histopathology of AD brain, there is also data emerging from
experimental in vivo and in vitro studies that have been important in characterizing typical
pathophysiological changes in AD. It has been described that long-term potentiation (LTP)
shows a strong correlation with learning and memory as well as synaptic plasticity in
different experimental in vitro and in vivo models (Haass and Selkoe, 2007). Several
electrophysiological studies in APP-transgenic mice carrying human AD mutations have
revealed significant deficits in basal synaptic transmission and/or LTP. These deficits were
shown to occur in the hippocampus well before the appearance of any detectable A
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deposits. Additionally, the LTP deficit in older mice was associated with impaired
performance in a spatial working memory task, but not with the loss of certain synaptic
markers, suggesting that functional – not structural – synaptic changes were responsible for
the cognitive deficits (Selkoe, 2002). There is now compelling evidence to suggest that the
maintenance of hippocampal LTP is inhibited by synthetic human A-derived diffusible
ligands (ADDLs) (Lambert et al., 1998) and soluble, low-number oligomers of naturally
secreted human A (Walsh et al., 2002; Kamenetz et al., 2003). A oligomers impair synaptic
plasticity by altering the balance between LTP and long-term depression (LTD) and by
reducing the number of dendritic spines. Furthermore, excess build-up of A and A
oligomers can induce neurotransmitter receptor internalization [such as N-methyl-D-
aspartate (NMDA) and -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)
receptors] and inhibition of voltage-gated calcium channels (VGCC), and nicotinic
acetylcholine receptors (nAChR) (Querfurth and LaFerla, 2010).
2.1.3 Neuroimaging and CSF biomarkers
Recently, more emphasis has been placed on attempts to diagnose AD at an earlier phase,
commonly referred to as mild cognitive impairment (MCI) (Petersen, 2004). In this phase,
the patient experiences mild cognitive deficits, but exhibits no functional decline. One
important challenge is to try to identify the disease at the pre-dementia stage and enhance
the specificity of the clinical diagnosis by using imaging and other biomarkers.
Additionally, from a therapeutic perspective, it is essential to reliably identify individuals
as early as possible during the disease course: the earlier the intervention takes place,
presumably, the better the chance to effectively intervene in the disease process.
Computed tomography (CT) and magnetic resonance imaging (MRI) techniques, among
others, can be used to reveal areas of neuronal death and brain atrophy caused by the
accumulation of plaques and tangles. CT or MRI are often used to detect intracranial lesions
or diseases that might cause (e.g. tumour or hydrocephalus) or contribute (e.g.
cerebrovascular disease) to dementia syndromes (Waldemar et al., 2007). For example,
semi-quantitative structural MRI has been successfully used to identify differences in
medial temporal lobe atrophy between patients with AD and age-matched control
individuals with sensitivity and specificity greater than 85%, (Waldemar et al., 2007). There
is some evidence that assessment of medial temporal atrophy could also be used to identify
patients with MCI that will eventually progress to AD. However, differential diagnosis in
medial temporal atrophy between AD and non-AD dementias is difficult, and the
differences in brain structure may well be too small for diagnostic purposes in individual
patients (Ballard et al., 2011).
Novel quantitative techniques, such as volumetric imaging, three-dimensional mapping of
the hippocampus, and cortical thickness measurement are promising markers in terms of
AD diagnostics (Querbes et al., 2009), and are being investigated as part of the AD
Neuroimaging Initiative (ADNI) multicentre study (Ballard et al., 2011). Radioisotopic scans
can measure blood flow with single-photon emission CT (SPECT) to distinguish AD from
frontotemporal dementia (FTD) (Ballard et al., 2011). Various ligands have also been
developed that visualise specific neurotransmitter systems with SPECT, which help to
distinguish AD from dementia with Lewy bodies and Parkinson-type of dementia
(McKeith et al., 2007). PET with fluorodeoxyglucose (FDG-PET) measures glucose
metabolism and has shown good accuracy in distinguishing patients with probable AD
from both normal control individuals and patients with non-AD dementias. This imaging
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method has been approved in the USA for diagnostic purposes and is sensitive and specific
for detection of AD in its early stages (Ballard et al., 2011). A reduction of glucose
metabolism in bilateral temporal parietal regions and in the posterior cingulate cortex is the
most commonly described diagnostic criterion for AD (Ballard et al., 2011). One of the most
promising novel imaging techniques is PET with A ligands, such as ¹¹C-labelled
Pittsburgh compound B (PiB) (Ikonomovic et al., 2008; Klunk et al., 2004) or other
radioligands with longer half-lives (for example florbetaben and ¹
F-AV-45) (Rowe et al.,
2008; Choi et al., 2009). These can be used to directly visualise A in vivo (Nordberg, 2004).
There is evidence that PiB binding as assessed with PET is significantly associated with the
amount of fibrillar A measured post-mortem in most patients with AD. PiB binding also
significantly correlates with CSF A biomarkers (Svedberg et al., 2009; Forsberg et al., 2010).
Despite the advancement in imaging techniques, clinical accuracy for patients with AD
versus control individuals has shown wide variation between studies, and constant
development of the technology is still needed in order to obtain reliable and sensitive
diagnostic tools for AD.
Over the past two decades, it has become possible to obtain in vivo evidence of the specific
neuropathology of AD by using validated and disease-specific biomarkers (Fagan et al.,
2006; Jagust et al., 2009; Mintun et al., 2006). These can be measured from the cerebrospinal
fluid (CSF) or by different brain imaging techniques. The concept of using biomarkers for
early diagnostic purposes has a long history, with many studies showing that AD
biomarkers can be used to predict conversion from MCI to AD (Jack et al., 2010). Laboratory
and neuroimaging biomarkers display high correlation coefficients with the
neuropathological lesions of AD (Buerger et al., 2006; Clark et al., 2003; Ikonomovic et al.,
2008). These biomarkers can be divided into pathophysiological and topographical markers
(Table 3) (Dubois et al., 2010).
Table 3. Categorization of the current, most-validated AD biomarkers.
Pathophysiological
markers
Topographical markers
Cerebrospinal fluid
 42
 Total tau, phosphorylated tau
Yes
Yes
No
No
PET
 Amyloid tracer uptake
 Fluorodeoxyglucose
Yes
No
No
Yes
Structural MRI
 Medial temporal atrophy No Yes
Adapted from Dubois et al., 2010.
Pathophysiological biomarkers reflect the two aetiological degenerative processes that
characterize AD pathology: the amyloidosis path to generate NPs and the tauopathy path
resulting in NFTs. They include reduced concentrations of A, increased total tau (t-tau),
and increased phosphorylated tau (p-tau) in the CSF (Buerger et al., 2006; Clark et al., 2003;
Strozyk et al., 2003; Tapiola et al., 2009; Blennow et al., 2010; Mattsson et al., 2009), and
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amyloid PET scanning with PiB or other radioligands (e.g. 18F). CSF biomarkers (low A
and, specifically, an abnormal ratio of tau to A) (Li et al., 2007) are associated with very
high rates of progression from amnestic MCI to AD dementia (Ewers et al., 2007; Mattsson
et al., 2009). These markers also have shown a consistently high sensitivity and specificity in
predictive models, such as assessing the value of CSF t-tau/A1-42 ratio or CSF p-tau levels
in prediction of MCI (Li et al., 2007; Ewers et al., 2007). High mean cortical binding values
for PiB-PET have been predictive of cognitive decline and development of AD clinical signs
in cognitively normal elderly individuals (Morris et al., 2009; Resnick et al., 2010). In vivo
pathophysiological markers correlate very well with their respective neuropathological
lesions. For example, CSF A and PiB-PET correlate well with the numbers of senile
plaques (Ikonomovic et al., 2008; Strozyk et al., 2003; Tapiola et al., 2009; Blennow et al.,
2010), and t-tau and p-tau with NFTs (Buerger et al., 2006; Clark et al., 2003; Tapiola et al.,
2009; Blennow et al., 2010).
Topographical markers are used to assess the less specific and downstream brain changes
that correlate with the regional distribution of Alzheimer’s pathology. These include medial
temporal lobe atrophy (Teipel et al., 2010; de Leon et al., 2006; Hampel et al., 2008) and
reduced glucose metabolism in temporo-parietal regions detected by FDG-PET
(Patwardhan et al., 2004). These markers are valuable indicators because structural brain
changes accurately map to the areas of the Braak stages of neurofibrillary tangle deposition
(Whitwell et al., 2008). MRI and PET markers have been consistently shown to predict the
development of AD dementia in MCI cohorts (de Leon et al., 2007; Morris et al., 2009; Okello
et al., 2009; Wolk et al., 2009) and to correlate with disease severity (Jack et al., 2002;
Nordberg et al., 2010).
In 2004, The Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative (referred
subsequently as ADNI 1) programme was launched as a collaboration between academic
and industrial investigators. The goal of ADNI 1 was to clarify the relationships between
demographic, genetic, clinical, cognitive, neuroimaging, and biochemical measures
throughout the course of AD pathogenesis, and to facilitate the development of effective
therapies. The project has delivered insights into disease mechanisms, and has provided
guidance for drug development programs based primarily on the use of standardized
biomarkers in longitudinal follow-up studies. Subsequently, ADNI-GO was established in
2010 focusing on imaging techniques and biomarkers in blood and CSF to identify AD at
the pre-dementia stage. ADNI 2 is an extension of the original ADNI 1 study and ADNI-
GO. ADNI 2 aims to understand the progression of AD and addresses the possible
utilization of neuroimaging and other biomarkers at the stage of early clinical symptom
presentation (eMCI).
ADNI and ADNI-GO are using neuroimaging and biomarker measurements to track the
changes taking place in the brains of approximately 1300 elderly people. These individuals
are either free of symptoms or have been diagnosed with early and/or late-stage mild
cognitive impairment (eMCI and LMCI, respectively) and EOAD, a condition that may
progress to AD. Based on these projects, a hypothetical model has been created to illustrate
the power of biomarkers relative to progression of AD (Figure 2) (Aisen et al., 2010). First,
accumulation of A42 is detected by molecular imaging techniques, such as PET scanning
using an amyloid-specific ligand or by measuring CSF A42 levels. The next step in the
disease progression involves neuronal injury and dysfunction. This may be detected by
FDG-PET as altered regional metabolic activity and as elevated levels of CSF t-tau,
indicative of neuronal damage, and p-tau reflecting the worsening tangle pathology, and as
MRI volumetric changes. When a threshold of neuronal dysfunction is reached, cognitive
and then functional manifestations of AD appear with increasing frequency. It is believed
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that early intervention is preferable compared to treating individuals only after the full-
blown dementia syndrome is present (Aisen et al., 2010; Jack et al., 2010). Figure 2 shows
that amyloid biomarker abnormalities are already present during the asymptomatic stage.
Ideally, one would hope to intervene at this point to have the greatest preventive effect on
subsequent neuronal damage.
Figure 2. Different biomarkers during the progression of AD. This hypothetical graph is designed
to illustrate the following points: (1) CSF A42 and amyloid PET, reflecting amyloid
accumulation in brain, move in tandem. (2) Amyloid accumulation precedes cognitive and
functional decline by years, and changes only gradually after symptoms develop. (3) CSF tau,
MRI volumes, and FDG-PET are more dynamic biomarkers of disease progression across the
spectrum of AD pathogenesis than CSF A42 and amyloid PET. (4) Cognitive decline becomes
evident at the onset of eMCI, and accelerates as the disease progresses. (5) Functional decline
becomes evident at the onset of dementia, and accelerates as the disease progresses. (6) All of
these points are conjectural to varying degrees and they require confirmation by long-term
longitudinal follow-up in ADNI 2 and beyond. LMCI, late stage of MCI; eMCI, early stage of MCI.
(Adapted from Aisen et al., 2010)
2.2 MOLECULAR MECHANISMS IN ALZHEIMER’S DISEASE
PATHOGENESIS
2.2.1 APP and A processing
2.2.1.1 APP
AD is pathologically characterized by the deposition of amyloid in the central nervous
system as neuritic plaques and in the cerebral vasculature. Glenner and Wong first
identified the major protein component of vascular amyloid, which was a low-molecular-
weight, 4-kDa polypeptide, now referred to as -amyloid () (Glenner and Wong, 1984).
15
Subsequent studies established that the same protein was the major component of amyloid
plaques (Masters et al., 1985). The complete amino acid sequence of  led to the
identification of its precursor, the amyloid precursor protein, APP (Kang et al., 1987).
Despite extensive efforts toward understanding the function of APP, its physiological
role(s) still remains poorly defined. A physiological role for APP has been suggested in
neurite outgrowth and synaptogenesis, neuronal protein trafficking along the axon,
transmembrane signal transduction, cell adhesion, calcium metabolism, cell migration and
synapse remodeling (Zheng and Koo, 2006).
The human APP gene is a gene with 19 exons which is located on the long arm of
chromosome 21 (Kang et al., 1987; Goldgaber et al., 1987; Tanzi et al., 1987; Yoshikai et al.,
1991). It is a member of a larger gene family, the amyloid precursor-like proteins (APLPs)
(Slunt et al., 1994), which display substantial homology, both within the large ectodomain
and particularly within the cytoplasmic tail, but are largely divergent in the A region. APP
comprises a heterogeneous group of ubiquitously expressed polypeptides in all mammals
(Selkoe et al., 1988). This heterogeneity arises first of all from alternative splicing of the APP
gene, which yields three major isoforms of 695, 751, and 770 amino acid residues (APP770 is
illustrated in Figure 3). Moreover, APP can be modified by a variety of post-translational
modifications, including the addition of N- and O-linked sugars (glucosylation), sulfation,
and phosphorylation (Oltersdorf et al., 1990; Walter et al., 1997; Weidemann et al., 1989). The
APP splice forms containing 751 or 770 amino acids are widely expressed in non-neuronal
cells throughout the body and also occur in neurons (Tanaka et al., 1989). However, neurons
predominantly express the 695-residue isoform, which occurs at very low abundance in
nonneuronal cells (Haass et al., 1991). The difference between the 751/ 770- and 695-residue
isoforms is due to the presence of an exon that encodes a 56-amino acid motif homologous
to the Kunitz-type of serine protease inhibitors (KPI) specifically in the longer isoform
(Figure 3) (Tanzi et al., 1988), suggesting one potential function for the longer APP isoforms
(Selkoe, 2001). According to the Alzheimer Disease & Frontotemporal Dementia Mutation
Database (http://www.molgen.ua.ac.be/ADMutations; retrieved on July 1st, 2011), 32
pathogenic mutations have been identified within the APP gene from 89 EOAD families.
The effects of many of these mutations on APP processing have been assessed in
subsequent functional studies (Theuns et al., 2006).
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Figure 3. Schematic representation of the domain structure of APP770 isoform and APP
mutations genetically linked to familial AD or related disorders. APP is a type I membrane
protein with an extracellular N-terminus and cytosolic C-terminus. Cleavage at positions 672
and 713 by - and -secretases, respectively, generates A peptide. The sequence within APP
that contains the A and transmembrane region is expanded and shown by the single-letter
amino acid code. The residues highlighted in grey represent the A1–42 peptide (amino acids
672-713). The area shaded in light grey indicates the location of the transmembrane domain
(TM). The bold letters in light gray designated with arrows highlight the currently known
missense mutations identified in certain patients with FAD and/or hereditary cerebral
hemorrhage with amyloidosis. Three-digit numbers above these letters refer to the residue
number according to the APP770 isoform. The black numbers above the figure (1, 17, 41 and
43) indicate amino acids of A domain at the corresponding secretase (-, -, and 40/42)
cleavage sites. In some APP isoforms, such as APP770, there is an alternatively spliced exon
that is homologous to the Kunitz-type serine protease inhibitor (KPI) family (grey box) located
between amino acids 289-344.
APP is a single-pass, type I cell membrane glycoprotein which has a large ectodomain
containing the N-terminus and a small cytoplasmic domain containing the C-terminus
(Figure 3) (Lazarov et al., 2005). During maturation, the nascent immature APP
(N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex through the
constitutive secretory pathway where complete maturation occurs (O-glycosylated and
sulfated) (Thinakaran and Koo, 2008). The majority of APP localizes in the Golgi and TGN
or is degraded in the endoplasmic reticulum, and only a small fraction (~10%) enters the
secretory pathway (Kuentzel et al., 1993; Citron, 2000). Once APP reaches the cell surface, it
may be cleaved to sAPP or become rapidly reinternalized via clathrin-coated pits to
endosomes and lysosomes (Small and Gandy, 2006; Koo et al., 1996). Amyloidogenic
processing of APP yielding the A peptides mostly takes place in these subcellular
compartments. Some APP accumulates in the secretory transport vesicles leaving the late
Golgi compartment and returns to the cell surface (Huse et al., 2000). In non-neuronal cells,
APP is internalized within minutes of its arrival at the cell surface due to the presence of the
YENPTY internalization motif near the C-terminus of APP (residues 682–687 of the APP695
isoform). Subcellular sorting and targeting of APP upon endocytosis appears to be critical
in A production and AD etiology. The retrieval of APP from endosomes to TGN (Figure 4,
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pathway no. 3) was recently found to involve the retromer complex and intermediate
clathrin-coated endocytic vesicles that carry the early endosomal Rab GTPase 5 (Rab5)
marker (Vieira et al., 2010). It was shown that APP phosphorylation at residue S655 within
the APP 653YTSI656 basolateral motif enhances APP retrieval via the retromer-mediated
process. Additionally, the experimental phosphomimetic APP S655E mutant displayed
decreased APP lysosomal targeting, enhanced half-life, and a decreased tendency towards
 production. Downregulation of VPS35, a central component of the retromer complex,
impairs the phosphorylation dependent APP retrieval to the TGN, and decreases APP half-
life (Vieira et al., 2010). The pathways of APP trafficking are depicted in Figure 4.
Figure 4. Intracellular trafficking of APP. Nascent APP molecules (grey bars) mature on the
constitutive secretory pathway (1). Once APP reaches the cell surface, it is rapidly internalized
(2) and subsequently trafficked through endocytic and recycling compartments back to the cell
surface (3) or degraded in the lysosome (4). Some APP molecules also undergo retromer-
mediated recycling from the endosomes back to the TGN. Non-amyloidogenic processing occurs
mainly at the cell surface, where -secretases are present. Amyloidogenic processing involves
transit through the endocytic organelles, where APP encounters -and -secretases. (Adapted
from Thinakaran and Koo, JBC, 2008)
APP can be processed at the cell surface by -secretase-mediated cleavage, resulting in the
shedding of the sAPP ectodomain (Sisodia, 1992). Activation of protein kinase C (PKC)
increases sAPP secretion by mechanisms involving the formation and release of secretory
vesicles from the TGN, thus enhancing APP (and possibly -secretase) trafficking to the cell
surface (Thinakaran and Koo, 2008). Alternatively, the APP ectodomain may be shed at a
different site by BACE1. This initiates the amyloidogenic processing pathway and leads to
 release by -secretase-mediated cleavage.  BACE1 is predominantly localized in the late
Golgi/TGN and endosomes, consistent with the amyloidogenic cleavage of wild-type APP
during endocytic/recycling steps (Koo and Squazzo, 1994; Vassar, 2009). The -secretase
complex is present and enzymatically active in multiple compartments, including the ER,
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ER-Golgi intermediate compartment, Golgi, TGN, endosomes, and plasma membrane.
Studies conducted in non-neuronal and neuroblastoma cell lines have revealed that A is
generated mainly in the TGN and endosomes as APP is trafficked through the secretory
and recycling pathways (Figure 4) (Small and Gandy, 2006). Evidence emerging from a
number of studies also suggests that amyloidogenic processing of APP occurs in
cholesterol- and sphingolipid-enriched membrane raft microdomains of intracellular
organelles (Riddell et al., 2001; Ehehalt et al., 2003; Vetrivel et al., 2004, 2005).
2.2.1.2  generation, degradation, and clearance
In the context of AD, the metabolism of APP occurs via a complex process involving the
activity of three enzymes termed -, - and -secretases (LaFerla et al., 2007). The secretases
cleave only a small portion of the total pool of APP, leaving the majority as intact
full-length APP (De Strooper and Annaert, 2000). Intact APP has been postulated to
mediate neuronal and synaptic functions, such as neurite outgrowth and synaptogenesis,
neuronal protein trafficking along the axon, cell migration, and synapse remodeling (Zheng
and Koo, 2006). In the non-amyloidogenic pathway, APP is cleaved protelytically at its
extracellular domain by the -secretase at a site 83 amino acids from the carboxy (C)
terminus, producing a large amino (N)-terminal ectodomain (sAPP), which is secreted
into the extracellular milieu, having a 83-amino-acid long C-terminal fragment, C83
(Allinson et al., 2003; LaFerla et al., 2007) (Figure 5). C83 is subsequently cleaved by the
-secretase, producing a short 3-kDa fragment p3 and APP intracellular domain (AICD)
(Haass et al., 1993; De Strooper and Annaert, 2000). Importantly, cleavage by the -secretase
occurs within the A region, thereby precluding formation of A.
The amyloidogenic pathway is an alternative cleavage pathway for APP, which leads to A
generation. The initial proteolysis is mediated by the -secretase or BACE1 at a position
located 99 amino acids from the C-terminus. BACE1 initiates A generation by cleaving
APP at the Asp+1 residue of A N-terminus (Figure 5) (Vassar, 2004). This cut results in the
release of sAPP into the extracellular space, and leaves the 99-amino-acid C-terminal stub
(C99, or -C terminal fragment, -CTF) within the membrane, with the newly generated
N-terminus corresponding to the first amino acid of A (Haass et al., 1993). In addition,
BACE1 can also cleave within the A domain between Tyr10 and Glu11 (‘-cleavage site)
producing the C89 C-terminal fragment. Subsequent cleavage of C99 (between residues 38
and 43) by the -secretase liberates an intact A1–x peptide and AICD (Golde et al., 1992).
In contrast, -secretase cleavage of C89 would result in the production of A11–x. Most of
the full-length A peptide produced is 40 residues in length (A40), whereas a small
proportion (~10%) is the 42-residue variant (A42). The A42 isoform is more hydrophobic
and more prone to fibril formation than A40 (Jarrett et al., 1993), and it is also the form that
is predominantly found in cerebral plaques (Younkin, 1998). AICD, in combination with
Fe65, is delivered to the nucleus by retrograde transport (Goodger et al., 2009), where it
binds to histone acetyltransferase Tip60. This complex can facilitate transcription of specific
genes, e.g. NEP (Belyaev et al., 2009), APP, BACE, and GSK3 (Konietzko et al., 2010; von
Rotz et al., 2004) genes (Figure 5). The amyloidogenic processing involves APP transit
through the endocytic organelles, in which APP encounters the - and -secretases (Small
and Gandy, 2006).
It depends on the cell type which pathway – amyloidogenic or non-amyloidogenic – is
preferentially utilized. Amyloidogenic processing is the favoured pathway of APP
metabolism in neurons, largely due to the greater abundance of BACE1, whereas the non-
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amyloidogenic pathway is predominant in all other cell types (Thinakaran and Koo, 2007).
Non-amyloidogenic processing of APP occurs mainly in the late Golgi compartment or in
caveolae (plasma membrane invaginations) (Ikezu et al., 1998). It destroys the A sequence
and thus prevents A formation. Commitment of these pathways can be differentially
modulated by the activation of cell-surface receptors such as the serotonin 5-
hydroxytryptamine (5-HT4) receptor, metabotrobic glutamate receptors, glutamate
receptors, muscarinic acetylcholine receptors, and the platelet-derived growth factor
receptor (Thinakaran and Koo, 2007). In addition, in many instances, an increase in
non-amyloidogenic APP metabolism is coupled to a reciprocal decrease in the
amyloidogenic processing pathway, and vice-versa, as the - and -secretase moieties
compete for APP substrate (Cole and Vassar, 2007).
42 is more neurotoxic as a result of its higher hydrophobicity, which causes more rapid
oligomerization and aggregation (Blennow, 2006). Therefore, A42 is essential for the
initiation of AD pathogenesis. Thus far, various longer A species, such as A43, have been
qualitatively described in the brains of individuals with Alzheimer's disease (Miravalle et
al., 2005). Further quantitative studies have revealed that A43 is deposited more
frequently than A40 in both LOAD and EOAD (Iizuka et al., 1995; Parvathy et al., 2001;
Welander et al., 2009).
Previous studies (Qi-Takahara et al., 2005; Takami et al., 2009) have demonstrated that it is
the positions of -secretase cleavage that control which A forms are produced. A43,
generated from A49 via A46, is subsequently converted to A40, whereas A42 is
independently generated from A48 via A45. It has also been reported that A43 appears
to be as prone to aggregate in vitro as A42 (Jarrett et al., 1993), leading to faster formation
of oligomers than with A40 (Bitan et al., 2003). Recently, it was reported that A43 could
contribute to AD pathology in an in vivo experiment with knock-in mice containing a
pathogenic PS1 R278I mutation that caused overproduction of A43. This led to short-term
memory loss before plaque formation and considerably accelerated amyloid pathology in
these mice (Saito et al., 2011).
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Figure 5. Schematic representation of the processing of APP through amyloidogenic (left) and
non-amyloidogenic (right) pathways. Non-amyloidogenic processing of APP refers to sequential
processing of APP by membrane-bound - and -secretases. -Secretases (ADAM9, ADAM10
and ADAM17; LaFerla et al., 2007) cleave within the A-domain, thus precluding the generation
of intact A peptide. After -secretase cleavage, sAPP is released, leaving C83 on the
membrane. Subsequent -secretase cleavage generates extracellular p3 fragment and APP
intracellular domain (AICD). AICD, in combination with Fe65, is delivered to the nucleus by
retrograde transport, where it binds to histone acetyltransferase Tip60. This complex can
facilitate gene transcription e.g. of the NEP, APP, BACE, and GSK3 genes. Amyloidogenic
processing of APP is carried out by sequential action of membrane-bound - (BACE1) and -
secretases releasing sAPP and generating C99. -Secretase-mediated cleavage occurs mainly
in acidic intracellular compartments, such as in endosomes (not shown in the figure) (Haass et
al., 1993). Extracellular A forms oligomers known to inhibit LTP, a phenomenon indicating
synaptic strengthening. Oligomers can further aggregate to form protofibrillis and A plaques.
A oligomers and plaques are synaptotoxic and induce inflammation and neuronal death. A
monomers may be internalized, where cytotoxic oligomers are also formed. In functional
neurons, A, A oligomers, and AICD are degraded by IDE and NEP. The intraneuronal presence
of A oligomers has many adverse consequences, including the facilitation of tau pathology. Tau
is abnormally hyperphosphorylated, leading to the formation of paired helical filaments (PHFs)
and neurofibrillary tangles (NFT). Numerous kinases and phosphatases have been implicated in
the regulation of tau hyperphosphorylation, including GSK3, CDK5, MARK, and PP2A (Iqbal et
al., 2005).
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 degradation
The accumulation of A is thought to be central to the pathogenesis of AD (Hardy, 1997).
Consequently, factors involved in modulating A levels, and in particular A42, have been
most intensely studied during the last decade. The majority of these studies have focused
on processes involved in A production, particularly on the activities of -, and -secretase,
which cleave APP to liberate A. However, the mechanism of A accumulation in the case
of LOAD is less clear. There is evidence that degradation and clearance of A might serve
an equally, if not even more, important role in A accumulation (Mawuenyega et al., 2010).
Several candidate A peptidases that enzymatically degrade A are expressed both
neuronally and within the cerebral vasculature.
The two major endopeptidases involved in A degradation are zinc
metalloendopeptidases, referred to as insulin-degrading enzyme (IDE) or insulysin (Selkoe,
2001), and neprilysin (NEP). IDE is a 110-kDa enzyme that hydrolyzes several regulatory
peptides (Duckworth et al., 1998), including insulin, glucagon, atrial natriuretic factor,
transforming growth factor , -endorphin, amylin, A, and AICD. Most of the IDE is
localized in the cytosol, but unlike NEP, only a small fraction resides in the plasma
membrane. Farris et al. demonstrated that IDE knockout mice had increased endogenous
levels of A and AICD in the brain (Farris et al., 2003). Additionally, heterozygous IDE+/
mice exhibited A levels that are intermediate between wild-type controls and
homozygous IDE/ mice. It also has been shown that primary neuronal cultures derived
from these mice were less efficient at degrading radiolabeled A in vitro. In another study,
chronic transgenic overexpression of IDE (2-fold compared to endogeneous levels)
decreased both soluble and insoluble AX-40 and AX-42 levels by 50% in mice
overexpressing human APP717 and APP670/671 missense mutations (Leissring et al., 2003).
Conversely, a 50% reduction in plaque burden was observed in these APP/IDE double
transgenic mice, and there was a significant reduction in the rate of premature death as
compared to the situation in age-matched APP transgenic littermates.
The other major peptidase responsible for the degradation of A is NEP. This is a type II
membrane protein and, like IDE, hydrolyzes circulating biologically active peptides,
including enkephalin, cholecystokinin, neuropeptide Y, and substance P (Turner et al.,
2001). NEP enzyme functions mostly in the brain where its localization on the plasma
membrane with its catalytic site exposed extracellularly makes this peptidase a prime
candidate for peptide degradation at extracellular sites of amyloid accumulation i.e., A-
containing diffuse deposits and neuritic plaques (Miners et al., 2008). A recent study noted
that NEP was able to decrease ipsilateral cortical amyloid deposits by 50% when human
NEP was injected intracerebrally via a lentiviral vector in a transgenic mouse model of
cerebral amyloidosis (Marr et al., 2003).
There are other potential metalloendopeptidase candidates, such as endothelin-converting
enzyme or ECE, as well as properly positioned circulating serine proteases, such as
urokinase-type plasminogen activator (uPA), tissue plasminogen activator (tPA), and
plasmin, which have been suggested to be able to degrade A. The latter three – uPA, tPA,
and plasmin – are anticipated to have a more significant impact on cerebrovascular amyloid
deposits or congophilic amyloid angiopathy (CAA) (Selkoe, 2001). Moreover, the
proteasome may play a key role in degrading intracellularly localized A, for example, as
part of the process of endoplasmic reticulum (ER)-associated proteolytic degradation
(Schmitz et al., 2004). One potential molecule in A proteolysis is transthyretin (TTR), which
has been shown to bind to A in the CSF and thus decrease A aggregation (Schwarzman
et al., 1994). A cleavage by TTR was inhibited in the presence of sAPP peptide containing
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the KPI domain but not in the presence of sAPP derived from the APP isoform 695
without the KPI domain. TTR is able to proteolytically cleave A at multiple sites (Costa
et al., 2008) and its over-expression was shown to protect APP23 AD mice from A toxicity
and also from the subsequent behavioral impairment (Buxbaum et al., 2008). Overall, the
literature emphasizes the importance of the major A-degrading enzymes, IDE and NEP, in
vivo and one could postulate that even moderate increases in IDE activity could lead to
dramatic changes in steady-state A levels as well as in the overall amyloid plaque burden.
Further support for the role of IDE in AD pathogenesis stems from reports of its genetic
association with LOAD (Tanzi et al., 2004).
 clearance
There is substantial evidence showing that the low-density lipoprotein receptor-related
protein (LRP) and the receptor for advanced glycation end products (RAGE) are involved
in receptor-mediated flux of A across the blood-brain barrier (BBB) (Zlokovic, 2004). Both
LRP and RAGE are cell surface receptors. LRP mediates the efflux of A from the brain to
the periphery, whereas RAGE is responsible for A influx back into the CNS. Additionally,
there is some evidence to suggest that 10 to 15% of A can pass into the CSF from the brain
interstitial fluid and onward into the bloodstream (Shibata et al., 2000).
LRP is a lipoprotein receptor with multifunctional signaling and scavenging properties on
the capillary endothelium. It can bind a variety of ligands, such as APP, APOE,
-2-macroglobulin (2M), and A (Herz, 2003). LRP antagonists have been shown to
specifically reduce the efflux of A from brain by up to 90% (Shibata et al., 2000) in mice
injected with radiolabeled A40. In another study, a 2-fold increase in cerebral amyloid
load was observed in AD animal models expressing low levels of LRP at the BBB (Van
Uden et al., 2002). In the process of LRP-mediated clearance, A can be transported across
the BBB and exported out of the brain into the bloodstream by direct binding to LRP
(Deane et al., 2004) or by first forming a complex with the LRP ligands, 2M or apoE on the
abluminal (=directed away from the lumen of a tubular structure) side of the endothelium.
The latter A/chaperone complex then binds to LRP and becomes internalized. LRP-ligand
complexes are then internalized to late endosomes, after which they can either be delivered
to lysosomes for subsequent degradation or be targeted for transcytosis across the BBB into
the plasma (Herz, 2003). On the other hand, fibrillogenic forms of A, which accumulate in
AD brain, may be difficult to remove from the CNS via LRP, because LRP favors the
clearance of A40 over the more detrimental A42 (Deane et al., 2004). The same study also
showed that A can promote the proteasome-dependent degradation of LRP, which may
explain the relatively low LRP activity in brain microvessels in AD patients and mutant
APP mouse models of -amyloidosis (Bertram and Tanzi, 2004).
Once A enters the bloodstream, it can gain re-entry to brain via RAGE, which is the
receptor most probably responsible for transport of A through the BBB (Zlokovic, 2004).
RAGE is a multifunctional receptor belonging to the immunoglobulin superfamily. Like
LRP, it can bind a large array of different ligands (Yan et al., 2000), one of which is A.
RAGE has been implicated in the regulation of neurite outgrowth and cell migration
(Huttunen et al., 2002, Srikrishna et al., 2002). In animal studies, it has been shown that
down-regulation of RAGE inhibits the influx of A from the periphery into the CNS (Deane
et al., 2003). Furthermore, the binding of A to RAGE is able to stimulate cellular responses
that are potentially pathological, including expression of proinflammatory cytokines and
decreased cerebral blood flow (Zlokovic, 2004). gp330/Megalin is another protein that has
been reported to transport circulating plasma A back into the brain in a complex with
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APOJ/clusterin (Zlokovic et al., 1996). However, since gp330/megalin is normally saturated
by abundant amounts of plasma APOJ/clusterin under physiological conditions, RAGE is
the most probable receptor responsible for the transport of A back into the brain
(Zlokovic, 2004).
2.2.2 Secretases processing APP
2.2.2.1 - and -secretase
Several zinc metalloproteinases, such as TACE (TNF converting enzyme)/ADAM17 (a
disintegrin and metalloprotease 17), ADAM9, ADAM10 and MDC-9
[metalloprotease/disintegrin/cysteine-rich protein, also known as meltrin  (Koike et al.,
1999)], and the aspartyl protease BACE2 can cleave APP at the -secretase cleavage site
within the A domain between Lys16 and Leu17 (Koike et al., 1999; Lammich et al., 1999;
Slack et al., 2001). The cleavage at this site precludes the generation of A (Allinson et al.,
2003). -Secretase cleavage generates sAPP, which has neurotrophic and neuroprotective
properties (Furukawa et al., 1996; Meziane et al., 1998; Stein et al., 2004; Hiltunen et al., 2009).
A recent in vitro study using a new, sAPP-specific antibody and two different cell lines as
well as primary neurons expressing endogenous APP, strongly suggests ADAM10, but not
ADAM9 or ADAM17, is the main -secretase for constitutive -cleavage in neurons (Kuhn
et al., 2010).
-Secretase is composed of four essential subunits: presenilin-1 or -2 (PSEN1 and PSEN2),
nicastrin, anterior pharynx-defective 1 (Aph-1), and presenilin enhancer (PEN-2) (Figure 6)
(Iwatsubo et al., 2004; Kaether et al., 2006). -Secretase attacks at multiple sites within the
transmembrane domain of APP, generating Apeptides of different lengths and releasing
AICD (Selkoe and Wolfe, 2007). Nearly 90% of secreted A ends in residue 40, whereas
42 accounts for approximately 10% of the secreted A (Thinakaran and Koo, 2008).
Moreover, minor amounts of longer (such as A43) as well as shorter (e.g. A38 and A37)
 peptides are also generated. Interestingly, familial AD-linked mutations in PSEN1 and
PSEN2 genes influence the specificity of the -secretase cleavage site by favoring
breakdown at position 42 relative to that at position 40, thus increasing the A42/40 ratio
(Selkoe and Wolfe, 2007). In addition to APP, -secretase has been shown to metabolize a
large number of other proteins as well. This suggests that in addition to its
pathophysiological role in AD, -secretase plays an important role in the normal
physiological signaling of a variety of proteins (Haapasalo and Kovacs, 2011).
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Figure 6. Schematic representation of membrane bound -secretase complex illustrating its
essential components Presenilin, Nicastrin, Aph-1 and Pen-2. Presenilin contains 9
transmembrane domains (TMDs; numbered) and the catalytic aspartic acid residues are marked
with stars in TMDs 6 and 7. N- and C-terminal fragments (NTFs and CTFs, respectively) of
presenilin are formed after proteolysis at the large cytoplasmic loop. Aph-1, anterior
pharynx-defective 1; Pen-2, presenilin enhancer 2. (Courtesy of A. Haapasalo).
2.2.2.2 BACE1
BACE1 (-site APP-cleaving enzyme 1), also known as Asp2 (novel aspartic protease 2) or
memapsin2 (membrane aspartic protease/pepsin 2), is a transmembrane aspartyl protease
and the major neuronal -secretase.  BACE1 mediates the first critical rate-limiting step in
 formation by creating the free N-terminus of A (Vassar et al., 1999; Vassar, 2002, 2009;
Citron, 2000). The BACE1 cleavage site is located at the N-terminus of A at Asp1.
BACE1-mediated cleavage generates a secreted N-terminal fragment, sAPP, and a
membrane-bound A-containing C-terminal fragment, CTF- (also referred to as C89 and
C99). sAPP seems to have a proapoptotic function (Nikolaev et al., 2009). Generation of the
N-terminus is followed by a C-terminal cleavage of the remaining CTF- by -secretase to
release the final A-product. In addition, BACE1 can also cleave within the A domain
between Tyr10 and Glu11 (’-cleavage site). BACE1 gene is located in chromosome 11
(Vassar, 2002).
BACE was independently discovered by five different laboratories approximately ten years
ago (Vassar et al., 1999; Yan et al., 1999; Sinha et al., 1999; Hussain et al., 1999; Lin et al., 2000).
There are two major forms of the enzyme, BACE1 (501 amino acids) and BACE2 (518 amino
acids). Their coding regions are 45% identical (Yan et al., 1999) and coding sequences 75%
homologous, but they show no similarity in their promoter regions (Sun et al., 2005). In
another study using the GrowTree algorithm comparison (Wisconsin Sequence Analysis
Package), BACE1 was shown to share 64% amino acid similarity with BACE2 (Bennett et al.,
2000). BACE2 interestingly maps in the long arm of chromosome 21 in the obligatory Down
syndrome region (Saunders et al., 1999). It also cleaves APP, but BACE1 has a much greater
preference for APP than BACE2 (Farzan, et al., 2000; Hussain et al., 2000). Two aspartic
protease active site motifs in the sequence DTGS (residues 93-96) and DSGT (residues 289-
292) are present in BACE1, and mutation of either aspartic acid renders the enzyme inactive
(Figure 7) (Hussain et al., 1999; Bennett et al., 2000; Vassar, 2009). BACE1 has an N-terminal
signal peptide sequence (SP) (residues 1-21) and a propeptide domain (Pro) (residues 22-45)
that are removed post-translationally, with the mature enzyme beginning at residue Glu46.
Importantly, BACE1 has a single transmembrane domain (TM) near to its C-terminus
(residues 455-480) (Vassar et al., 2009). Thus, BACE1 is a type I membrane protein with a
lumenal active site, which are features predicted for the -secretase. The position of the
BACE1 active site within the lumen of intracellular compartments suggests that BACE1
possesses the correct topological orientation to undertake cleavage of APP at the -secretase
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site. As observed with other aspartic acid proteases, BACE1 has six luminal cysteine
residues that form three intramolecular disulfide bonds and several N-linked glycosylation
sites (Haniu et al., 2000).
Figure 7. Structure of the 501 amino acid long BACE1 protein showing the signal peptide (SP),
propeptide domain (Pro), and active site motifs D92TG and D289SG (asterisks). Furin is a major
BACE1 proprotein convertase. The arrow indicates the N-terminal position (Glu46) where the
mature BACE1 is cleaved in the Golgi apparatus before targeting via the secretory pathway to
the plasma membrane. BACE1 is phosphorylated by casein kinase 1 on Serine 498 (Ser498),
and this phosphorylation together with a C-terminal dileucine motif (adjacent to Ser498)
regulates BACE1 recycling between the cell surface and endosomal compartments (Huse et al.,
2000; Walter et al., 2001). The numbers below indicate the first and the last amino acid of
BACE1. C’/N’, C-/N-terminal domain; TM, transmembrane domain.
BACE1 primarily localizes in the Golgi apparatus and late endosomes, which is consistent
with its optimal activity at low pH (Vassar et al., 1999). BACE1 is highly expressed in brain
and pancreas, but is also found in other organs although at low levels (Vassar et al., 1999;
Marcinkiewicz and Seidah, 2000). In contrast, BACE2 is present at varying levels in most
peripheral tissues with the highest levels being found in the kidney (Bennett et al., 2000).
Within the brain, BACE2 is believed to reside mostly in astrocytes, whereas BACE1 is
largely neuronal (Basi et al., 2003; Irizarry et al., 2001). BACE2 cleaves APP between Phe19
and Phe20 (Cole and Vassar, 2007) which abolishes the A production. A recent study has
indicated that BACE2 has a role in insulin receptor trafficking, which is a critical step in
insulin signaling and sensitivity. Therefore BACE2 might function as a sensor in the plasma
membrane to signal mobilization of the insulin receptor -subunit (IR) (Casas et al., 2010).
BACE1 has its maximal enzymatic activity at acidic pH, since agents that elevate
intracellular pH also inhibit -secretase activity (Haass et al., 1993). Moreover, -secretase
activity is highest in the acidic subcellular compartments of the secretory pathway,
including the Golgi apparatus and endosomes (Vassar, 2002). These data suggest that the
active site of -secretase is located within the lumen of acidic intracellular compartments.
Site-directed mutagenesis of the amino acids surrounding the cleavage site in APP has
demonstrated the sequence specificity of the -secretase (Citron et al., 1995). Substitutions
with a large hydrophobic amino acid (such as Leu found in the Swedish FAD mutation) at
the Met residue at P1 site before the BACE1 cleavage site in APP improve the efficiency of
the -secretase-mediated cleavage (Figure 5). Conversely, substitution with a small
hydrophobic amino acid, Val, at the same position inhibits the cleavage. Many other
substitutions at this site or at surrounding positions decrease cleavage activity evidence
that the -secretase cleavage is highly sequence-specific.
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2.2.2.3 Intracellular trafficking and post-translational modifications of BACE1
Attempts to gain insights into the regulation of BACE1 and to identify potentially
therapeutic targets in the -secretase pathway must be based on an understanding of the
cell biology of BACE1 protein, particularly its post-translational modifications and
intracellular trafficking. BACE1 is initially synthesized in the endoplasmic reticulum (ER)
as an immature precursor protein (proBACE1) with a molecular mass of ~60 kDa (Haniu et
al., 2000; Huse et al., 2000). ProBACE1 is short-lived and undergoes rapid maturation into a
~70 kDa form in the Golgi apparatus. This process involves addition of complex
carbohydrates and removal of the propeptide domain (Figure 7). The mature enzyme is
quite stable, having a half-life of over 9 h in cultured cells. Unusually, the propeptide
domain does not suppress protease activity, and proBACE1 may cleave APP to generate a
potentially toxic intracellular A pool (Cole and Vassar, 2007). BACE1 is glycosylated at
four N-linked sites, but does not exhibit O-glycosylation (Haniu et al., 2000). The
N-glycosylation of BACE1 affects its protease activity, since abolishing two out of four N-
linked sites by site-directed mutagenesis significantly reduces -secretase activity
(Charlwood et al., 2001). Glycosylation may not directly affect BACE1 activity, but it may
promote proper folding, and modify the solubility, or stability of the BACE1 protein.
Mature N-glycosylated moieties of BACE1 are sulfated. Furthermore, three cysteine
residues within the cytosolic tail of BACE1 can be palmitoylated, which might influence
BACE1 intracellular localization or trafficking (Benjannet et al., 2001). Although the majority
of BACE1 in cells is produced as an integral membrane protein, a small fraction of BACE1
undergoes ectodomain shedding, a process that is suppressed by palmitoylation. Co-
overexpression of APP and the soluble ectodomain of BACE1 in cells appears to enhance
the generation of A, suggesting that BACE1 ectodomain shedding may increase the
amyloidogenic processing of APP (Benjannet et al., 2001).
Related to intracellular trafficking of BACE1, a recent study demonstrates that BACE1 is
sorted to early endosomes via a route controlled by the small GTPase ADP ribosylation
factor 6 (ARF6) (Sannerud et al., 2011). Alterations in ARF6 levels or its activity affects
endosomal sorting of BACE1, and consequently results in altered APP processing and A
production. Furthermore, sorting of newly internalized BACE1 from ARF6-positive
towards Rab5-positive early endosomes depends on its C-terminal short acidic
cluster-dileucine motif. This ARF6-mediated sorting of BACE1 is confined to the
somatodendritic compartment of polarized neurons in agreement with A peptides being
primarily secreted from this site. This study demonstrated a spatial separation between
APP and BACE1 during surface-to-endosome transport, pointing to subcellular trafficking
as a regulatory mechanism for this proteolytic processing step (Sannerud et al., 2011).
BACE1 is localized in cholesterol-rich lipid rafts, and specific lipids stimulate BACE1
activity (Vetrivel et al., 2009). Although BACE1 homodimers exhibit enhanced catalytic
activity, the protease interacts with several other proteins (e.g. reticulon/Nogo proteins,
SorLA/LR11) that modulate the BACE1-APP interaction and/or BACE1 activity (Cole and
Vassar, 2007). Such interactions may provide clues for the therapeutic strategies to inhibit
BACE1. Signals, including the acid cluster-dileucine motif in the C-terminal tail, control
BACE1 trafficking and subcellular localization.  Members of the GGA (Golgi localized -
ear-containing ADP-ribosylation factor (ARF) -binding) protein family interact with BACE1
to regulate this process (discussed further in chapter 2.2.2.5) (Tesco et al., 2007).
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2.2.2.4 BACE1 functions in the amyloidogenic pathway
Interestingly, the mutations in APP that cause familial AD are all located near to the
secretase cleavage sites and they directly affect the efficiency or position of the cleavages.
For example, the Swedish mutation is the amino acid substitution LysMetAsnLeu at the
P2-P1 positions immediately N-terminal to the -secretase cleavage site in APP (Mullan
et al., 1992) (Figures 3 and 8). This mutation makes APP a much better substrate for
-secretase and dramatically increases the efficiency of cleavage at the -secretase site
leading to increased production of A. Several other familial AD mutations have been
identified near the -secretase cleavage site and these mutations shift the position of
-secretase cleavage and specifically lead to increased generation of A42 (Hutton et al.,
1998). Familial AD mutations also exist near the -secretase site. These mutations appear to
reduce the efficiency of -secretase cleavage, thus providing more APP for -
secretase-mediated cleavage and potentially leading to enhanced production of A (Vassar,
2004). Moreover, high level neuronal expression of BACE1 preferentially channels APP
through the amyloidogenic processing pathway in the brain (Thinakaran and Koo, 2008).
Figure 8. APP cleavage sites of -, -, and -secretase. Schematic structure of APP is shown with
 domain shaded in grey and enlarged. The sites of cleavage by -, -, and -secretases are
indicated along with A numbering from the N-terminus of A (Asp1). Another BACE cleavage
site (’) is also indicated. TM, transmembrane domain.
Evidently, BACE1 is critical for A generation, and normal neuronal A production
indicates that the peptide may have physiological function(s). Indeed, the complete absence
of A in BACE1/ mice caused a specific memory impairment, suggesting that A is
required for normal memory (Ohno et al., 2004). This is consistent with the involvement of
 also in non-pathogenic neuronal function (Kamenetz et al., 2003). Although neuronal
BACE1 can cleave a large proportion of APP, APP is predominantly broken down by -
secretase in non-neuronal tissues. Recent studies have shown that several other putative
BACE1 substrates exist in addition to APP (Cole and Vassar, 2007), implicating BACE1 in
the regulation of different physiological functions. The identification of neuregulin-1 and
the sodium channel 2-subunit as BACE1 substrates implicates BACE1 function in
myelination and neuronal activity, respectively (Cole and Vassar, 2007; Kim et al., 2005,
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2007; Willem et al., 2006; Wong et al., 2005). Furthermore, many of these novel putative
BACE1 substrates are involved in the response to stress and/or injury (Cole and Vassar,
2007). The fact that BACE1 levels are elevated under stressful conditions suggests that
BACE1 functions as a stress-response protein and that cleavage of specific BACE1
substrates may facilitate recovery after acute stress/injury. It has also been hypothesized
that elevated BACE1 levels become pathogenic and facilitate harmful A formation during
chronic stress or injury (Cole and Vassar, 2007; Hiltunen et al., 2009).
Recent findings propose that BACE1 is able to cleave APP efficiently in both lipid raft and
non-raft microdomains (Vetrivel et al., 2009). Moreover, it seems that cholesterol is not only
important in -amyloidogenic processing of APP, but it is also able to modulate
-induced neurotoxicity in AD (Fernández et al., 2009). In addition to this, BACE1
expression is regulated in a transcriptional (Guglielmotto et al., 2009) and translational
manner (O’Connor et al., 2008) during different stress conditions. Energy deprivation
induces phosphorylation of the translation initiation factor eIF2 leading to increased
BACE1 levels both in vitro and in vivo (O’Connor et al., 2008). This study showed that
BACE1 is translationally controlled by its complex 5’-untranslated region encompassing
three upstream open reading frames, which regulate the translation of BACE1 mRNA
depending on the eIF2 phosphorylation status.
Since its discovery almost a decade ago, there have been major advances in the
understanding of BACE1 function and regulation. However, despite the promising reports
of BACE1 inhibitor development, routine clinical use of such therapeutic agents for AD
treatment is yet to become a reality. Although there is good reason to believe that BACE1 is
the principle -secretase responsible for the production of A in the brain, its physiological
role in the brain and in AD is not fully understood. Several studies support the concept that
regulation of BACE1 expression in AD is a complex process, which likely involves several
regulatory mechanisms simultaneously affecting BACE1 levels and activity.
2.2.2.5 BACE1 and GGA3
GGA1, 2, and 3 (Golgi-localized -ear-containing ARF binding proteins) are monomeric
adaptor proteins that are recruited to the TGN by the ARF1-GTPase. Recent studies have
indicated that GGA proteins are key regulators of BACE1 levels in cells (Tesco et al., 2007).
GGAs consist of four distinct segments: a VHS [VPS27 (Vacuolar protein sorting protein
27), Hrs (Hepatocyte growth factor-regulated substrate), and STAM (Signal-transducing
adaptor molecule)] domain that binds the acidic dileucine sorting signal DXXLL; a GAT
(GGA and Tom1) domain, which binds ARF:GTP; a hinge region which recruits clathrin;
and a GAE (-adaptin ear homology) domain, which exhibits sequence similarity to the ear
region of -adaptin and recruits a number of accessory proteins (Figure 9) (Tesco et al.,
2007). GGAs are necessary for the sorting of acid hydrolases to the lysosomes. Newly
synthesized acid hydrolases modified with mannose 6-phosphate groups bind to mannose
6-phosphate receptors (MPRs). MPRs bind to the VHS domain of GGAs via the DXXLL
motif (Bonifacino, 2004). GGAs are likely involved in the transport of proteins containing
the DXXLL signal from the Golgi complex to the endosomes (Kang et al., 2010) and also in
the delivery of endosomal cargoes to lysosomes (Tesco et al., 2007). However, recent studies
have shown that cargo proteins can be recruited in the GGA pathway not only by the di-
leucine sorting motif but also by ubiquitin (Puertollano and Bonifacino, 2004; Scott, et al.,
2004; Lauwers et al., 2009). It has been shown that RNAi-mediated silencing of GGA1,
GGA2, and GGA3 significantly increases the levels of BACE in endosomes (He et al., 2005).
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Figure 9. A schematic representation of GGA3 (Golgi-localized -ear-containing ARF binding
protein 3) illustrating its four distinct domains: a VHS (VPS27, Hrs, and STAM) domain that
binds the acidic di-leucine sorting signal, DXXLL in the BACE1 C-terminal fragment; a GAT (GGA
and Tom1) domain that binds ARF:GTP; a hinge region which recruits clathrin; and a -adaptin
ear homology domain that recruits a number of accessory proteins.
GGA3 is responsible for targetting BACE1 to the lysosomes for degradation. Previously
Tesco et al. demonstrated that RNAi-mediated depletion of GGA3 resulted in impaired
degradation of BACE1, consequently increased levels and activity of BACE1 and elevated
 levels in vitro (Figure 10) (Tesco et al., 2007). Importantly, both in vitro and in vivo
experiments have revealed that GGA3 is cleaved by activated caspase-3 and that the
depletion of GGA3 resulted in increases in BACE1 levels and activity through post-
translational stabilization. This finding is important in the context of AD, because apoptosis
induced by oxidative stress plays an essential role in the disease pathogenesis (Greeve et al.,
2000). Moreover, it emphasizes the importance of post-translational regulation of BACE1
levels and activity. Furthermore, it has been shown that GGA3 regulates BACE1
degradation via binding to the ubiquitin sorting machinery, and this regulation does not
require an interaction with the VHS/di-leucine motif (Kang et al., 2010) corroborating the
fact that GGA3 is an important mediator in post-translational regulation of BACE1 levels.
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Figure 10. Model of BACE1 stabilization during apoptosis. (A) Under normal conditions, BACE1 is
transported (1) from the trans-Golgi network (TGN) to the plasma membrane (PM). There it
undergoes endocytosis (2a) into endosomes (E). Alternatively, BACE1 can directly traffic to the
endosomes from TGN (2b). In the endosome, GGA3 binds to the cytosolic tail (dileucine motif)
of BACE1 and targets it (3) to the lysosome (L) for degradation. Caspase-3 is inactive under
normal conditions (4). (B) During apoptosis, caspase-3 is activated. As a result, BACE1 sorting
to the lysosome is reduced (3), thereby stabilizing BACE1 in the endosome where it
accumulates and elevates A generation. TGN, trans-Golgi network; E, endosome; L, lysosome;
PM, plasma membrane. (Adapted from Vassar, Neuron, 2007).
2.2.3 Tau hyperphosphorylation
Another histopathological hallmark in AD is the formation of intraneuronal filamentous
inclusions or neurofibrillary tangles (NFT) that are composed of aggregated
hyperphosphorylated tau protein (Buee et al., 2000). Tau is transcribed from the MAPT
(Microtubule-associated protein tau) gene on chromosome 17q21. Tau proteins belong to
the family of microtubule-associated proteins (MAP) (Grundke-Iqbal et al., 1986). The six
tau isoforms that are generated by alternative splicing of the MAPT gene are differentially
expressed in neurons (Buee et al., 2000). In the normal brain, tau stabilizes axonal
microtubules, modulates signal transduction, interacts with the actin cytoskeleton,
modulates neurite outgrowth, anchors enzymes such as kinases and phosphatases, and
regulates intracellular vesicle transport (Hernandez and Avila, 2007). The abnormal tau
modifications found in AD include hyperphosphorylation, glycation, ubiquitination,
oxidation, and truncation and these typically enhance tau aggregation and interfere with
the normal functions of tau (Hernandez and Avila, 2007).
In AD, tau undergoes abnormal hyperphosphorylation. This may result from either
increased activity of the kinases that phosphorylate tau (such as GSK3, CDK5, and MARK;
see also figure 5) or decreased activity of phosphatases, such as PP1, PP2A and PP2B, that
dephosphorylate tau (Iqbal et al., 2009). Phosphorylated tau may be degraded by the
ubiquitin-proteasome system (Iqbal et al., 2009). However, tau hyperphosphorylation leads
to tau accumulation and aggregation and consequently to destabilization of microtubules.
This can cause an impairment in axonal transport and neuronal dysfunction. Self-assembly
of hyperphosphorylated tau results in the formation of NFTs (Iqbal et al., 2009).
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There is an increasing amount of evidence suggesting that A may induce tau pathology by
a variety of mechanisms. For example, inflammation triggered by the accumulation of
extracellular A deposits alters the cytokine profile in the brain, creating an environment
that is favourable for the formation of tau pathology (Kitazawa et al., 2005). Interestingly,
different forms of A may differentially induce tau pathology. Extracellular A plays a role
in the inflammation-mediated induction of pathogenic tau hyperphosphorylation, but
oligomeric intraneuronal A alters CHIP [C-terminus of Hsc70 (heat-shock cognate 70)-
interacting protein] levels and thus induces pathogenic tau hyperphosphorylation (Oddo et
al., 2008). In a recent study, Jin et al. used extracts which had been purified directly from the
brains of AD patients, and demonstrated for the first time that these isolated A dimers of
human origin were able to induce tau hyperphosphorylation at AD-relevant epitopes and
evoke neuritic degeneration in primary cultures of rat neurons (Jin et al., 2011). This study
strongly supports not only the validity of amyloid cascade hypothesis but also the idea
according to which A deposits are in a close relationship to neurofibrillary tangle
formation in AD pathogenesis.
The MAPT gene encoding tau is not genetically linked to AD, but tau mutations cause
FTDP-17 (Frontotemporal dementia with Parkinsonism linked to chromosome 17) (Hutton
et al., 1998). The identification of disease-causing mutations in tau supports the hypothesis
that tau dysfunction is involved in the neurodegeneration (Hutton et al., 1998). The lack of
genetic association to AD, however, further corroborates the suspicion that tau lies
downstream of A in the neurodegenerative cascade (LaFerla and Oddo, 2005).
2.2.4 -associated toxicity
Much AD research has focused upon determining the mechanisms underlying
-associated toxicity. One major area of research has centered around calcium-mediated
neurotoxicity. A peptides can (i) increase calcium influx through voltage-gated calcium
channels (N- and L-type channels); (ii) reduce magnesium blockade of NMDA receptors to
allow increased calcium influx, and (iii) form a cation-selective ion channel after A peptide
incorporation into the cellular membrane (Pearson et al., 2000; Kawahara and Kudora, 2000;
Zhu et al., 2000). Cation channels are induced by soluble A peptides (Bhatia et al., 2000).
Thus, A peptides may be toxic even prior to fibril formation. There is recent evidence to
suggest that copper and zinc may modulate the structure of the A peptides to allow either
their pore formation or their precipitation (Curtain et al., 2001).
It is evident that there is a reciprocal interaction between calcium and A pathology
(Supnet and Bezprozvanny, 2010; Demuro et al., 2010). A plaques have been shown to
impair calcium homeostasis in the mouse models of AD (Kuchibhotla et al., 2008), while
sustained increase in cytosolic calcium levels induced by KCl-mediated depolarization in
neuronal cultures triggered intraneuronal A1-42 production and neuronal death (Pierrot
et al., 2004). Furthermore, due to the interaction of soluble A oligomers with certain lipids
and receptors at the plasma membrane, increased calcium influx could well be an outcome
of disrupted membrane lipid integrity, A-mediated pore formation, or modulation of
certain ion channels, such as NMDA and AMPA receptors (Demuro et al., 2010). In
addition, it was recently shown that APP could regulate intracellular trafficking of
voltage-gated L-type calcium channels (Cav1.2) by retrieving Cav1.2 into intracellular
compartments away from the plasma membrane (Yang et al., 2009). This means that
alterations in APP expression or its processing can affect the levels of Cav1.2 at the plasma
membrane and thus modulate calcium influx.
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Many neurodegenerative disorders are characterized by the formation of insoluble
inclusions. However, recent evidence indicates that these deposits might not be directly
responsible for the primary neurotoxic effects and memory loss in these disorders. The
inclusions might function as a reservoir for soluble oligomers, which are able to diffuse
through the brain parenchyma and into synaptic clefts. Insoluble deposits and diffusible
oligomers in different diseases are composed of diverse amyloidogenic proteins, such as A
tau, prion protein (PrP), -synuclein, or huntingtin. These might share common structural
epitopes and mechanisms of neurotoxicity and memory impairment (Kayed et al., 2003).
The identification of soluble, diffusible oligomers of A that are capable of interfering with
synaptic function and integrity could provide an important new perspective for
understanding the basis of memory loss in AD (Haass and Selkoe, 2007).
Other major areas of research regarding A toxicity include the enhancement of
excitotoxicity via reduction of inhibitory signals, induction of inflammatory responses, and
free radical formation. A peptides induce the release of pro-inflammatory cytokines that
trigger an inflammatory cascade resulting in neuronal death (Manelli et al., 1995; Leonard
et al., 2001). Production of reactive oxygen species (ROS), including nitric oxide, is regulated
by multiple factors including calcium, inflammatory cascades, and mitochondrial processes
(Law et al., 2001; Leonard et al., 2001).
2.2.5 Amyloid cascade hypothesis
A series of genetic and experimental findings form the basis of the amyloid cascade
hypothesis that was first introduced in 1991 to describe the progression of AD pathogenesis
(Hardy and Allsop, 1991; Hardy and Selkoe, 2002; Tanzi and Bertram, 2005). This
hypothesis represents a causality model, in which the increased A levels are the prime
pathogenic driver leading to a series of molecular downstream events (e.g. tau
hyperphosphorylation) and, subsequently, histological and clinical features of AD (Figure
7). In familial EOAD, mutations in the APP, PSEN1 and PSEN2 genes increase A
production. Additionally, A levels are strongly elevated in the brain of DS patients due to
increased APP gene dose. The mechanism by which excessive A accumulation occurs in
LOAD remains unclear. Reduced A clearance and/or degradation is one potential
mechanism leading to increased cerebral A levels in AD. However, it is also possible that
minor increases in A production over time may tip the balance toward A accumulation
(Cole and Vassar, 2007). The histological and clinical phenotypes of EOAD and LOAD,
however, are rather similar, and thus the amyloid cascade hypothesis has been proposed to
underlie all forms of AD. In particular, the increased production of A oligomers is linked
to synaptic toxicity, A aggregation, and amyloid plaque formation (Figure 11 and 12; see
also Figure 5), which eventually initiates inflammatory response by activating microglia
and astrocytes. The increased production of ROS affects the activation of different kinases
and phosphatases, leading to tau hyperphosphorylation and formation of PHFs and NFTs.
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Figure 11. Amyloid cascade hypothesis. According to this hypothesis, the central event in the
disease pathogenesis is an imbalance between A production and clearance. In FAD, there is
increased A production, whereas A clearance is decreased in sporadic disease. A oligomers
could directly inhibit hippocampal long-term potentiation and impair synaptic function, while
aggregated and deposited A causes inflammatory reaction and oxidative stress. These
processes impair neuronal and synaptic function and consequently result in deficits in
neurotransmission and cognitive symptoms. Tau pathology with tangle formation is regarded as
a downstream event, but it could contribute to neuronal dysfunction and the cognitive
symptoms (Tanzi et al., 2004). (Adapted from Blennow et al., 2006, and Hardy and Selkoe,
2002).
Since the introduction of the original amyloid cascade hypothesis more than two decades
ago, several additional molecular players have been postulated to affect the disease
pathogenesis. Related to this, a novel dual hypothesis was created (Small and Duff, 2008).
This hypothesis links A and tau as drivers of LOAD through independent but parallel
mechanisms (Figure 12). Several lines of evidence favour this alternative hypothesis. First,
the major risk gene in AD, APOE, has been shown to associate with an increased risk of
developing both EOAD and LOAD (Tanzi and Bertram, 2005). Second, APOE has been
shown to affect both A and misfolded tau formation via separate mechanisms (Brecht
et al., 2004; Harris et al., 2003; Huang et al., 2001). APOE4 allele was proposed to be linked
to decreased A clearance (Bales et al., 2002; DeMattos et al., 2004; Dodart et al., 2005). On
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the other hand, the same allele was observed to regulate GSK3 activation – an important
kinase responsible for tau phosphorylation (Cedazo-Minguez et al., 2003; Hoe et al., 2006;
Ohkubo et al., 2003). Finally, the recent studies demonstrate that A and phosphorylated
tau induce neurotoxicity in a different, possibly synergistic, manner through microglial
activation (Hauptmann et al., 2006; Reddy et al., 2008). Moreover, Ittner et al. have recently
demonstrated a molecular mechanism that links tau to A toxicity occurring at the synapse
(Ittner et al., 2010). In that study it was shown that tau – having a previously unknown role
in the dendrites – could target the Src kinase Fyn to the NMDA receptor. This allowed tau
to mediate A-induced excitotoxicity at the synapse. When tau is deleted or mistargeted in
an AD model mouse, survival and memory improve to similar levels to the wild-type mice,
although plaque burden and A levels do not change. Other studies also support the
hypothesis that tau likely to play a role in mediating A toxicity in synapses (Rapoport et
al., 2002; Vossel et al., 2010).
Figure 12. Amyloid cascade hypothesis and a newly hypothesized dual pathway model linking
core features of AD. The traditional amyloid hypothesis (left) assumes a serial model of
causality, whereby abnormal elevations in A drive tau hyperphosphorylation and other
downstream manifestations of the disease. According to the dual pathway hypothesis, A
elevations and tau hyperphosphorylation can be linked by separate mechanisms driven by a
common upstream molecular defect. (Adapted from Citron et al., 2004, and Small and Duff,
2008)
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2.3 GENETICS OF AD
2.3.1 Identification of AD-related genes
To facilitate the design of novel intervention approaches for AD, it is important to identify
and functionally characterize genetic alterations, which play a role in AD pathogenesis.
Initially, most of the genetic reports came from linkage analyses and case-control
association studies that had examined the association of single-nucleotide polymorphisms
(SNPs), usually in a single candidate gene. These studies were conducted in the
case-control cohorts varying from hundreds to a couple of thousand subjects. In addition,
the selection of a candidate gene was based on the function and relevance of its encoding
protein in AD pathogenesis, as in the case of BACE1 (Murphy et al., 2001). This study
represents a good example of a situation in which polymorphisms within a gene do not
necessarily display a risk association with AD despite the fact that BACE1 was identified as
a key enzyme in the amyloidogenic pathway.
Over the past decade, hundreds of genetic variants have been suggested as possible risk
factors, mostly for the LOAD. Unfortunately, quite often replication studies were not able
to replicate the promising results of the initial study. This led to the idea of creating an
AD-related database, in which researchers could evaluate the risk effects of a particular
candidate. For that purpose, the AlzGene database (http://www.alzgene.org) was launched
in 2004 (Bertram et al., 2007). At present, after systemic meta-analysis of almost 1400 papers
covering nearly 3000 polymorphisms in approximately 700 genes, the most viable
susceptibility gene candidates are now identified and published in the database (Bertram
et al., 2007). This publicly available databank represented a useful tool for researchers all
over the world to examine which genes might be worth exploring in greater detail.
It was soon realized that new AD risk genes can be found by applying the genome-wide
association (GWA) approach. The development of public databases to catalog variation
between individuals (SNPs) and advances in high-throughput, high-density genotyping
technology together with the recent decline in the costs have led to a massive increase in the
number of GWA studies. The clear benefit of GWA studies compared to the candidate gene
approach is that the GWA technique simultaneously tests a very large number of genetic
markers, normally several hundreds of thousands, in a largely hypothesis-independent
fashion (Bertram and Tanzi, 2008). The markers in a GWA array consist of SNPs which are
chosen based on their ability to cover common variation in the human genome. GWA
studies have emerged as an increasingly effective tool for identifying genetic contributions
to complex diseases such as AD, and understanding the underlying etiologic, biological,
and pathologic mechanisms associated with the disease. The number of subjects in GWA
studies is usually around several thousands, which also favours the advantage of this
method in terms of statistical power.
SNPs can also be analyzed in another way. Haplotype analysis is the method that specifies
the genetic information descending through a pedigree. In AD gene mapping, a set of
haplotypes from individuals who have AD can be used to predict the locus of a disease
susceptibility gene. In addition, a set of haplotypes from healthy controls is utililzed. A
haplotype for a given certain individual and a set of loci are defined as the set of alleles
inherited, one per locus, from the same parent (Figure 13). Haplotype patterns shared by
(or over-represented in) the cases that predict the gene to be close to the best patterns are
36
searched. Haplotype association analysis is useful in population isolates where individuals
carrying the mutated gene have potentially inherited it from a relatively recent common
ancestor, because they most likely share common haplotype patterns around that gene. The
disadvantages of haplotype analysis are the weak effects of genes, diagnostic problems,
gene-gene interactions, gene-environment interactions, and small data sets.
Figure 13. Illustration of a haplotype. Nucleotides, or alleles, in a gene of interest (grey boxes)
inherited from the father and the mother in each individual form a particular variant in a marker
(e.g. c/a or 1/2). Haplotype (H) is a series (two or more) of alleles along a single chromosome:
Hfather = (c, a, a, t), Hmother = (a, c, c, g).
2.3.1.1 Causative gene mutations in AD
APP gene
During the early 1980’s it was discovered that the “amyloid protein” isolated from the
brains of AD patients had the same biochemical properties and amino acid sequence as that
isolated from DS brains (Glenner et al., 1984; Masters et al., 1985). Because of the clinical,
histopathological, and biochemical association of DS with AD and the existence of an extra
copy of chromosome 21 in DS, researchers started to focus on chromosome 21 as the
possible location for an AD susceptibility gene. In 1987, a linkage to a locus on chromosome
21 was found in extended families with the autosomal dominant form of EOAD
(St George Hyslop et al., 1987). Soon after this two related articles reported the mapping of
the APP gene found in the brains of AD and DS patients to a region on chromosome 21 that
was near to the newly identified AD locus (Goldgaber et al., 1987; Tanzi et al. 1987). At the
end of the 1980’s, Goate et al. first found evidence of linkage to chromosome 21 in
autosomal dominant EOAD families (Goate et al., 1989), and then identified a missense
mutation in the APP gene segregating with AD in some of the families they analyzed
(Goate et al., 1991). The mutation occurred in exon 17 of the APP gene and led to a valine to
isoleucine change at amino acid 717 (Val717Ile) located in the transmembrane domain of
the protein (Figure 3). It was thus predicted that this first familial EOAD mutation (London
mutation) would lead to AD through its effects on A. Since then, according to the
Alzheimer Disease & Frontotemporal Dementia Mutation Database
(http://www.molgen.ua.ac.be/ADMutations; retrieved in July 1st, 2011), 32 pathogenic
mutations have been identified within the APP gene in 89 EOAD families. Many of these
mutations have been functionally assessed for their effects on APP processing. The
mutations are strategically located either immediately before the -secretase cleavage site,
shortly after the -secretase site, or slightly COOH-terminal to the -secretase cleavage site
(Figure 3). These missense mutations lead to AD by altering APP proteolytic processing at
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the three secretase sites in subtly different ways (Selkoe, 2001). This has been supported by
several studies analysing each of the mutations in transfected cells or primary cells from
patients and then in transgenic mouse models (Selkoe, 1997). Families harboring APP
missense mutations generally have the onset of the disorder before age 65, often even in
their 50s (Selkoe, 2001).
Presenilins (PSEN1, PSEN2)
After identification of mutations in APP, it soon became apparent that these mutations
would account for only a minor fraction of all familial EOAD cases. In 1995, PSEN1 and
PSEN2 genes were reported as novel familial EOAD genes on chromosomes 14 and 1,
respectively (Levy-Lahad et al., 1995, Rogaev et al., 1995; Sherrington et al., 1995). The PSs
are serpentine proteins believed to have eight transmembrane domains (TMD) and large
hydrophilic, cytoplasmic loops. However, the precise topology has not been unequivocally
determined, some studies have found nine TMDs (Laudon et al., 2005; Kornilova et al.,
2006). Of these TMDs, the third cytoplasmic loop between TMDs 6 and 7 undergoes
regulated endoproteolytic cleavage to produce PSEN N- and C-terminal fragments
(Thinakaran et al., 1997). PSEN1 missense mutations cause the most aggressive form of AD,
commonly leading to onset of symptoms before the age of 50 and death of the patients in
their 60s. Unlike the case with PSEN1, mutations in PSEN2 are rare. To date, 182 rare,
autosomal-dominant mutations have been found in PSEN1, and 13 in PSEN2
(http://www.molgen.ua.ac.be/ADMutations; retrieved in July 1st, 2011).
2.3.1.2 Risk genes in AD
Among the several genetic factors, which have been implicated in AD, mutations in only a
few genes (e.g. APP) are thought to be causative for the disease. In the majority of sporadic
AD cases, genetic alterations seem to act as predisposing factors that increase the risk, but
do not directly cause the disease. The risk genes probably exert their pathogenic effect by
acting together with environmental or other pathogenic factors. They may also interact
between themselves to further enhance the probability of inducing the disease (synergistic
effect) (Rocchi et al., 2003).
A number of putative risk genes have been considered as possible candidates in the
association studies on the basis of their function. The typical approach to evaluate the
genetic contribution of a particular gene to the risk for AD is to compare the frequency of
the allelic variation at polymorphic sites of the gene in cases and controls. Many of the
potential candidiate genes are enzymes, plasma proteins, growth factors, or membrane
receptors, which may exist as different allelic variants. Some polymorphic variants have
particular properties that could explain their role as genetic risk factors. For example,
polymorphism in a gene may lead to an altered biological function (e.g. transcription),
which may contribute to the pathogenesis of AD. Many of the potential risk genes are have
been proposed to be involved in APP processing and/or in the degradation and clearance of
 (Rocchi et al., 2003).
In 1993 it was reported that the 4 allele in APOE gene leads to a remarkable increase in AD
risk by ~4-fold as compared to non-carriers (Schmechel et al., 1993; Strittmatter et al., 1993).
This has been replicated in essentially all independent follow-up studies showing that
APOE is thus far the strongest known risk factor for LOAD (Bertram et al., 2007). In Finnish
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population, the risk effect has been seen both in EOAD and LOAD (Lehtimaki et al., 1995).
Since the identification of APOE, more than 1400 genetic studies employing SNPs or other
genetic variations have revealed hundreds of potential candidate genes and
polymorphisms that are associated with AD worldwide. The latest GWA studies have
identified several susceptibility genes in large case cohorts and in different populations that
associate to AD, such as ABCA7, MS4A6A/MS4A4E, EPHA1, CD33, CD2AP, CLU, CR1,
(Lambert et al., 2009; Hollingworth et al., 2011; Naj et al., 2011). According to the Alzgene
database, with the exception of APOE, the majority of the most commonly identified
candidate genes have a relative risk effect of 1.1–1.3 (Table 4).
Table 4. List of the current top 10 risk genes in AD (Retrieved and adapted from Alzgene
database, 18th of April, 2011). Chromosomal locations are according to NCBI gene database
(http://www.ncbi.nlm.nih.gov).
Rank Gene Chromosomal
location
Odds ratio
[95% CI] *
Protein
1. APOE
2/3/4
19q13.2 3.69 [3.30, 4.11] Apolipoprotein E
2. BIN1 2q14 1.17 [1.13, 1.20] Bridging integrator 1
3. CLU 8p21-p12 0.88 [0.86, 0.91] Clusterin
4. ABCA7 19p13.3 1.23 [1.18, 1.28] ATP-binding cassette, sub-family A (ABC1),
member 7
5. CR1 1q32 1.17 [1.11, 1.20] Complement component (3b/4b) receptor 1
(Knops blood group)
6. PICALM 11q14 0.88 [0.86, 0.9] Phosphatidylinositol-binding clathrin assembly
protein
7. MS4A6A 11q12.1 0.90 [0.88, 0.93] Membrane-spanning 4-domains, subfamily A,
member 6A
8. CD33 19q13.3 0.89 [0.86, 0.93] CD33
9. MS4A4E 11q12.2 1.08 [1.05, 1.11] Membrane-spanning 4-domains, subfamily A,
member 4E
10. CD2AP 6p12 1.12 [1.08, 1.16] CD2-associated protein
* Odds ratio was calculated from all studies including the initial one.
2.3.1.3 Seladin-1/DHCR24
Although not ranked in the top ten list of candidate genes (table 4), seladin-1 (selective AD
indicator 1) or DHCR24 is an interesting candidate since the studies from the last decade
reporting its association to AD. Seladin-1 gene was first described by Greeve et al. in 2000
(Greeve et al., 2000). Seladin-1 expression was observed to be downregulated in large
pyramidal neurons in specific regions in AD brain and thus suggested to be a cause for
selective vulnerability in AD. Furthermore, previous studies have shown that decreased
seladin-1 mRNA levels inversely correlate with hyperphosphorylated tau levels in AD
brain (Iivonen et al., 2002) and that specific seladin-1/DHCR24 gene variants associate with
increased AD risk (Lamsa et al., 2007).
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Functional characterization has revealed that seladin-1 confers specific protective properties
against A-mediated and oxidative stress-induced apoptosis by inhibiting caspase-3
activity (Greeve et al., 2000; Luciani et al., 2005; Di Stasi et al., 2005). The protective function
of seladin-1 is postulated to be mediated by its C-terminal domain harboring scavenging
activity toward ROS in the ER (Lu et al., 2008) or through a p53-dependent mechanism
(Kuehnle et al., 2008), possibly by preventing Ras-induced senescence (Wu et al., 2004).
Seladin-1 also has specific enzymatic activity. It catalyzes the reduction of the 24 double
bond of desmosterol, the immediate precursor of cholesterol, to form cholesterol
(Waterham et al., 2001). This implies that seladin-1 has a role in the formation of cholesterol-
rich detergent-resistant membrane domains, also known as lipid rafts (Abad-Rodriguez
et al., 2004). On the other hand, lipid rafts have been found to affect - and -secretase-
mediated APP cleavage and A generation in vitro and in vivo (Crameri et al., 2006;
Abad-Rodriguez et al., 2004). Furthermore, ~50% reduction in seladin-1 levels was shown to
decrease cholesterol levels, which was accompanied by a disorganization of lipid raft
domains (Crameri et al., 2006) in heterozygous seladin-1 knockout mouse brain. This led to
an increase in APP C99 and A production, suggesting that -secretase-mediated cleavage
of APP was enhanced in the brain of seladin-1-deficient mice. However, another study did
not identify a similar role of the lipid raft domains in A production. The authors
demonstrated that APP processing and A generation were unaffected in cells stably
expressing a BACE1 (BACE1-4C/A) mutant with an alanine substitution in its cysteine
residues. The mutant BACE1 failed to undergo S-palmitoylation, a reversible
post-translational modification responsible for targeting BACE1 to the lipid raft
microdomains. In contrast, the authors observed an increase in the levels of APP CTFs in
detergent-soluble fractions of cells expressing BACE1-4C/A as compared with cells
expressing wild-type BACE1. These data suggest that BACE1 is able to efficiently cleave
APP in both lipid raft and non-raft microdomains (Vetrivel et al., 2009). Similarly, it is also
possible that the protective effect of seladin-1 does not necessarily depend on its association
to lipid rafts organization (or cholesterol), but it may be mediated through some other still
unknown mechanism.
The nomenclature of seladin-1 protein and genes has varied in the publications. According
to NCBI gene database (http://www.ncbi.nlm.nih.gov/gene) the official name for the gene is
DHCR24, and seladin-1 is one of the aliases. The general protein information prefers the
name delta-24 (24)-sterol reductase for the encoding protein, but also other names are
used, such as seladin-1, 3--hydroxysterol 24-reductase, and diminuto/dwarf1 homolog.
In this thesis, “seladin-1/DHCR24” is used for the gene, and “seladin-1” for the protein.
2.3.1.4 G protein-coupled receptors (GPCRs) - -opioid receptor 1
GPCRs
GPCRs are important in many fundamental physiological functions and mediate the
actions of the majority of known neurotransmitters and hormones (Waldhoer et al., 2004).
Ligand-bound GPCRs activate heterotrimeric G proteins, inducing the exchange of
guanosine diphosphate (GDP) for guanosine triphosphate (GTP). This leads to the
formation of a GTP-bound G subunit and the release of the G dimer. The G protein
subunits then activate specific effector molecules, such as adenylyl cyclase (AC),
phospholipase C (PLC), or phospholipase A2 (PLA2), leading to the generation of second
messengers and the activation of extracellular signal-regulated kinase 1/2 (ERK1/2), Janus
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kinase (JAK) or phosphatidylinsitol-3-kinase (PI3K). The activation of certain GPCRs is
known to modulate the -secretase-mediated cleavage. In the case of the M1 muscarinic
acetylcholine receptor (M1 mAChR), the group I metabotropic glutamate receptors
(mGluRs) and the 5-hydroxytryptamine receptors 5-HT2A/2CR and 5-HT4R, agonist
stimulation leads to an increase in sAPP release, a decrease in A generation, a decrease in
tau phosphorylation, and/or an alleviation of cognitive deficits in a mouse model of AD
(Thathiah and Strooper, 2011). Conversely, agonist stimulation of the Group II mGluRs
evokes an increase in A42 generation and tau phosphorylation, and an exacerbation of the
cognitive deficits in AD mice. In the case of the 5-HT6 receptor, antagonism of the receptor
leads to an improvement in cognition (Thathiah and Strooper, 2011).
Recently, several studies have shown compelling evidence implicating GPCRs in the
pathogenesis of AD and in the processing of APP. GPCRs affect the cleavage of APP by -,
-, and -secretases and thus the extent of A generation. On the other hand, A can
directly or indirectly affect GPCR function (Thathiah and Strooper, 2011). With respect to
the GPCRs that regulate APP processing, the -opioid receptor (OR) and the adenosine
A2A receptor (A2AR) have been shown to modulate -secretase-mediated cleavage of APP
(Teng et al., 2010; Dall'Igna et al., 2003, 2007) In addition, OR, 2 adrenergic receptor
2AR), G protein-coupled receptor 3, and CXC-chemokine receptor 2 modulate -secretase-
mediated cleavage of C99 or C83 (Ni et al., 2006; Teng et al., 2010, Thathiah et al., 2009;
Bakshi et al., 2008, 2011).
The -secretase-mediated cleavage of APP is regulated by PKC (Buxbaum et al., 1990;
Caporaso et al., 1992), cyclic AMP–protein kinase A (PKA) (Xu et al., 1996), sequential
activation of MAPK and extracellular signal-regulated kinase (ERK) (Mills et al., 1997), and
PI3K (Solano et al., 2000). Specifically, activation of these signalling cascades shifts APP
metabolism towards the -secretase-mediated pathway and away from
-secretase-mediated A generation (Buxbaum et al., 1993; Ishida et al., 1997; Hung et al.,
1993). Conversely, a recent study has suggested that chronic, rather than acute, activation of
PKC could differentially regulate the PKC and PKC isozymes, leading to increased A
generation (da Cruz e Silva et al., 2009). Nevertheless, numerous studies have claimed that
many GPCRs and activation of their downstream signalling cascades can increase the
non-amyloidogenic processing of APP.
-Opioid receptor (OR)
OR is a GPCR with a typical seven-transmembrane helix (7TM) topology. ORs have been
implicated in the presynaptic modulation of synaptic function and in the regulation of pain
and mood (Bie et al., 2010; Zhang and Pan, 2010). Furthermore, assessments of postmortem
brain samples have revealed that different opioid receptor populations (such as OR and
OR) are differentially altered in distinct areas of postmortem brain specimens
(Mathieu-Kia et al., 2001). The only non-synonymous SNP T80G (rs1042114) in the coding
region of OPRD1, leading to Phe27Cys amino acid substitution in OR, has been reported
to associate with opioid dependence (Zhang et al., 2008), although another study found no
association (Xuei et al., 2007). Like other GPCRs, ORs not only act as monomers but can
form homomeric complexes  with other opioid receptor subtypes and heteromeric
complexes with other GPCRs, creating new receptors with novel pharmacological
properties (van Rijn et al., 2010).
It has been previously shown that the presence of cysteine at position 27 affects the
maturation and subcellular localization of OR in non-neuronal cells (Leskela et al., 2009;
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Petaja-Repo et al., 2000). More specifically, the OR-Cys27 variant displayed a low
maturation efficiency, and lower stability at the cell surface than the OR-Phe27 variant.
These features of the OR-Cys27 receptor resulted in the retention of receptor precursors in
the ER and enhanced turnover of mature cell surface receptors. Thus, it was proposed that
the OR-Cys27 variant may cause a gain-of-function phenotype with possible
pathophysiological consequences due to the intracellular accumulation of the receptor
(Leskela et al., 2009).
OR, which plays important roles in learning and memory, is deregulated in specific
regions of the AD brain (Mathieu-Kia et al., 2001). There is evidence that both OR and
2AR can promote the -secretase-mediated cleavage of C99 (Ni et al., 2006). A more recent
study by the same group suggested that activation of the OR promotes the translocation of
a complex consisting of OR, -secretase and -secretase from the cell surface to the late
endosomes and lysosomes (LEL). This resulted in enhanced - and -secretase-mediated
proteolysis of APP (Teng et al., 2010). In a mouse model of AD, administration of
natrindole, a selective OR antagonist, improved spatial learning and reference memory
and reduced the amyloid plaque burden (Teng et al., 2010). Similarly, in vivo knockdown of
the OR reduced A40 accumulation in the hippocampus of AD mice. However, there was
no effect on the more hydrophobic (and therefore more toxic) A42 (Teng et al., 2010).
Overall, the above-mentioned studies hint that OR may play a significant role on AD
pathogenesis.
2.4 ALZHEIMER’S DISEASE-RELATED CO-MORBIDITIES
Several studies have shown that AD and several other brain disorders, such as cerebral
ischemia, traumatic brain injury (TBI) and normal pressure hydrocephalus (NPH), share
similar neuropathological features. These features include altered APP processing, and
accumulation of calcium and A levels (Abe et al., 1991, Pluta et al., 1994; Koistinaho et al.,
1996; Blasko et al., 2004). Importantly, the common factor for the above-mentioned
disorders is that they all show increase in expression and activity of BACE1. Identification
of these overlapping factors is valuable for achieving a better understanding of the key
molecular mechanisms in AD and AD-related co-morbidities. In the following chapters,
central findings in other brain injuries and disorders similar to those in AD are introduced.
2.4.1 Traumatic brain injury (TBI)
There is solid evidence that traumatic brain injury (TBI) is a risk factor for AD and that
disturbances in the balance between the production and degradation of A play a crucial
role in the disorder (Blasko et al., 2004). Post-mortem analysis of the brains of long-term
survivors as well as patients surviving only a few days after brain trauma have
demonstrated a widespread deposition of A peptides (Graham et al., 1995; Jellinger et al.,
2001; Roberts et al., 1991). Increased A levels in the CSF (Emmerling et al., 2000; Raby et al.,
1998) and marked overproduction of sAPP in neurons of injured humans or experimental
animals have also been observed (Blasko et al. 2004). Moreover, activity of BACE1, which is
known to be activated in stress, has been shown to increase after TBI (Blasko et al., 2004).
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2.4.2 Cerebral ischemia
Cerebral ischemia has been reported to significantly increase the risk of AD (Zlokovic, 2002;
Honig et al., 2003). Moreover, individuals diagnosed with severe cognitive decline or
possible AD are at increased risk for ischemic events in the brain (Koistinaho and
Koistinaho, 2005). Cerebral ischemia leads to transient up-regulation and accumulation of
APP and its proteolytic fragments in the cortex adjacent to the boundary of the ischemic
lesion and white matter (Abe et al., 1991; Koistinaho et al., 1996; Lin et al., 1999; Pluta et al.,
2006, 2009), pointing to an interplay between cerebrovascular and amyloid pathology.
It is well-established that astrogliosis and the expression of proinflammatory cytokines are
induced in cerebral ischaemia (Fan et al., 1996; van Groen et al., 2005; Sriram et al., 2006). In
addition, middle cerebral artery occlusion (MCAO) in in vivo animal models promotes
secondary degeneration in the thalamus (Iizuka et al., 1990; Ross and Ebner, 1990; Wei et al.,
2004, van Groen et al., 2005) and enhances APP processing and A generation (van Groen
et al., 2005; Makinen et al., 2008; Hiltunen et al., 2009), and BACE levels and activity (Wen et
al., 2004). Lastly, A-degrading enzyme NEP expression was decreased in the rat model of
four-vessel occlusion ischemia (Nalivaevaa et al., 2004).
2.4.3 Normal pressure hydrocephalus (NPH)
Abnormalities in CSF production and turnover in normal pressure hydrocephalus (NPH)
and in AD may be important causes of amyloid retention in the brain in these two diseases
(Silverberg et al., 2006). Furthermore, CSF circulatory failure in AD and NPH may result in
reduced CSF clearance and accumulation of tau protein (Silverberg et al., 2003). Patients
with clinical and radiographic evidence of NPH also show typical pathological changes of
AD, including plaques and tangles (Silverberg, 2004). There are also AD-like lesions seen in
the brains of NPH patients (Bech et al., 1999). Furthermore, in a large follow-up study,
Leinonen et al. assessed the A and p-tau protein levels of a total of 433 cortical biopsy
samples from the brains of elderly patients with suspected NPH and revealed that the
presence of A and p-tau associated with the presence or later development of clinical AD
(Leinonen et al., 2010).
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3 Aims of the study
To facilitate the design of novel biomarkers and the design of novel intervention
approaches for AD, it is important to identify and functionally characterize genetic
alterations involved in AD pathogenesis. The aim of this thesis was to investigate the
genetic and mechanistic roles of specific risk genes linked to AD. The study population
consisted of LOAD patients and age-matched control subjects originating from Eastern
Finland. In addition, the familial AD sample set originating from USA was used as a
replication cohort. Special emphasis was laid on elucidating the underlying molecular
mechanisms of seladin-1, OR and BACE1 in the pathogenesis of AD. Furthermore, a non-
selective calcium channel blocker and -secretase inhibitor, bepridil, was used to treat
ischemic rats after MCAO. In these MCAO rats, A and calcium accumulate in the
ipsilateral thalamus. Therefore, they provide a feasible in vivo model to study drug effects
on A and calcium pathology, which are among key pathogenic features of AD.
The specific aims were:
1. To assess the risk effects of candidate gene polymorphisms selected on the basis of
meta-analyses performed in AlzGene database among the Eastern Finnish
case-control cohort (Study I).
2. To study the genetic and/or functional role of seladin-1, BACE1, and OR in the
processes relevant for AD pathogenesis, such as generation and accumulation of A in
different in vivo and in vitro models (Studies II-IV).
3. To study the effects of novel -secretase inhibitor, bepridil, on the thalamic A and
calcium pathology in MCAO rats (Study IV).
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4 Subjects, materials and methods
4.1 SUBJECTS (STUDIES I AND III)
4.1.1 AD patients and controls (Studies I and III)
In the case-control studies I and III, all subjects originated from Eastern Finland and were
examined at the Department of Neurology, Kuopio University Hospital (Table 5). Patients
fulfilled the NINCDS-ADRDA criteria for probable AD (McKhann et al., 1984). Early-onset
AD patients (onset age 65 years) did not display any conclusive evidence of autosomal
dominant transmission (Lehtovirta et al., 1996) and there were no APP or PSEN1/2
mutations. Control subjects had no signs of dementia according to the interview and
neuropsychological testing (Hänninen et al., 2002). Ethical approval was provided by the
Ethics Committee of the Kuopio University Hospital.
Table 5. Subject parameters in Eastern Finnish case-control cohort (studies I and III).
AD patients Controls All
Descriptive
Age: 43 to 89 years
1Mean: 717 years
Age: 37 to 87 years
1Mean: 696 years
Women Men Total Women Men Total
Study I
N
(% in status)
434 (67.6) 208 (32.4) 642 411 (60.3) 271 (39.7) 682 1324
Study III
N
(% in status)
368 (69.0) 165 (31.0) 533 401 (59.8) 270 (40.2) 671 1204
1Mean age of onset of AD patients and at the time of neuropsychological examination of
controls.
4.1.2 Family-based sample set (study III)
An AD family sample set previously used for GWAS was used in study III (Bertram et al.,
2008). The National Institute of Mental Health (NIMH) Genetics Initiative Study (Blacker et
al., 1997) sample contained 1376 individuals across 410 AD families, in which all members
were of self-reported European ancestry.
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4.2 GENOTYPING (STUDIES I AND III)
DNA samples were isolated from peripheral lymphocytes using the Blood Prep™
Chemistry kit (Applied Biosystems).
Study I
DNA samples were randomly placed on 384 well plates and genotyped using Sequenom
iPLEX platform (Sequenom®, Hamburg, Germany). Genotyped SNPs were selected on the
basis of meta-analyses retrieved from AlzGene database (http://www.alzgene.org/)
(Table 6). Sequencing around the rs760678 site in NEDD9 gene was performed from 47
randomly selected DNA samples using BigDye™ Terminator sequencing kit (Applied
Biosystems, Foster City, USA) and ABI PRISM® 3100 Genetic Analyzer (Applied
Biosystems, Foster City, USA). APOE genotyping was performed as described previously
(Tsukamoto et al., 1993).
Table 6. Summary of 21 genes, SNPs, and their allelic variation among Finnish AD patients and
controls analyzed in study I.
Gene Polymorphism 1Allele Variation AD patients (N) Controls (N)
ACE
CH25H
CHRNB2
DAPK1
ENTPD7
GAB2
GALP
GAPDHS
GWA_14q32.13
hCG2039140
IL1B
IL33
LOC651924
MAPT/STH
MTHFR
NEDD9
PGBD1
SORCS1
TF
TFAM
TNF
rs4343
rs13500
rs4845378
rs4878104
rs911541
rs2373115
rs3745833
rs4806173
rs11622883
rs1903908
rs1143634 (+3953)
rs7044343
rs6907175
rs2471738 (intron 9)
rs1801133 (C677T)
rs760678
rs3800324
rs600879
rs1049296 (P570S)
rs2306604
rs1800629 (-308)
G/A
T/C
T/G
T/C
G/A
T/G
C/G
G/C
A/T
T/C
T/C
C/T
A/G
T/C
T/C
G/C
A/G
A/G
T/C
C/T
A/G
553
617
573
624
500
621
621
567
615
613
620
567
607
562
617
528
560
620
506
622
563
579
666
592
661
546
672
665
590
654
663
668
590
653
680
662
548
592
668
587
667
591
1Major/minor, minor allele based on information from Alzforum (wwwl.alz.org).
Study III
Four tag SNPs (rs678849, rs760588, rs4654323 and rs529520) within the OPRD1 gene were
selected from the Applied Biosystems database (Human Pre-Designed Assays) using the
SNPBrowser™ 3.0 software and one SNP (rs1042114) was designed with Custom TaqMan®
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SNP Genotyping Assay Design Tool (Table 7). The selected SNPs captured all the genetic
information within OPDR1 gene according to the HapMap database
(http://www.hapmap.org/) in CEU population. SNP genotyping was performed by using
TaqMan Allelic Discrimination Assays (Applied Biosystems). The TaqMan PCR reactions
were done on a Research Peltier Thermal Cycler (PTC 200) and the fluorescence was
detected on an ABI Prism 7000 sequence detector (Applied Biosystems). APOE genotyping
was performed as previously described (Lehtovirta et al., 1996). Genotyping of the NIMH
Genetics Initiative Study sample set was completed with the GeneChip Human Mapping
500K Array Set from Affymetrix (Bertram et al., 2008). Hardy-Weinberg equilibrium for
each SNP in AD patient and control cohorts was calculated using the GenePop program
(http://genepop.curtin.edu.au/genepop/genepop_op1.html).
Table 7. SNP’s in OPDR1 gene used in study III.
aSNP and location (kb)
Allele polymorphisms
(major  minor)
rs1042114 (0) T  G
rs678849 (6.2) T  C
rs706588 (23.6) A  G
rs4654323 (30) G  T
rs4654323 (30) C  A
aLocations of SNPs are indicated in 5' to 3' orientation with
respect to SNP rs1042114.
4.3 IMPUTATION ANALYSIS (STUDY III)
Markers for the NIMH families were generated as part of a GWAS as previously described
(Bertram et al., 2008). Since SNP rs1042114 in study III was not directly genotyped on the
Affymetrix 500K SNP array, we inferred genotypes at this site via imputation using
IMPUTE v2.0 (Marchini et al., 2007). As reference panels, the precompiled HapMap 3 and
1000 Genomes Project G“CEU TSI” panels from the IMPUTE website (obtained on 2 June
2010) were used. These contain HapMap 3 data (from release 2 of February 2009) and 1000
Genomes Project data from Pilot 1 genotypes (released in August 2009) for autosomal
SNPs.
4.4 CELL CULTURE EXPERIMENTS (STUDIES II AND III)
4.4.1 siRNA and plasmid constructs (Studies II and III)
In study II, SMARTselection™ pre-designed ON TARGETplus SMARTpool small
interfering RNAs (siRNAs) (Thermo Scientific Dharmacon) targeted to human
seladin-1/DHCR24 gene (GGAGUACAUUCCCUUGAGA, AGAACUAUCUGA-
AGACAAA, GCACAGGCAUCG-AGUCAUC and GAAAUGAGGCAGAGCUCUA) were
used to down-regulate seladin-1 (siSel). Negative control siRNA (siCtrl; Thermo Scientific
Dharmacon) Duplex with 3' AlexaFluor488 (Qiagen) was used as a control in RNAi
47
experiments. cDNAs for human APP751 isoform and BACE1 (3' tagged with Myc; BACE1-
Myc) cloned into pcDNA 3.1 vector were used to create stable cell lines.
The Myc-OR-Flag-pFT-SMMF and HA-OR-pcDNA5/FRT/TO constructs (study III),
encoding the human OR-Cys27 and OR-Phe27 variants, have been described previously
(Leskela et al., 2007, 2009). All OR constructs contained a cleavable HA signal peptide and
either an N-terminal Myc tag and a C-terminal Flag tag or an N-terminal HA tag with a
native C-terminus. The enhanced yellow fluorescent protein (EYFP)-Golgi compartment,
enhanced green fluorescent protein (EGFP)-Rab7 (a marker for LEL), EGFP-Rab9 (a marker
for lysosomes), and EGFP-Rab11 (a marker for recycling endosomes) constructs have been
described previously (Choudhury et al., 2002).
4.4.2 Stable cell lines (studies II and III)
SH-SY5Y human neuroblastoma cells were transfected with APP751 and BACE1-Myc
plasmid constructs using Effectene transfection reagent (Qiagen) to create stable cells lines
overexpressing APP751 (SH-SY5Y-APP751) (Studies II and III) and BACE1-Myc
(SH-SY5Y-BACE1-Myc) (Study II). The BACE1-Myc cell line lacked an endogenous
promoter and 5'-UTR regions of BACE1, thus making it possible to elucidate the underlying
molecular mechanisms of seladin-1 knockdown on the post-translational stability of BACE1
in study II. After the transfections, cells were cultured in Dulbecco's Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin,
100 μg/ml streptomycin, and 2 mM L-glutamine (DMEM-C). Two days after the
transfection, 800 μg/ml G418 (G-418, Geneticin®; Invitrogen) was added to induce selection
of APP751- and BACE1-Myc overexpressing cell clones. Three weeks after selection, clones
overexpressing either APP751 or BACE1-Myc were identified using APP-, BACE1- and
Myc-specific antibodies in Western blotting.
In study III, HEK293 cells over-expressing AP (alkalic phosphatase) and APP695 fusion
protein (HEK293-AP-APP) were grown as described previously (Lichtenthaler et al., 2003).
The AP ectodomain was fused to the N-terminus of the full length APP695 lacking a signal
peptide (Neumann et al., 2006). Preparation and maintenance of stable HEK293i cell lines
with inducible expression of the epitope tagged OR cysteine 27 and phenylalanine 27
OR-Cys27 and OR-Phe27, respectively) variants have been described earlier (Leskela
et al., 2007, 2009).
4.4.3 Transfections (Studies II and III)
Selected clones were subsequently cultured in DMEM-C containing 200 μg/ml G418. siRNA
and plasmid constructs were transfected into SH-SY5Y-APP751 (studies II and III),
SH-SY5Y-BACE1-Myc (study II), and HEK293-AP-APP (study III) cells using Lipofectamin
2000™ reagent (Invitrogen) according to the manufacturer's instructions. OR expression
was induced for 24-48 h by adding 0.5 μg/ml tetracycline (Invitrogen) to the culture
medium. Opioid ligands in study III were added in the concentrations and for the
incubation periods indicated in Table 8.
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Table 8. Ligands and inhibitors/activators used in study III.
Ligand Concentration
M)
Induction
period (h)
Role Provider
Naltrexone
(NTX)
10 48 OR antagonist Tocris
Naltriben (NTB) 10 48 OR antagonist Tocris
ICI-174,864 5 48 OR inverse agonist Tocris
SNC-80 10 48 OR agonist Tocris
Bisindolyl-
maleimide I
(Bis I)
1-10 4-24 protein kinase C (PKC)
inhibitor
Enzo Life
Sciences, Inc.
Protein
phosphatase 2
(PP2)
1-5 24 specifc inhibitor of Src
family kinases
Enzo Life
Sciences, Inc.
Phorbol-12-
myristate-13
acetate (PMA)
1 4 protein kinase C (PKC)
activator
Sigma
4.4.4 Metabolic labeling (Study III)
HEK293iOR-Cys27 cells were cultivated in a medium lacking cysteine and methionine,
supplemented with FBS, penicillin, streptomycin, tetracycline, and 100 μCi/ml EXPRE35S35S
labeling mix (Perkin-Elmer). Fresh label (50 μCi/ml) was added after 24-h incubation for 60
min to ensure efficient labeling of newly synthesized proteins. Sequential
immunoprecipitation with anti-FLAG M2 and C-terminal anti-APP antibodies (Table 10)
was performed from mixed cellular extracts and samples were analyzed by SDS-PAGE and
fluorography.
4.5 RNA EXTRACTION AND REAL-TIME PCR (STUDIES II AND IV)
In study II, total RNA was extracted from transfected cells using TRIzol® Reagent
(Invitrogen). In study IV, tissue samples from the ipsilateral and contralateral thalamus of
MCAO- or sham-operated rats were first weighed and mechanically homogenized in 400 μl
of Dulbecco’s phosphate buffered saline (DPBS, Lonza) in an ice bath. Approximately
10-fold excess of PBS/mg tissue was used. Then, the tissue homogenate was mixed with 500
μl of TRIzol® reagent for total RNA extraction. RNA sample quality was controlled with
NanoDrop 2000 (Thermo Scientific) by calculating the A260/280 ratio. Moreover, RNA
profile for 18S and 28S RNAs was assessed in 1.5% agarose gel electrophoresis before the
cDNA synthesis. To conduct real-time PCR in studies II and IV, equal amounts of total
RNA samples were subjected to cDNA synthesis using Superscript III Reverse
Transcriptase (Invitrogen). Subsequently, SYBR Green Master PCR Mix (Applied
Biosystems) and target specific PCR primers (Table 9) were used for amplification of cDNA
samples by using real time quantitative PCR (qPCR) machine (7500 Fast Real Time PCR
System, Applied Biosystems). PCR primers were designed to anneal to sequences at least in
two different exons on opposite sides of an intron. The qPCR cycles were set as 40
repetitions and annealing temperature 55°C. The mRNA levels of each gene were
normalized to those of GAPDH from the same samples.
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Table 9. PCR primers used in studies II and IV.
Study Primer
Primer sequence 5’-3’
F R
II, IV Human Seladin-1 CAAGCCGTGGTTCTTTAAGC CATCCAGCCAAAGAGGTAGC
II Human GAPDH GATCATTCAGCTCAGCAAACA GTGAGGGTCTCTCTCTTCCT
IV Mouse GAPDH CGTCCCGTAGACAAAATGGT TCTCAATGGTGGTGAAGACA
IV Mouse TNF CGAGTGACAAGCCTGTAGCC GTGGGTGAGGAGCACGTAGT
IV Mouse LTCC TTCGATGTGAAGGCACTGAG TATGCCCTCCTGGTTGTAGC
IV Mouse IDE TCCATACCACTGCTCTGTGC TGGAGTGCTCACAGCTGAAT
IV Mouse NEP TCTTATCATCAGTGCCAACAAAA AGGCGGACAACCTCTACTCA
4.6 PROTEIN EXTRACTION AND WESTERN BLOT ANALYSIS (STUDIES II,
III AND IV)
Brain tissue samples in study IV were mechanically homogenized in 400 μl DPBS (Lonza)
solution. Total proteins from both homogenized brain cells in study IV and human
secondary cells in studies II and III were extracted by using the TPER extraction buffer
(Pierce) containing the EDTA-free protease inhibitor cocktail (Thermo Scientific) or lysed in
DDM buffer [0.5% n-dodecyl--D-maltodextrine (DDM; Alexis)] (study III). The DDM
solubilized samples in study III were further incubated for 60 min at 4°C with constant
rotation and the insoluble material was removed by 11000 × g centrifugation for 30 min, and
membrane extracts were prepared as described earlier (Tuusa et al., 2007).
Total protein concentrations of the lysates were quantified using either BCA (studies II, III
and IV) or DC (study III) protein assays (Pierce and Bio-Rad, respectively) and,
subsequently, 10 to 50 μg of each lysate were subjected to 4-12% Bis-Tris polyacrylamide
gel electrophoresis (PAGE; Invitrogen) (studies II, III and IV) or to 10 or 14% SDS PAGE
(Bio-Rad) (study III) and blotted onto Immun-Blot (Bio Rad) or Immobilon P (Millipore)
polyvinylidene fluoride membranes. Primary antibodies used in studies II, III and IV are
indicated in Table 10. After incubation with appropriate horse radish peroxidase (HRP)
conjugated secondary antibodies (GE Healthcare), enhanced chemiluminescence substrate
(Amersham Biosciences) was applied to membranes and detection of protein bands was
performed with ImageQuant RT ECL camera (studies II and III) or by ECL hyperfilm
(study III) (both GE Healthcare) scanned with a Umax Powerlook 1120 color scanner using
the Image Master 2D Platinum 6.0 software (Amersham Bioscience). The band intensities
were quantified using Quantity One (Bio Rad) (studies II and III) or Image J 1.41 (public
domain, National Institute of Health) (study III) software. The housekeeping protein
GAPDH was used to normalize the protein levels in each sample. In study IV, human
SH-SY5Y-APP751 cell lysates were used as a control in protein fragment visualization.
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4.6.1  and sAPP measurements
40 levels in the SH-SY5Y-APP751 cell culture media in study II and III were determined
by using the human A40 enzyme-linked immunosorbent (hAmyloid 40) ELISA assay kit
(The Genetics Company). In study IV, soluble or insoluble A x-40 and A x-42 (A40 and
42) levels were measured from the total protein suspended in DPBS containing
EDTA-free protease and phosphatase inhibitors (1:100). Aliquots in study IV were first
ultracentrifuged (100000 × g, 50.4 Ti rotor; Beckman) for two hours at +4°C, and the
supernatant (= soluble fraction) was collected. Subsequently, the remaining pellet was
resuspended in guanidine buffer (5 M guanidine-HCl/50 mM Tris-HCl, pH 8.0), incubated
for 2 hours at room temperature on a shaker, and diluted 1:50 in BSAT-DPBS [5% BSA
(Bovine serum albumin)/0.03% Tween-20 in DPBS, pH 9.0] (BSA from Sigma) containing
protease and phosphatase inhibitors. Finally, the suspension was centrifuged for 20
minutes at 15700 × g and the supernatant (= insoluble fraction) was collected for A
measurements. Both insoluble and soluble A40 and A42 levels were determined using
monoclonal and HRP-conjugated antibody-based Human/Rat  Amyloid 40 (294-62501)
and  Amyloid 42 (High-Sensitive; 290-62601) ELISA Kit (Wako). After a thirty-minute
incubation at room temperature, the reaction was terminated and the absorbance was
measured at 450 nm with an ELISA microplate reader (Wallac). A40 levels in studies II
and III were normalized to the total protein levels, which were determined from the lysates
of the same cells from which the culture media had been initially collected. In study IV, A
concentrations were normalized to the tissue weights in each sample.
Soluble APP (sAPP; studies II, III and IV) (sAPP; -secretase cleaved N-terminal APP
fragment) as well as total sAPP (sAPPtot = sAPP + sAPP; -secretase cleaved N-terminal
APP fragment) levels were detected either from the tissue protein homogenates suspended
in DPBS containing EDTA-free protease and phosphatase inhibitors (1:100; study IV) or
from SH-SY5Y-APP751 cell culture media (studies II and III) using Western blot analysis
with 6E10 (Signet Laboratories) and 22C11 (Mab348, Millipore) antibodies, respectively
(Table 10). In study III, sAP-APP measurements from HEK293 AP-APP cells were
performed as previously described (Hiltunen et al., 2006). sAPP (studies II and III) and sAP-
APP (study III) levels were subsequently normalized to the total protein levels, which were
determined from the lysates of the same cells from which the culture media had been
initially collected. In study IV, GAPDH normalized sAPP levels in the ipsilateral thalamus
were compared relative to the contralateral thalamus (100%).
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Table 10. Antibodies used in Western blotting in studies II, III and IV.
Study Primary ab Recognizes 1Clonality Cat. no
       2Dilution
 Provider
WB IF
II
seladin-1/
DHCR24
(C59D8)
seladin-1/
DHCR24
M 2033 1:800 Cell Signalling
II, IV GGA3 GGA3 M 612310 1:2500
BD
Transduction
Labs
II, III
c-Myc
(4A6)
c-Myc M 05-724 1:1000
1:100
and
1:200
Millipore
III A-14 c-Myc P sc-789 1:1000 Santa Cruz
III 9E10 c-Myc M sc-40 1:10000 Santa Cruz
III M2 FLAG M F3165 0.5 g/mL Sigma
II BACE1 BACE1 P PA1-757 1:1000 ABR/ Thermo
II Caspase-3 Caspase-3 P 9662 1:1000 Cell Signalling
II, III,
IV
Alzheimer
precursor
protein
(A8717)
APP C-
terminus,
C83, C89,
C99, AICD
M A8717 1:2000
1:250
and
1:1000
Sigma
III AC-15 -actin M A5441 1:15000 Sigma
III
Alzheimer
precursor
protein A4
(22C11)
APP N-
terminus,
sAPPtot
M MAB348 1:1000 1:100 Millipore
III
-amyloid
(6E10)
sAPP M SIG-
39320
1:1000
BioSite
(Signet)
II
GAPDH
(6C5)
GAPDH M ab8245 1:15000 Abcam
IV GFAP Glial fibrillary
acidic protein
M G3893 1:1000 Sigma Aldrich
IV
Insulin-
degrading
enzyme
IDE C-
terminus
P ab32216 1:500 Abcam
IV
Neprilysin
(AB5458)
NEP P ab5458 1:1000 Chemicon
IV LRP (EPR3724) Low density
LRP
M ab92544 1:1000 Abcam
II, III LAMP2a Lysosomes P ab18528 1:200 Abcam
II, III
EEA1
(clone 14)
Early
endosomes
M 610456 1:200 BD
Biosciences
III
Calnexin
(clone C37)
Calnexin
protein in ER
M 610523 1:100 BD
Biosciences
III
LBPA
(clone 6C4)
Lysobis-
phosphatidic
acid, MVB
M Z-SLBPA 1:100 Echelon
Biosciences
II, III
Transferrin
(H68.4)
Transferrin
receptor
M 13-6800 1:200 Zymed
1M, mouse monoclonal; P, rabbit polyclonal; 2Dilutions for Western blotting (WB) and
immunofluorescence (IF); ER, endoplasmic reticulum; MVB, multivesicular bodies.
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4.7 IMMUNOPRECIPITATIONS (STUDY III)
Whole cell extracts containing equal amounts of protein were supplemented with 0.1% BSA
and pre-cleared with mouse-IgG agarose. The pre-cleared samples were
immunoprecipitated with the anti-FLAG M2 antibody affinity gel (Sigma). They were
washed once with DDM buffer, twice with the same buffer containing 300 mM NaCl, twice
with DDM buffer, and finally three times with DDM buffer containing 0.1%, instead of
0.5%, DDM. Bound proteins were eluted with 200 μg/ml FLAG peptide (Sigma). In the
extract mixing experiments, the anti-FLAG M2 antibody affinity gel was used for the first
immunoprecipitation step. After an overnight incubation, the resin was washed five times
with DDM buffer, and the bound proteins were eluted with 1% SDS, 25 mM Tris-HCl
pH 7.5, at +95°C for 5 min. The eluted samples were diluted 10-fold with DDM buffer
supplemented with 0.1% BSA and used for a second immunoprecipitation with the
anti-APP-CTF antibody (A8717) coupled to Protein A Sepharose (GE Healthcare), followed
by washes as described above and elution with the SDS-PAGE sample buffer. Aliquots of
immunoprecipitates and of whole cell extracts containing equal amounts of protein were
separated in 10% SDS-PAGE and analyzed by Western blotting or fluorography as
described previously (Tuusa et al., 2007).
4.8 CALCIUM MEASUREMENT (STUDY IV)
Tissue homogenate samples (20 μl) were digested (CEM MDS 2000 microwave digestor,
Akribis Metrology Ltd) in 100 μl suprapur nitric acid (Merck). After digestion, 100 μl 2%
lanthanum solution (Riedel de Haen) was added and the samples were diluted to a volume
of 1 ml with Milli Q water. Calcium measurements were carried out on a ZEEnit 700 atomic
absorption spectrometer (Analytik Jena AG) with a calcium hollow cathode lamp at
wavelength 422.7 nm using an air-acetylene flame and SFS6 injection module. Calcium
concentrations were normalized to the tissue weights of each sample.
4.9 ENZYME ACTIVITY ASSAY (STUDIES II AND IV)
In study IV, - and -Secretase Activity Kits (FP001 and FP002, respectively; R&D Systems)
were used to measure - and -secretase activities from the total protein lysates of thalamic
tissue homogenates suspended in DPBS (without protein or phosphatase inhibitors)
according to the manufacturer's instructions. Briefly, equal amounts of membrane protein
fractions were incubated at +37°C for two hours with the secretase specific substrate
peptides conjugated to fluorescent reporter molecules EDANS and DABCYL. Subsequently,
emitted light (510 nm) was detected on a fluorescence microplate reader (Wallac) after
EDANS excitation at 355 nm.
-Secretase activity was measured in study IV from the thalamic tissue homogenates as
previously described (Farmery et al., 2003). In brief, 60 μg of solubilized membrane protein
preparation was incubated at 37°C overnight in 150 μl of assay buffer containing 50 mM
Tris-HCl, pH 6.8, 2 mM EDTA, 0.7% CHAPSO (w/v), and 8 μM fluorogenic -secretase
substrate (NMA-GGVVIATVK(DNP)- D R D R D R-NH 2, Cat nr. 565764, Calbiochem). At
the same time, -secretase inhibitor L685,458 (Sigma) was used to validate the specificity of
the -secretase activity assay. After incubation, the incubates were centrifuged at 15700 × g
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for 10 min and transferred to a 96 well plate. Fluorescence was measured using a plate
reader (Fluorstar Galaxy) with excitation wavelength at 355 nm and emission wavelength
at 440 nm. Background fluorescence from substrate samples was subtracted in the final
analysis.
In study II, caspase-3 activity assay was performed in total protein lysates in reaction
mixtures containing 20 mM HEPES (pH 7.5), 10% glycerol, 2 mM dithiothreitol and
Ac-DEVD-AMC (N-acetyl-Asp-Glu-Val-Asp-7-amino-4-methylcoumarin) Fluorogenic
Substrate (BD Pharmigen). After 60 min of incubation at +37 °C, production of AMC
(7-amino-4-methylcoumarin), as an indication of caspase-3 activity, was measured at
thirty-minute intervals for 60 min in a Victor 1420 multilabel counter 96-well plate ELISA
reader (Wallac) using excitation wavelength of 380 nm, and emission wavelength of
460 nm. The data are shown as relative fluorescence units (RFU).
4.10 IN VITRO AICD GENERATION ASSAY (STUDY III)
For the in vitro AICD generation assay, a protocol similar to that described by Pinnix et al.
was used (Pinnix et al., 2001). Briefly, SH-SY5Y-APP751 cells were plated at a density of
200000 cells/cm2. The cells were scraped in buffer A (50 mM HEPES, 150 mM NaCl, 5 mM
1,10-phenanthroline, pH 7.4) and homogenized by passing through a 25G 5/8 needle 10
times. The homogenates were centrifuged at 10000 × g for 15 min. The resulting membrane
fractions (P10) were washed once with buffer A and centrifuged at 10000 × g. Total protein
concentrations were measured in the P10 fraction, and the same amounts of protein in each
sample were incubated in 30 μl of buffer B (50 mM HEPES, 150 mM NaCl, 5 mM
1,10-phenanthroline, pH 7.0 and the protease inhibitor cocktail; Roche) for 2 h on ice (as a
negative control), or at +37°C to allow the release of AICD. The samples were then
centrifuged at 10000 × g for 15 min. The supernatants and solubilized pellets were analyzed
by Western blot using the anti-APP-CTF antibody (A8717) to detect APP C83 and AICD,
respectively (Table 10).
4.11 STAUROSPORINE TREATMENT AND CELL VIABILITY ASSAY (STUDY
II)
SH-SY5Y-APP751 and SH-SY5Y-BACE1-Myc cells were induced with apoptosis by treating
the cells for 6 and/or 10 hours with 1 μM staurosporin (STS; Sigma). 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT; Invitrogen) assay was used to assess cell
viability after treatment of the cells with STS. After the addition of MTT, cells were
incubated for 60 min at +37°C, after which the formazan granules were solubilized in 99.7%
DMSO (Dimethyl sulfoxide, Hybri Max™, Sigma). Finally, cell viability was determined as
the optical density (OD) at 595 nm with a Victor 1420 ELISA reader and expressed as
percentage of untreated control cells.
54
4.12 FLOW CYTOMETRY (STUDY III)
Cell surface receptors expressed in stably transfected HEK293i cells after a 48-h induction
were analyzed by flow cytometry as described earlier (Petaja-Repo et al., 2006) using
1 μg/ml anti-c-Myc 9E10 antibody and 1 μg/ml phycoerythrin-conjugated secondary
antibody (BD Biosciences). To assess constitutive internalization, the protocol devised by
Markkanen and Petaja-Repo was applied (Markkanen and Petaja-Repo, 2008). Briefly, cell
surface receptors on stably transfected HEK293i cells were labeled on 12-well plates (2 x 106
cells/well) with the anti-c-Myc 9E10 antibody (1 μg/ml), washed and pulsechased for 4 h at
+37°C after a 24-h induction period. The c-Src inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-
(dimethylethyl)pyrazolo[3,4-d]pyrimidine) (4 μM) (see also Table 8) was added together
with the antibody and was maintained throughout the incubations. The controls were
treated with a vehicle (DMSO). The remaining antibody-labeled receptors at the cell surface
were stained with the phycoerythrin-conjugated secondary antibody (2 μg/ml). The
fluorescence of live cells was measured in a Becton-Dickinson FACSCalibur flow cytometer
and analyzed by the CellQuestPro 6.0 software (both from BD Biosciences) as described
previously (Markkanen and Petaja-Repo, 2008).
4.13 MICROSCOPY (STUDIES II AND III)
4.13.1 Confocal microscopy (Studies II and III)
In study II, SH-SY5Y-BACE1-Myc cells were plated on sterile coverslips coated with 100
μg/ml poly-D-lysine (Sigma), transfected with siRNA (seladin-1/DHCR24 or control) and
treated with or without STS. Similarly in study III, SH-SY5Y-APP751 cells were transfected
with OR-Cys27, OR-Phe27 constructs, control pcDNA, or left untransfected. In order to
inhibit PKC activity in study III, SH-SY5Y-APP751 cells were treated with 1 μM Bis I for 4
h. In the APP subcellular localization experiments (study III), SH-SY5Y-APP751 cells were
plated on chamber slides (Lab-Tek) and transfected with EYFP-Golgi, EGFP-Rab7, EGFP-
Rab9, or EGFP-Rab11 constructs (Choudhury et al., 2002).
Next in both studies II and III, the cells were fixed in 4% paraformaldehyde for 15 min at
room temperature. After incubation in blocking and permeabilization buffer with 5% (also
0.5%, study III) BSA and 0.1% Triton X-100 (BHD Laboratory Supplies) in PBS (Invitrogen),
the cells were stained with primary antibodies as indicated in Table 10 (see “Dilution” for
IF). Alexa Fluor® 488 goat anti mouse, Alexa Fluor® 568 goat anti rabbit (Invitrogen; 1:250 or
1:500), Cy3 sheep anti-mouse (C 2181, Sigma; 1:500) (studies II and III), or Cy5 goat anti
rabbit (Jackson ImmunoResearch Laboratories; 1:1000, study III), were used as secondary
antibodies. Single optical z-sections were examined in a Nikon Eclipse TE300 microscope
together with the Ultra VIEW laser scanning confocal unit (Perkin Elmer) or, alternatively
with Carl Zeiss LSM 700 or LSM510 confocal laser scanning microscopes. The images were
processed with Adobe Photoshop™ CS4 software (version 11.0; Adobe Systems Inc., USA).
4.13.2 Electron microscopy (study III)
Induced (24 h) or mock-induced HEK293i-hOR-Cys27 cells were rinsed with phosphate
buffered saline and fixed with 4% paraformaldehyde in 0.1 M phosphate buffer containing
2.5% sucrose. The cryosectioning, immunolabeling and imaging were done as described
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earlier (Apaja et al., 2006) with minor modifications. Antibodies against LBPA and APP
C-terminus (Table 10) were used for immunodetection, followed by incubations with
Protein A-conjugated 5 nm and 10 nm of gold prepared as described by Slot and Geuze,
respectively (Slot and Geuze, 1985). The sections were embedded in methylcellulose and
examined in Philips CM100 (FEI company). Images were captured by Morada CCD camera
(Olympus Soft Imaging Solutions GMBH).
4.14 ANIMAL EXPERIMENTS (STUDY IV)
4.14.1 Animals and MCAO
In study IV, thirty-one male Wistar rats (age 2-3 months) from Laboratory Animal Centre,
Kuopio, were induced by either MCAO, (n=23) or sham operation (n=8). The rats were
housed under 12:12 h light/dark conditions in a temperature-controlled environment
(20±1 °C). Food and water were available ad libitum. All experimental procedures were
conducted in accordance with the directives of Commission of the European communities
COM(2008)543 and the study was approved by the National Animal Experiment Board
(Licence nr. ESLH-2008-07622/Ym-23).
Focal cerebral ischemia was induced by the intraluminal filament technique (Longa et al.,
1989). Anesthesia was induced in a chamber using 5% halothane in 30% O2/ 70% N2O. In
the surgery, the filament was inserted into the internal common carotid artery and held in
place with a tightened suture and microvascular clip around the artery. After 120 min of
MCA occlusion, the filament was removed and the external carotid artery was permanently
closed. The sham-operated rats were treated in a similar manner excluding the filament
insertion.
4.14.2 Drug treatment and behavioral experiments
Two days after surgery, MCAO animals were assigned to behaviorally equivalent
experimental groups: MCAO (vehicle treatment, n = 7), MCAO+BEP (50 mg/kg bepridil
treatment, n = 5) and SHAM (vehicle treatment, n = 6) for 27 days. Animals were subjected
to three different behavioral tests as described in Figure 13.
i)  Limb-placing test
The modified version of the limb-placing test was used to assess hindlimb and
forelimb responses to tactile and proprioceptive stimulation (Jolkkonen et al., 2000;
Puurunen et al., 2001). The rats were habituated for handling and tested before
ischemia induction and then again on postoperative days 2, 4, 7, 10, 14, 21 and 28.
ii)  Cylinder test
The cylinder test was used to assess imbalances between the impaired and
nonimpaired forelimb use (Karhunen et al., 2003). The number of contacts by both
forelimbs and by either impaired or unimpaired forelimb was counted. The cylinder
test was carried out on the day before the MCAO operation and on postoperative
days 14 and 28.
iii)  Tapered/ledged beam walking test
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Sensorimotor functions of hindlimbs were tested using a tapered/ledged beam (Zhao et al.,
2005). The rats were pretrained for 3 days to traverse the beam before ischemia induction.
The beam walking apparatus consisted of a tapered beam with underhanging ledges on
each side to permit foot faults without falling. Each rat’s performance was analyzed by
calculating the slip ratio for the impaired (contralateral to lesion) forelimb and hindlimb.
The test was carried out one day before the MCAO operation and on postoperative days 14
and 28.
Figure 13. Study design in study IV.
4.15 STATISTICAL ANALYSES
Genetic analyses, studies I and III
Single locus allele and genotype frequencies utilizing two-sided Pearson 2 and Fisher’s
exact tests, logistic regression, and Kaplan-Meier survival analyses were performed to
assess disease association and age of onset effects with the studied SNPs among the
unstratified case-control cohort. Additionally, multivariate logistic regression analysis was
applied to assess age, gender and APOE4 adjusted risk effects. In study I, non-parametric
Mann-Whitney U test (equal variances not assumed) was used to investigate possible
differences in CSF A42, t-tau, or p-tau levels with respect to the studied SNPs. Bonferroni
correction was not applied in study I, since this study was based on the previously
described risk gene polymorphisms studied in the context of AD (see more in Discussion).
In study III, Hardy-Weinberg equilibrium of SNPs in the AD patient and control cohorts
was calculated using the GenePop program
(http://genepop.curtin.edu.au/genepop/genepop_ op1.html). Pairwise LD values and
estimation of haplotypes and haplotype blocks were performed with the HaploView
program (http://www.broadinstitute.org/scientific-community/science/programs/medical-
and-population-genetics/haploview/haploview). Association analyses in the NIMH GWAS
data set in study III were conducted using PBAT v3.6 as previously described (Bertram et
al., 2008). Effect sizes in the family data were estimated in SAS v9.2 using conditional
logistic regression stratified by family as described previously (Schjeide et al., 2009). Meta-
analyses were based on random-effect models and were performed in R programming
Days 	
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language, version 2.10.0, using rmeta, version 2.16. Final results are based on the
meta-analyzed data combined from two independent, familial and case-control sample sets.
Functional quantifications, studies II, III and IV
The GraphPad Prism 4.01 software was used for one-way analysis of variance (ANOVA) in
study I, followed by Bonferroni’s post-hoc test, in experiments with more than one variable.
In all other studies, the SPSS/Win statistical program (version 14.0.1) was used to perform
statistical analyses. In experiments with only one variable, paired t tests, independent-
sample t tests (equal variances assumed), or Mann-Whitney U tests (equal variances not
assumed) were used to test statistical significance between the sample groups. The values
are reported as means ± standard deviations (SD). The level of statistical significance was
defined as p < 0.05.
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5 Results
5.1 META-ANALYSIS-BASED ASSESSMENT OF RISK GENES IN FINNISH
CASE-CONTROL COHORT: STUDY I
Over the past 30 years, nearly 1400 studies have assessed almost 700 different genes as
potential risk factors for AD, mostly using the candidate gene-based approach (Bertram
et al., 2007; Bertram and Tanzi, 2008). However, with the exception of one genetic variant,
the 4 allele of APOE gene (Strittmatter et al., 1993; Saunders et al., 1993), none of these
candidates has been proven to consistently influence the disease risk or onset age in
different populations. As most of the AD cases represent the more complex, LOAD form of
the disease and APOE4 alone is estimated to explain only a fraction of this form, further
efforts are needed to reveal other possible genetic risk factors for the disease.
To assess the risk gene effects in Finnish AD case-cohort cohort, 21 candidate gene
polymorphisms were selected for genotyping on the basis of the meta-analyses retrieved
from the AlzGene database. The distribution of APOE2/3/4 alleles was 0.04/0.80/0.16 and
0.01/0.54/0.45 in control and AD groups (p < 0.001), respectively, indicating that the APOE
4 allele was significantly over-represented among the AD patients (p < 0.001, OR = 6.00;
95% CI 4.73 to 7.61). All the genotyped SNPs were found to be in Hardy-Weinberg
equilibrium (HWE) in both AD and control groups, except for the SNP rs760678. As a
control measure, ~4% of the randomly selected DNA samples were cycle-sequenced at the
rs760678 site and a subsequent comparison of the results did not reveal discrepancies in the
genotype distribution between two genotyping approaches.
The results indicated that there was an association especially of two additional genes with
AD. A statistically significant genotype and allele association with AD was observed with
rs1800629 in the TNF gene. APOE, gender and age-adjusted logistic regression analysis
revealed a protective effect for the A allele carriers of rs1800629 (p = 0.02; OR = 0.69, 95% CI
0.49-0.95). In addition, a significant difference we found in genotype but not in allele
distribution between the AD and control groups with rs1143634 in the IL1B gene.
Next, it was decided to assess the possible effects of the studied SNPs on CSF A42, t-tau,
or p-tau levels among a subset of AD patients. Interestingly, there was a significant
decrease in the CSF A42 levels (p=0.002) among AD patients carrying the A allele (GA+AA
vs. GG) of rs1800629 in TNF gene, while the T allele carriers (CT+TT vs. CC) of rs1143634 in
IL1B gene associated with increased CSF p-tau levels (p = 0.05). Moreover, AD patients
carrying the A allele (GA+AA vs. GG) of rs600879 in SORCS1 gene exhibited a statistically
significant increase in the CSF A42 levels (p = 0.03), but SORCS1 did not show statistically
significant allele or genotype association with AD. Kaplan-Meier survival analyses with the
studied SNPs did not reveal significant age of onset effects among AD patients.
In summary, AlzGene-based top hit screening in study I revealed two proinflammatory
genes, TNF and IL1B, which genetically associated with AD and altered CSF biomarker
levels among Finnish population. In addition to being important players in the innate
inflammatory response induced by factors, such as A, the current study points to the
potential underlying role of genetic alterations in the TNF and IL1B genes in affecting the
susceptibility for AD.
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5.2 DOWN-REGULATION OF SELADIN-1 INCREASES BACE1 LEVELS AND
ACTIVITY THROUGH ENHANCED GGA3 DEPLETION DURING APOPTOSIS:
STUDY II
Seladin-1 is a neuroprotective protein selectively down-regulated in brain regions affected
in AD. Seladin-1 is also known to protect cells against A42- and oxidative stress-induced
apoptosis activated by caspase-3, a key mediator of apoptosis. Study II utilized RNA
interference (RNAi) to assess the molecular effects of seladin-1 down-regulation on the
BACE1 function and APP processing in SH-SY5Y human neuroblastoma cells in both
normal and apoptotic conditions.
Down-regulation of seladin-1 in SH-SY5Y-APP751 cells (siSel) showed an average of a
1.3-fold increase in APP C-terminal fragment (C83 and C99) levels, although the levels of
secreted APP (sAPP and sAPPtot) and A40 remained unchanged. During staurosporin
(STS)-induced apoptosis, down-regulation of seladin-1 mRNA levels by approximately 60%
resulted in augmented caspase-3 activity, as indicated by the 1.5 to 2.0-fold increase in
active caspase-3 cleavage fragments (~14 and 17 kDa) This, in turn, correlated with 30 to
40% decrease in full-length GGA3 protein levels compared with those in control cells.
Since GGA3 is known to target BACE1 to the lysosomes for degradation, it was decided to
assess whether the decrease in GGA3 levels affected BACE1 protein levels and activity in
SH-SY5Y-BACE1-Myc cells stably over-expressing BACE1. Similar to SH-SY5Y-APP751
cells, STS treatment led to augmented caspase-3 activity as well as decreased full-length
GGA3 levels in cells with seladin-1 down-regulation compared to the levels in cells
transfected with control siRNA (siCtrl). Importantly, these alterations coincided with an
average of 1.5-fold increase in BACE1 levels. Furthermore, no differences in BACE1 or
full-length GGA3 protein levels were found between siSel- and siCtrl-transfected cells
under normal growth conditions. Moreover, cleaved caspase-3 fragments were not
observed under normal conditions.
Next, it was to investigated whether the observed increase in BACE1 levels led to enhanced
amyloidogenic APP processing under apoptotic conditions. It was discovered that seladin-1
knockdown increased the production of APP -CTF and A40 levels in
SH-SY5Y-BACE1-Myc cells, while C83 levels remained undetectable. Furthermore, a
significant decrease in cell viability (~30%) was observed after seladin-1 knockdown as
compared to siCtrl-transfected cells.
Finally, confocal microscope analysis showed that more BACE1-Myc was co-localizing with
TfR (transferrin receptor), a marker for early endosomes and the plasma membrane, in
siSel-transfected cells than in siCtrl-transfected cells. This colocalization was observed in
the subcellular compartments near or at the plasma membrane. A similar result was also
obtained using co-staining with an antibody against EEA1, another marker for early
endosomes (data not shown). In addition, some co-localization of BACE1-Myc with
LAMP2a (a lysosomal marker) was detectable in intracellular structures, most likely
lysosomes, in cells transfected with siCtrl. This is in line with previous reports on BACE1
subcellular localization of BACE1 (Huse et al., 2000). However, co-localization of BACE1-
Myc with LAMP2a appeared to decrease during apoptosis. In addition, more BACE1-Myc
seemed to reside near or at the plasma membrane in siSel- than in siCtrl-transfected cells
under apoptotic conditions. Hence, the depletion of GGA3 levels due to seladin-1
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knockdown may have affected the BACE1 subcellular localization in SH-SY5Y-BACE1-Myc
cells during apoptosis.
Taken together, these findings in study II suggest that even a moderate decrease in
seladin-1 expression may increase caspase-3 activity. This appears to sensitize cells to
apoptosis and consequently to augment BACE1 levels and activity through depletion of the
BACE1-sorting protein, GGA3. Therefore, seladin-1 may play an important role in the early
phases of the disease and prove to be a potential biomarker for AD.
5.3 CYSTEINE 27 VARIANT OF -OPIOID RECEPTOR AFFECTS APP
PROCESSING THROUGH ALTERED ENDOCYTIC TRAFFICKING: STUDY III
There is recent evidence indicating that agonist-induced activation of OR can contribute to
AD pathogenesis by affecting A generation in vitro and in vivo (Ni et al., 2006; Teng et al.,
2010). Moreover, it has been demonstrated that two different forms of OR – the OR-Phe27
variant and the less common OR-Cys27 variant – significantly differ in receptor
maturation and intracellular localization (Leskela et al., 2009). Hence, study III examined
whether these two variants differentially affect APP processing and A generation when
expressed in agonist-independent conditions in in vitro. In this way, the genetic role of
OPRD1 in AD could be clarified by assessing the risk effect of T80G variation (rs1042114) in
both case-control and familial AD sample sets.
Transient overexpression of the N- and C-terminally tagged OR-Cys27 variant led to a
robust accumulation of APP C83 and AICD, while total sAPP and particularly A40 levels
were decreased. Nevertheless, the increase in APP C83 levels was not related to the
augmented -secretase activity. As total protein-normalized A40 levels were significantly
decreased in the OR-Cys27-transfected cell medium, the in vitro AICD generation assay
did not reveal any changes in the -secretase activity in SH-SY5Y-APP751 cells after OR
transfection. There were no significant alterations in sAPP and APP C99 CTF levels,
suggesting that OR-Cys27 overexpression does not lead to any general enhancement of
APP processing. In addition to these findings, confocal microscope analysis of
SH-SY5Y-APP751 cells showed a markedly augmented intracellular localization of the
OR-Cys27 variant as compared to OR-Phe27 variant. This is in line with the previous
observations that the OR-Cys27 variant undergoes constitutive internalization (Leskela et
al., 2009). The co-immunoprecipitation assay did not detect evidence for the formation of a
stable complex between APP and OR variants in HEK293i cells, suggesting that APP and
OR may not be interacting directly, but instead could reside in the same complexes via an
interaction with another protein(s).
As the OR variants significantly differed in receptor maturation when expressed in
SH-SY5Y-APP751 cells, the next experiment assessed whether the observed changes in APP
processing in the OR-Cys27-expressing cells were related to the inefficient receptor
maturation. After inducing HEK293iOR-Cys27 cells with saturating concentrations of
different pharmacological OR ligands, it was found that 48-h treatment with some ligands
(naltrexone and ICI 174,864) significantly suppressed the OR-Cys27-induced increase in
APP C83 levels. However, this occurred in a manner that was not directly related to their
ability to enhance receptor maturation.
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The observed APP processing phenotype in the OR-Cys27-overexpressing cells appears to
be related to the possibly altered nature of mature receptors that have reached the cell
surface. Thus, it was next examined whether specific OR-linked signal transduction
pathways might be involved. After screening of several GPCR inhibitors, we found that the
c-Src tyrosine kinase inhibitor PP2 was found to strongly suppress the increase of APP C83
levels and the constitutive receptor internalization in HEK293iOR-Cys27 cells. In addition,
flow-cytometry revealed that PP2 treatment had increased the number of the ORs at the
cell surface.
Similar to pH-neutralizing conditions (Vingtdeux et al., 2007), inhibition of PKC is known to
alter the endocytic trafficking of internalized cell surface proteins to the perinuclear area
(Kermorgant et al., 2003). Therefore, it was interesting that in the screen of inhibitors of
GPCR signaling molecules, Bis I, a specific inhibitor of all PKC isoforms, was found to
change APP processing in a manner that closely mimicked that evoked by OR-Cys27
overexpression. Exposure of uninduced HEK293iOR-Cys27 cells and parental HEK293i
cells to increasing concentrations of Bis I led to the accumulation of APP CTFs and AICD in
a concentration-dependent manner without an increase in the sAPP levels. As expected,
an increased sAPP secretion was observed when PKC was activated by PMA (Racchi et al.,
2003). These results suggest that the OR-Cys27 expression-induced, agonist-independent,
increase in the APP C83 levels is related to disturbances in a constitutive cellular process(es)
rather than to PKC-dependent or -independent induction of the nonamyloidogenic APP
processing as described for several other GPCRs upon agonist-mediated activation
(Camden et al., 2005; Nitsch et al., 1992, 1993).
Confocal microscopy revealed that inhibition of PKC caused a robust dispersion of the
APP-containing vesicles to the cell periphery in the SH-SY5Y-APP751 cells, as detected by
an antibody specifically recognizing APP C-terminus. Hence, it is conceivable that the APP
processing phenotype in cells expressing OR-Cys27 under agonist-independent conditions
might be related to impairment in PKC-dependent cellular trafficking. This is in line with
the concept that altered processing and impaired trafficking of APP may be coupled.
APP C83 has previously been shown to accumulate under pH-neutralizing conditions. This
was proposed to take place because of reduced degradation of C83 in the LEL compartment
as well as through partial -secretase-mediated conversion of C99 to C83 (Waldron et al.,
2008). Therefore, it was decided to elucidate whether overexpression of the OR-Cys27
variant could affect the subcellular localization of APP CTFs in SH-SY5Y-APP751 cells. To
results of confocal microscopy using an antibody against APP C-terminus found that APP
CTFs mostly localized in a compact juxtanuclear structure with a partial localization at or
near the plasma membrane in the OR-Phe27-expressing and untransfected cells. In the
OR-Cys27-overexpressing cells, however, APP was localized ubiquitously, suggesting that
APP had dispersed away from the juxtanuclear compartment(s) in OR-Cys27-transfected
cells. Co-staining of the untransfected cells with APP N- and C-terminal antibodies
confirmed the suspicion that the APP staining in the juxtanuclear structure had originated
mainly from the APP CTFs and not from the full-length form of APP. Subsequent
characterization revealed that APP CTFs predominantly co-localized with LEL in
untransfected SH-SY5Y-APP751 cells. Partial colocalization was also observed with a
marker of the Golgi compartment. Quantification showed that there was on average 60%
less colocalization of APP with OR-Cys27 than with the OR-Phe27 variant (p < 0.05) in the
juxtanuclear structures. In OR-Cys27-transfected cells, APP CTFs were also found to
partially co-localize with the lysosomal marker LAMP2a and the multivesicular body
(MVB) marker lysobisphosphatidic acid (LBPA). Moreover, immunoelectron microscopy in
HEK293 cells showed an increased number of LBPA-positive vesicle clusters with or
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without the MVB-type outer membrane in cells expressing OR-Cys27 compared to control
cells. Interestingly, APP CTFs were abundantly concentrated in these vesicles. These
vesicles may represent intermediates which have failed to mature and/or move to the
LEL/Golgi compartments. Taken together, the OR-Cys27variant appears to interfere with
the normal subcellular trafficking of APP, possibly via affecting PKC-mediated intracellular
signaling.
Finally, it was decided to assess whether or not genetic variations in OPRD1 affect the risk
for AD in case-control and family-based (GWAS) AD cohorts. According to the allele and
genotype association analyses of SNPs (rs1042114, rs678849, rs706588, rs4654323, and
rs4654323), only rs1042114 showed a borderline genotype association with AD (p = 0.07).
This was caused by TG heterozygotes (OR-Phe27Cys), who were marginally more
frequent in AD cases vs. controls [p = 0.07; OR = 2.5, 95% CI (0.94-6.50)] (Table 11). The age
of onset and cerebrospinal fluid A42 analyses with respect to the rs1042114 variation did
not reveal any statistically significant changes among the AD patients. In an attempt to
independently replicate the results observed with rs1042114, it was decided to extract this
SNP from a GWAS dataset of Caucasian AD families from the National Institute of Mental
Health (NIMH) Genetics Initiative Study (Bertram et al., 2008). Since the rs1042114 variant
was not included in the Affymetrix 500K GWAS array, genotypes of this SNP were inferred
by imputation via IMPUTE v2.0 using HapMap CEU and 1000 Genomes Project pilot
release data. In these independent, family-based data observed an overtransmission of the
heterozygous TG genotype was detected in the affected individuals (p = 0.021). Using
conditional logistic regression stratified on family, this translated into an OR of 1.62 (95%
CI: 1.00-2.64). Combining these data with the case-control results via random-effects meta-
analysis yielded an OR 1.77 (95% CI: 1.14-2.74; p = 0.011). Collectively, these data suggest
that the Phe27Cys variation in OR may play a role in AD.
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Table 11. Summary of allele and genotype frequencies of OPRD1 SNPs among Finnish AD
patients and controls.
aSNP and location
(kb)
Allele Frequency Genotype Frequency
Allele Controls AD bp-value Genotype Controls AD bp-value
rs1042114 (0) n=1324 n=1002 n=662 n=501
T
G
0.875
0.125
0.865
0.135
0.47
GG
TG
TT
0.024
0.201
0.775
0.012
0.246
0.743
0.07
rs678849 (6.2) n=1340 n=1062 n=670 n=531
T
C
0.534
0.466
0.518
0.482
0.44
TT
TC
CC
0.209
0.515
0.276
0.271
0.493
0.235
0.54
rs706588 (23.6) n=1340 n=1064 n=670 n=532
A
G
0.678
0.322
0.675
0.325
0.88
AA
AG
GG
0.460
0.436
0.104
0.438
0.474
0.088
0.36
rs4654323 (30) n=1340 n=1062 n=670 n=531
G
T
0.701
0.299
0.699
0.301
0.88
TT
TG
GG
0.090
0.418
0.493
0.079
0.444
0.476
0.60
rs4654323 (30) n=1342 n=1066 n=671 n=533
C
A
0.569
0.431
0.540
0.460
0.17
CC
AC
AA
0.306
0.526
0.168
0.287
0.507
0.206
0.24
aLocation of SNPs are indicated in the 5' to 3' orientation with respect to SNP rs1042114.
bAllele and genotype frequencies were compared using two-sided Pearson´s 
2 test. All the
studied SNPs were in Hardy-Weinberg equilibrium in both cases and controls (p < 0.05).
5.4 BEPRIDIL DECREASES A AND CALCIUM LEVELS IN THALAMUS
AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN RATS: STUDY IV
AD and cerebral ischemia share similar features in terms of altered APP processing and A
accumulation. It was previously shown that A and calcium deposition and -secretase
activity are robustly increased in the ipsilateral thalamus after transient MCAO in rats (van
Groen et al., 2005; Hiltunen et al., 2009). Since there exists an intimate link between A and
calcium in AD pathology (Supnet and Bezprozvanny, 2010; Demuro et al., 2010), it was
decided to investigate in study IV whether the non-selective calcium channel blocker
bepridil could affect thalamic accumulation of A and calcium and in turn improve the
functional recovery in rats subjected to MCAO. Interestingly, bepridil is also able to inhibit
-secretase cleavage of APP in vitro and in vivo (Mitterreiter et al., 2010).
Consistent with the previous findings (van Groen et al., 2005; Makinen et al., 2008; Hiltunen
et al., 2009), soluble A40 and A42 levels were significantly increased in the ipsilateral
thalamus of MCAO rats. Bepridil treatment decreased both soluble A40 and A42 levels
in the ipsilateral thalamus by 1.8- and 2.3-fold, respectively, when compared to
vehicle-treated MCAO rats. However, bepridil treatment did not affect the levels of soluble
40 and A42 or insoluble A42 in the contralateral thalamus when compared to
vehicle-treated or sham-operated rats.
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Enhanced accumulation of A has been shown to coincide with increased calcium levels in
the ipsilateral thalamus of MCAO rats (Makinen et al., 2008; Hiltunen et al., 2009). Here, a
robust increase was also observed in the calcium levels in the ipsilateral thalamus when
compared to the contralateral side in MCAO rats. Importantly, calcium levels in the
ipsilateral thalamus were significantly reduced (~3-fold) in MCAO rats treated with
bepridil. When compared to the sham-operated rats, however, calcium levels in the
ipsilateral thalamus of bepridil-treated MCAO rats were still significantly higher, indicating
that bepridil treatment was not able to fully normalize the calcium levels. Conversely, no
difference in calcium levels was observed in the contralateral thalamus between vehicle-
and bepridil-treated or sham-operated rats. Correlation analysis revealed a positive
correlation between A42 and calcium (r = 0.85, p < 0.001) and A40 and calcium (r = 0.74,
p < 0.001) levels in the ipsilateral thalamus.
It was next investigated whether bepridil-related changes were linked to altered expression
and/or processing of APP in the ipsilateral thalamus. Consistent with the previous findings
(Hiltunen et al., 2009), a significant increase (~1.4 fold) in CTF levels was observed in the
ipsilateral thalamus when compared to contralateral thalamus after MCAO. Moreover, total
APP (=APP695 immature + APP695 mature) levels were significantly decreased. In the
bepridil-treated MCAO rats, however, there were no significant APP-related alterations in
the ipsilateral thalamus. In addition, the GGA3 protein levels declined by about half
concomitantly with an increase (~1.8-fold) in BACE activity in the ipsilateral thalamus of
both vehicle- and bepridil-treated MCAO rats. Similarly to the apoptotic conditions in
study II and data from Tesco et al. (Tesco et al., 2007), the reduction of full-length GGA3
protein levels coincided with the increase in GGA3-specific cleavage product of ~50 kDa in
both vehicle- and bepridil-treated samples. This suggests that full-length GGA3 had been
proteolytically cleaved by some yet unknown protease(s). These changes were not observed
in the ipsilateral thalamus of sham-operated rats. - and -secretase activities were not
significantly altered in the ipsilateral thalamus of vehicle- or bepridil-treated MCAO rats.
The levels of sAPP were measured to further assess possible APP-related alterations. Total
sAPP levels were significantly increased, particularly in the ipsilateral thalamus of
vehicle-treated MCAO rats (~2.3 fold), but also in the bepridil-treated MCAO rats (~1.8
fold). Moreover, sAPPtot levels showed a positive correlation with BACE activity in the
ipsilateral thalamus (r = 0.55, p < 0.05; data not shown). Since a cell culture medium sample
from SH-SY5Y-APP751 cells was used as a control in the Western blots, it was possible to
explore the isoform expression profiles of sAPPtot in the thalamic samples. In addition to
the expected elevation of total sAPP695, in the ipsilateral thalamus of vehicle- and bepridil-
treated MCAO rats there was the appearance of an APP-specific band, which was similar in
size as the total sAPP751 in the SH-SY5Y-APP751 control sample. This is in line with the
previous findings showing an up-regulation in the APP751 isoform-specific expression in
the ipsilateral thalamus after 30 days of MCAO (Hiltunen et al., 2009). Taken together, these
results suggest that the treatment of MCAO rats with bepridil had affected APP processing
in the ipsilateral thalamus in a manner that may not have involved alterations in -, -, or
-secretase activities.
Apart from the altered APP processing and A production, it is also possible that
alterations in A degradation and/or clearance account for the observed decrease in A
levels in bepridil-treated MCAO rats. To address this possibility, it was decided to
investigate the protein levels of IDE, NEP, and LRP, which are involved in the degradation
and clearance of A. Similar to our previous observations (Hiltunen et al., 2009), IDE levels
were significantly increased in the ipsilateral thalamus of vehicle-treated MCAO rats.
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Bepridil treatment, however, did not affect IDE levels. NEP and LRP levels were
unchanged in the ipsilateral thalamus of vehicle- and bepridil-treated MCAO rats as well as
sham-operated rats.
Since MCAO promotes astrogliosis in the rat thalamus (Hiltunen et al., 2009; van Groen
et al., 2005), it was decided next to assess the effects of bepridil treatment on the
inflammatory response by determining the levels of GFAP and TNF expression in the
ipsilateral thalamus. Western blot analysis revealed a strong ~10 fold increase in GFAP
protein expression in the ipsilateral thalamus of vehicle-treated MCAO rats. Similarly, a
robust ~3.5 fold increase in the GAPDH-normalized TNF mRNA levels was observed in
the ipsilateral thalamus of vehicle-treated MCAO rats. However, bepridil did not prevent
the up-regulation of these markers of astrogliosis and inflammation after MCAO. Taken
together, these results suggest that bepridil treatment does not affect the expression of well-
known regulators of A degradation or clearance nor alleviate astrogliosis or TNF
activation in the ipsilateral thalamus of MCAO rats.
Given the putative neuroprotective role of seladin-1 in study II (see also chapter 2.3.1.3), it
was next decided to assess whether seladin-1 mRNA levels were altered in the ipsilateral
thalamus of MCAO rats. Quantitative PCR analysis revealed a significant ~40% decrease in
seladin-1 mRNA levels in the ipsilateral thalamus of MCAO rats. Interestingly, no similar
kind of decline in seladin-1 mRNA levels was observed in bepridil-treated MCAO rats.
Instead, a trend towards a statistically significant difference (p = 0.057) in seladin-1 mRNA
levels in the ipsilateral thalamus was observed in the bepridil-treated MCAO rats as
compared to vehicle-treated rats. Correlation analyses were conducted between seladin-1
and calcium levels as well as seladin-1 and A levels; there was a significant inverse
correlation between seladin-1 mRNA and calcium (r = 0.70, p < 0.01) as well as with
insoluble A42 levels (r = 0.64, p < 0.05), suggesting that the reduction in seladin-1
expression was associated with the thalamic pathology emerging after MCAO.
To elucidate the underlying molecular mechanisms related to the reduced calcium levels in
bepridil-treated MCAO rats, it was decided to determine the mRNA levels of voltage-
dependent L-type calcium channel subunit -1C (LTCC) in the thalamus. The rationale for
this experiment originated from a previous study, which showed that bepridil treatment
could change the LTCC expression in canine atria (Nishida et al., 2007). A significant
decrease in LTCC mRNA levels was observed in the ipsilateral thalamus of rats with
MCAO but there was no difference between vehicle- and bepridil-treated MCAO rats.
Collectively, these data suggest that bepridil treatment could increase seladin-1 but not
LTCC levels in the ipsilateral thalamus of MCAO rats. Thus, increased seladin-1 expression
could be a reflection of improved neuronal survival in the ipsilateral thalamus of MCAO
rats after bepridil treatment.
Sensorimotor impairment and recovery of function after MCAO was assessed in three
behavioral tests (see 4.14.2). There was no significant difference between the treatment
goups in forelimb use. However, ANOVA for repeated measures showed a significant
group × time interaction (p < 0.01), indicating that sensorimotor recovery did differ between
the groups. A more detailed analysis revealed that bepridil-treated MCAO rats increased
the use of the impaired forelimb on post-operative day 28 compared to vehicle-treated
MCAO rats. The limb-placing test was used to assess forelimb and hind limb responses to
tactile and proprioceptive stimulation. The test showed that MCAO rats were initially
severely impaired, but this was followed by partial recovery. The significant overall group
effect was explained by the difference between sham-operated and MCAO rats throughout
the follow-up (p < 0.01). Test results in the vehicle treated and bepridil-treated MCAO rats
66
did not differ from each other. Tapered/ledged beam-walking test was used as a measure of
hind limb function. The special feature of the test is that the ledge allows the rat to display a
deficit normally hidden by compensatory adjustment. All rats showed an increase in slips
made (foot faults) with no apparent recovery after MCAO. A significant overall group
effect was reflected in the MCAO rats making significantly more slips compared to
sham-operated rats (p < 0.05). There was no difference between vehicle- and
bepridil-treated MCAO rats during the follow-up. All in all, the behavioral tests
demonstrated a slight functional improvement in MCAO rats after treatment with bepridil
that may have been associated with reduced thalamic pathology.
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6 Discussion
6.1 AN ASSOCIATION STUDY OF AD RISK GENES IN A FINNISH
POPULATION: STUDY I
Study I revealed polymorphisms in two inflammatory response-related genes, TNF and
IL1B, which significantly associated with AD and altered CSF biomarker levels. Several top
AlzGene hits were also studied, such as ABCA7, APOE, BIN-1, CALHM1, CLU, CR1, CST3,
GRN, LDLR, MS4A6A/MS4A4E, and PICALM among the Finnish population (Lehtovirta et
al., 1996; Lamsa et al., 2008; Bertram et al., 2008; Lambert et al., 2009; Helisalmi et al., 2009;
Viswanathan et al., 2009; Hollingworth et al., 2011). The current study on AlzGene-based
top hit screening of 21 potential risk genes emphasized that genetic alterations in TNF and
IL1B genes may play an important role in AD. This was an interesting finding considering
that the cytokines TNF and interleukin 1 are key mediators of inflammation and
apoptosis during neurodegeneration in AD. They also modulate synaptic memory
mechanisms, such as LTP (Tarkowski, 2002; Rowan et al., 2007).
Since the variation rs1800629 in TNF gene displayed a significant variation in all the
parameters of the study [i.e. difference in genotype and allele frequency between patients
and controls, as well as in risk ratio (OR) among AD patients], we examined this gene more
closely in the context of AD. The rs1800629 polymorphism in TNF has been indicated to
associate with AD risk also in other studies. The mechanism of how this particular
polymorphism may affect TNF gene function could be mediated by transcriptional
regulation, since the polymorphic site of rs1800629 is located at the promoter region (308)
of the TNF gene. In the genetic analysis, the A allele carriers of TNF showed protective
effect against AD. In another study, the A allele carriers were shown be more likely subjects
with reduced TNF mRNA levels during severe sepsis (O’Dwyer et al., 2008). Furthermore, it
was recently shown that high serum TNF levels accompanied by systemic inflammatory
events (SIE) in AD patients associated with a more pronounced cognitive decline during a
6-month follow-up period as compared to patients with low levels of serum TNF and the
absence of SIE (Holmes et al., 2009). Thus, it is possible that the A allele at position 308 or a
nearby allele, which is in linkage disequilibrium with the A allele, exerts a protective effect
against AD through reduced transcription of the TNF gene. However, based on the
AlzGene data (http://www.alzgene.org), it should be emphazised that the A allele of
rs1800629 has been shown to significantly associate with both increased and decreased risk
of AD in different populations.
The biomarker analysis detected a significant decrease in CSF A42 levels among AD
patients carrying the A allele (GA+AA vs. GG) of rs1800629 in TNF gene, while the T allele
carriers (CT + TT vs. CC) of rs1143634 in IL1B gene associated with increased CSF p-tau
levels. Moreover, AD patients carrying the A allele (GA+AA vs. GG) of rs600879 in SORCS1
gene showed a statistically significant increase in the CSF A42 levels (p = 0.03) even
though the SNP data from genotype and allele frequency as well as logistic regression
analysis did not show any significant association with AD. Collectively, these results
confirm the findings in genotype and allele frequency analyses as well as logistic
regression, and support the idea that biomarkers in CSF are indicative for pathogenic
mechanisms in AD.
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Since this study was based on the previously identified risk gene polymorphisms in AD,
significant p-values were not corrected for multiple testing. However, it should be noted
that after Bonferroni correction, significant p-values did not remain statistically significant.
This means that further genetic studies in different sample sets are still needed to establish
the role of TNF and IL1B in AD.
In conclusion, the AlzGene-based top hit screening revealed genetic variations in two
candidate genes, TNF and IL1B, which genetically associated with AD and altered CSF
biomarker levels among Finnish population. Apart from being important players in the
innate inflammatory response induced by factors such as A, the current study points to
the underlying role of genetic alterations in the TNF and IL1B genes in AD by thus far
unknown mechanisms.
6.2 DOWN-REGULATION OF SELADIN-1 INCREASES BACE1 LEVELS AND
ACTIVITY DURING APOPTOSIS: STUDY II
In study II, the effects of seladin-1 down-regulation on BACE1-mediated processing of APP
in SH-SY5Y human neuroblastoma cells were studied. The results show that
down-regulation of seladin-1 expression under apoptotic conditions resulted in augmented
BACE1 levels and activity. This was mediated by increased caspase-3 activation and
subsequently enhanced depletion of the BACE1-sorting protein GGA3, which regulates
trafficking of BACE1 to the lysosomes for degradation (Tesco et al., 2007). Depletion of
GGA3 after seladin-1 knockdown appeared to associate with an altered subcellular
localization of BACE1. More BACE1 accumulated in early endosomes and near to the
plasma membrane in apoptotic conditions as compared to normal conditions. These
observations suggest that lysosomal sorting and thereby degradation of BACE1 is reduced
under apoptosis. This leads to increased levels and activity of BACE1 by post-translational
stabilization. Stabilization of BACE1 resulted in increased BACE1-mediated cleavage of
APP leading to elevated production of APP -CTFs and A as well as decreased viability of
SH-SY5Y cells over-expressing BACE1 under apoptosis. The above-mentioned cascade may
take place also during AD pathogenesis due to the fact that seladin-1 is down-regulated in
the temporal cortex of AD patients by ~40% (Greeve et al., 2000; Iivonen et al., 2002).
Decreased seladin-1 mRNA levels also correlated with increased phosphorylated tau levels
in AD brain (Iivonen et al., 2002). Furthermore, a recent genetic study revealed that genetic
alterations in the seladin-1/DHCR24 gene increased the risk of AD, suggesting that genetic
predisposition may also contribute to the observed down-regulation of seladin-1 expression
in AD brain (Lamsa et al., 2007).
Collectively, these results implicate that seladin-1 plays an important role in AD
pathogenesis. Thereby, even a moderate decrease in seladin-1 expression due to genetic
and/or environmental factors (oxidative stress-induced apoptosis, ER stress, etc.) may
initiate a vicious cascade resulting in increased BACE1 activity and ultimately augmented
 production (Figure 4). Increased production of APP -CTFs and A may further
reinforce seladin-1 down-regulation and/or caspase-3 activation, possibly augmenting the
vicious cycle of pathogenic events.
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Figure 14. Suggested mechanism of the effects of reduced seladin-1 expression on BACE1
stabilization and BACE1-mediated processing of APP under apoptosis.
Strong evidence from several functional studies suggest that seladin-1 is protective against
-mediated and oxidative stress-induced apoptosis by inhibiting caspase-3 activity
(Greeve et al., 2000; Luciani et al., 2005, Di Stasi et al., 2005). The protective function of
seladin-1 could be partially associated with its C-terminally located scavenging activity
toward ROS in the ER (Lu et al., 2008). Alternatively, seladin-1-mediated neuroprotection
could be p53-dependent (Kuehnle et al., 2008), possibly preventing the Ras-induced
senescence (Wu et al., 2004). In addition to its effects in neuroprotection, seladin-1 also has a
specific enzymatic activity, which catalyzes the reduction of the 24 double bond of
desmosterol to form cholesterol (Waterham et al., 2001). This function implies that seladin-1
has a role in the formation of cholesterol-rich detergent-resistant membrane domains, also
known as lipid rafts (Abad-Rodriguez et al., 2004). Lipid rafts have been found to affect -
and -secretase-mediated APP cleavage and A generation in vitro and in vivo (Crameri et
al., 2006; Abad-Rodriguez et al., 2004). Interestingly, ~50% reduction in seladin-1 levels was
shown to decrease cholesterol levels, which was accompanied by a disorganization of lipid
raft domains (Crameri et al., 2006) in seladin-1 heterozygous knockout mouse brain. This
defect led to an increase in APP C99 (and a moderate increase in APP C83) and A
production in the brain of seladin-1-deficient mice. Similar to this study, a moderate
increase (~1.3-fold) occurred in the levels of APP C99 as well as an augmentation of the
APP C83 levels after seladin-1 knockdown in SH-SY5Y-APP751 cells. This suggests that
APP processing in general was moderately enhanced rather than there being exclusively a
change in the -secretase-mediated cleavage of APP. In contrast to findings from Crameri et
al., we did not detect any increase in A levels which may be related to differences between
the in vitro and in vivo knockdown models of seladin-1 in general.
Interestingly, recent findings propose that BACE1 is able to efficiently cleave APP in both
lipid raft and non-raft microdomains (Vetrivel et al., 2009). Moreover, it appears that
cholesterol is not only important in -amyloidogenic processing of APP but it is also able to
modulate A-induced neurotoxicity in AD (Fernández et al., 2009). Together these data
imply that there are different plausible mechanisms by which down-regulation of seladin-1
during apoptosis might be harmful. However, the present study suggests that it is more
likely that the pro-apoptotic effects of seladin-1 down-regulation are linked to the
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scavenging activity of seladin-1 protein rather than depletion of de novo-synthesized
cholesterol. This proposal is based on the fact that the serum-containing cell culture
medium contained extracellular cholesterol and thereby supplemented the potentially
reduced de novo synthesis of cholesterol during the acute STS treatment (6 h).
It is well known that BACE1 is a stress-induced protease, e.g. its activity has been shown to
increase after TBI (Blasko et al., 2004; Loane et al., 2009), oxidative stress (Tong et al., 2005),
and cerebral ischemia (Tesco et al., 2007; Wen et al., 2004; Hiltunen et al., 2009). In addition,
it has been recently shown that BACE1 expression is regulated in a transcriptional
(Guglielmotto et al., 2009) and translational manner (depending on the eIF2
phosphorylation status; O’Connor et al., 2008) during different stress conditions. In the
present study, however, translational regulation of BACE1 was not expected to take place
because a BACE1-Myc cDNA construct was used, which did not include the native 5’ or 3’
UTRs important in the regulation of BACE1 translation. This made it possible to specifically
examine the effects of seladin-1 knockdown on post-translational stability of BACE1.
The possible molecular mechanisms related to seladin-1 down-regulation were elucidated
in the AD brain. These findings suggest that seladin-1 down-regulation exacerbates
caspase-3 activity under staurosporine-induced stress conditions. This sensitizes cells to
apoptosis and consequently augments BACE1 levels and activity through depletion of the
BACE1 sorting protein, GGA3. Although the initial cause(s) for seladin-1 down-regulation
in AD is still elusive, this data support the idea that seladin-1 is a plausible target for
disease-modifying therapies for AD as well as other pathologic conditions involved in
oxidative-stress-induced apoptosis, such as cerebral ischemia.
6.3 CYSTEINE 27 VARIANT OF THE -OPIOID RECEPTOR AFFECTS APP
PROCESSING: STUDY III
It was recently demonstrated that GPCRs, such as 2-AR and OR, are linked to AD
pathogenesis by affecting A generation in vitro and in vivo (Ni et al., 2006; Teng et al., 2010).
This was indicated by the findings that agonist-induced stimulation of 2-AR or OR led to
their endocytosis and consequent trafficking of -secretase to late endosomes and
lysosomes and enhanced A production (Ni et al., 2006).  A subsequent study showed that
OR directly forms a complex with both BACE1 and -secretase, which results in the
co-endocytic sorting of OR and the secretases and increased APP processing (Teng et al.,
2010). Keeping in mind this intimate link, it was decided to assess whether the
phenylalanine-to-cysteine substitution at position 27 of OR (OR-Cys27Phe) plays a
functional role in APP metabolism in vitro.
It was previously shown that Cys27 substitution affects the maturation and subcellular
localization of OR in non-neuronal cells (Leskela et al., 2009; Petaja-Repo et al., 2000).
OR-Cys27 variant exhibited a decreased mature/precursor receptor ratio, which was
related to the retention of receptor precursors in the ER and enhanced turnover of mature
receptors at the cell surface (Leskela et al., 2009). Similarly, study III demonstrated that the
OR-Cys27 variant underwent less efficient maturation compared to OR-Phe27 in human
SH-SY5Y-APP751 neuroblastoma cells. This indicated that the receptor maturation
phenotypes are similar in neuronal and non-neuronal cells. Furthermore, a robust
accumulation of APP C83 and AICD was observed, but not of APP C99, in both SH-SY5Y
and HEK293 cells expressing OR-Cys27. Total APP levels remained unchanged in these
cells. These effects were not evident in cells expressing OR-Phe27. The similar results
71
obtained in the cells expressing exogenous or endogenous APP confirmed that the observed
changes in APP processing were not caused by APP over-expression per se. Furthermore,
sAPP levels were not altered, while total sAPP and A40 levels were significantly
decreased in OR-Cys27-expressing cells. These data suggest that cellular events affecting
APP processing, such as the altered trafficking of newly synthesized APP in the secretory
pathway, do not cause the observed changes in OR-Cys27-expressing cells. No signs of
enhanced - or -secretase activity were detected, which excludes the possibility that C83
accumulation would have been caused by increased secretase-mediated cleavage of APP.
Confocal microscopy results suggested that in OR-Cys27-expressing cells, the endocytic
trafficking of APP CTFs to LEL was reduced. This led to the accumulation of APP CTFs due
to its inefficient degradation, as indicated by the strongly increased levels of C83 detected
in the Western blots. Moreover, the OR-Cys27 variant expression resulted in similar
alterations in APP processing to those previously observed under pH-neutralizing
conditions (Waldron et al., 2008), where C83 accumulated at the cost of C99 without any
increase in total APP levels or -secretase activity. Consistent with this finding, it was
recently shown that C99 was processed by -secretase (ADAM10) to C83 (Kuhn et al., 2010).
Furthermore, it has also been reported that alkalizing drugs, such as bafilomycin A1, could
induce the accumulation of APP C83 and AICD in luminal MVB vesicles (Vingtdeux et al.,
2007). MVBs are transport intermediates between early and late endosomes involved in
receptor recycling and protein degradation processes (Gruenberg and Stenmark, 2004).
They are also suggested to play a role in AD pathogenesis (Takahashi et al., 2002) as well as
in a transgenic mouse model of amyloidosis (Langui et al., 2004). These similarities between
the alkalization and OR-Cys27 variant phenotypes in terms of altered APP processing
point to the involvement of overlapping molecular mechanisms, which are related to
changes in the endocytic trafficking pathway.
When investigating the difference in constitutive downstream signaling between the OR
variants, it was found that c-Src and possibly PKC activity may regulate the molecular
events underlying the altered endocytic trafficking of APP CTFs in cells expressing the
OR-Cys27 variant. Thus, it could be proposed that the altered APP processing caused by
OR-Cys27 expression is different from the classical non-amyloidogenic APP processing
and that it is related to constitutive OR internalization and altered endocytic trafficking.
The fact that the OR-Cys27 variant robustly affected the endocytic trafficking of APP
prompted us an investigation into the genetic variants of OPRD1 in an unbiased manner in
two independent AD cohorts. Interestingly, this data suggest that the rs1042114 variation
may play a role in AD as the meta-analysis of combined case-control and familial data
pointed to a statistically significant risk effect for TG heterozygotes. The T	G allele change
at the rs1042114 site leads to a phenylalanine-to-cysteine substitution in the N-terminal
domain of OR. It is therefore possible that this variation itself rather than some other
proximal genetic alteration, which is in LD with rs1042114, may have functional relevance
in AD.
The present results have significant relevance in the context of AD pathogenesis, as the
intervention approaches focusing on the formation and trafficking of the GPCR/- and
-secretase complexes have been suggested as a novel strategy against AD (Ni et al., 2006;
Teng et al., 2010). Since ~25% of AD patients are heterozygous for the OR-Phe27Cys
variation, it is possible that these patients could well respond to OR antagonist treatments
differently from the OR-Phe27 homozygotes. These facts emphasize the importance of
determining the genetic background of the patients with respect to their OR-Phe27Cys
genotype. Moreover, little is known what is the functional role of OR heteromers
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composed of the two different OR variants in receptor signaling and other events, such as
APP processing in vitro and in vivo. Taken together, these results underscore the importance
of taking into account the genetic profile of the OR-Phe27Cys SNP when developing
potential OR-related therapeutic strategies against AD.
6.4 BEPRIDIL DECREASES A AND CALCIUM LEVELS IN THE THALAMUS
AFTER MIDDLE CEREBRAL ARTERY OCCLUSION IN RATS: STUDY IV
It has previously been shown that APP and A or their fragments are present and
aggregate in the dense plaque-like deposits and that altered APP processing and expression
of A-degrading enzymes take place in the ipsilateral thalamus of rats subjected to
transient MCAO (van Groen et al., 2005; Hiltunen et al., 2009). These alterations coincided
with significantly augmented calcium levels, depletion of GGA3 protein, and increased
BACE activity in the ipsilateral thalamus. Based on these findings, it could be postulated
that the observed alterations related to A accumulation were linked to disrupted calcium
homeostasis, which initiated secondary degeneration in the thalamus known to take place
after MCAO (Iizuka et al., 1990; Ross and Ebner, 1990; Wei et al., 2004). Considering the
intimate link between calcium and A in AD pathology (Supnet and Bezprozvanny, 2010;
Demuro et al., 2010), drugs, which modulate both calcium and A dyshomeostasis, are
potentially interesting therapeutic candidates. One such drug candidate is bepridil, a non-
selective calcium channel blocker (Flaim et al., 1985; Yatani et al., 1986; Van Amsterdam et
al., 1989), which has been used as an anti-anginal drug (Hollingshead et al., 1992). Bepridil
was recently shown to also inhibit BACE-mediated cleavage of APP both in vitro and in vivo
by increasing the membrane-proximal, endosomal pH (Mitterreiter et al., 2010).
Interestingly, bepridil also modulated -secretase function of APP independently of
endosomal alkalization (Mitterreiter et al., 2010). Thus, it is possible that bepridil can
modulate both calcium and A pathology in the thalamus of MCAO rats.
It was found that chronic treatment of MCAO rats with bepridil significantly decreased
both soluble A40 and A42 levels as well as insoluble A42 levels in the ipsilateral
thalamus without affecting the A42/40 ratio. This ratio was significantly higher in the
ipsilateral than in the contralateral thalamus of MCAO rats, confirming the previous
findings that MCAO robustly increased A production. Furthermore, bepridil treatment
significantly decreased the calcium levels and this decline strongly correlated with the
reduction in A42 and A40 levels in the ipsilateral thalamus. As shown previously after
MCAO (Hiltunen et al., 2009), it was observed that a significant increase in APP CTF
production could be found in vehicle-treated MCAO rats in the ipsilateral thalamus. In
contrast, bepridil-treated MCAO rats did not exhibit any statistically significant changes in
APP CTF levels. Consistent with the increased APP CTF production, sAPPtot levels
measured from the soluble protein fraction were also significantly increased in the vehicle-
treated MCAO rats. An increase in sAPPtot levels was also observed in the ipsilateral
thalamus of bepridil-treated rats, but this increase was ~30% less extensive.  BACE1 activity
was increased ~2.0-fold in the ipsilateral thalamus following MCAO, consistent with
previous findings (Hiltunen et al., 2009). However, this change was not affected by bepridil
treatment and BACE1 activity remained elevated. There were no statistically significant
changes in - or -secretase activities in either vehicle- or bepridil-treated MCAO rats.
However, it should be noted that the in vitro activity assays were performed using a
procedure in which tissue homogenates were incubated at +37°C together with secretase-
specific substrate peptides. Given the fact that BACE activity in HEK293-AP-APP cell
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lysates was not blocked by bepridil according to a previous in vitro activity assay
(Mitterreiter et al., 2010) it may be impossible to detect bepridil-mediated changes in BACE
activity in tissue homogenates. Taken together, these data suggest that bepridil treatment
could affect APP processing in the ipsilateral thalamus of MCAO rats, which may have
been the mechanism mediating the reduction in A levels. However, since calcium levels
were simultaneously decreased, it is difficult to dissect whether the changes in calcium
homeostasis contributed to the production of A or whether the BACE cleavage of APP
was directly inhibited by bepridil. Alternatively, it is also possible that these two
independent mechanisms were both modulating the levels of A.
In addition to the alterations in APP processing and A production, it is possible that
changes in A degradation or clearance also contributed to the present data. To address this
question, the expression levels of IDE and NEP were determined; these are the
enzymes/proteases intimately involved in A degradation in the brain (Miners et al., 2008).
It was found that IDE protein levels were increased in ipsilateral thalamus of both vehicle-
and bepridil-treated MCAO rats, while no alterations were observed in the levels of NEP.
The effect of MCAO on IDE levels in the ipsilateral thalamus is in line with a previous
study (Hiltunen et al. 2009). In addition, there were no significant changes in the expression
of LRP, which is a key component in the receptor-mediated clearance of A (Tanzi et al.,
2004), in vehicle- or bepridil-treated MCAO rats. These results suggest that bepridil
treatment does not affect the expression of well-known regulators involved in the
degradation and clearance of A in the ipsilateral thalamus of MCAO rats. However,
owing to the fact that there are several other enzymes or proteases within the brain that are
capable of degrading or clearing A (Miners et al., 2008), one cannot rule out the possibility
that some of these components may have been affected by bepridil treatment after MCAO.
It is well-established that astrogliosis and proinflammatory cytokine expression are
induced in cerebral ischemia (Fan et al., 1996; van Groen et al., 2005; Sriram et al., 2006) and
that MCAO promotes secondary degeneration in the thalamus (Iizuka et al., 1990; Ross and
Ebner, 1990; Wei et al., 2004, van Groen et al., 2005). Here, an increase in GFAP and TNF
expression levels ware also detected in the ipsilateral thalamus of both vehicle- and
bepridil-treated MCAO rats, indicating that bepridil did not mitigate the astrogliosis or the
inflammatory response occurring after MCAO. The reduced seladin-1 mRNA levels are
believed to be linked to neurodegeneration in AD (Greeve et al., 2000; Iivonen et al., 2002).
Interestingly here seladin-1 mRNA levels were significantly reduced in the ipsilateral
thalamus of vehicle-treated MCAO rats, but not in the bepridil-treated MCAO rats.
Furthermore, correlation analysis revealed that there was a significant inverse correlation
between seladin-1 mRNA and calcium levels as well as seladin-1 mRNA and insoluble
42 levels. This suggests that seladin-1 mRNA expression is down-regulated in response
to calcium and A dysregulation in the ipsilateral thalamus of MCAO rats in a similar
manner to the affected brain regions in AD (Greeve et al., 2000; Iivonen et al., 2002).
Previous studies have revealed that the over-expression of seladin-1 could protect neuronal
cells from A-induced toxicity in vitro (Greeve et al., 2000; Kuehnle et al., 2008). Study II
noted that the down-regulation of seladin-1 sensitized neuronal cells to apoptosis. On the
basis of these data, these results suggest that increased seladin-1 mRNA expression in the
ipsilateral thalamus of bepridil-treated MCAO rats could be a reflection of imncreased
neuronal survival. This in turn could be linked with the improved functional recovery in
the bepridil-treated MCAO rats.
It is evident that there is a reciprocal interaction between calcium homeostasis and A
pathology (Supnet and Bezprozvanny, 2010; Demuro et al., 2010). A plaques have been
shown to impair calcium homeostasis in mouse models of AD (Kuchibhotla et al., 2008). On
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the other hand, KCl-mediated depolarization induced a sustained increase in cytosolic
calcium levels in neuronal cultures, which triggered intraneuronal A1-42 production and
neuronal death (Pierrot et al., 2004). Furthermore, soluble A oligomers interact with critical
lipids and receptors at the plasma membrane. Thus, it has been suggested that the
increased calcium influx could be an outcome of disrupted membrane lipid integrity,
-mediated pore formation, or modulation of receptor-gated ion channels, such as NMDA
and AMPA receptors (Demuro et al., 2010). In addition, it was recently shown that APP
could regulate intracellular trafficking of voltage-gated L-type calcium channel Cav1.2 by
retrieving the channel into intracellular compartments away from the plasma membrane
(Yang et al., 2009). This means that alterations in APP expression or its processing can affect
the levels of Cav1.2 at the plasma membrane and thus modulate calcium influx. Bepridil
treatment also affected the mRNA expression of -1C subunit of Cav1.2 in a canine model
of atrial tachycardia (Inoue et al., 2006). Here it was found that the mRNA levels of -1C
subunit were reduced in the ipsilateral thalamus of vehicle-treated MCAO and that bepridil
treatment of MCAO rats did not affect these levels in the thalamus. This finding indicates
that there may be a feedback mechanism that down-regulates Cav1.2 expression when
calcium homeostasis is impaired in the thalamus. It is also possible that bepridil does not
exert its effects through the inhibition of voltage-gated calcium channels but instead via
inhibition of sodium-calcium exchangers (Stys and Lopachin, 1998). This concept is
supported by the findings in anoxic myelinated CNS axons, in which the influx of calcium
was blocked by bepridil but not by specific inhibitors of L-type calcium channels,
suggesting that the calcium entry occurring during CNS anoxia takes place primarily
through reverse operation of sodium-calcium exchange (Stys and Lopachin, 1998).
Reduction of A and calcium levels by bepridil also appeared to affect behavioral recovery
in MCAO rats. Improved limb-placing scores and particularly improved sensorimotor
performance in the cylinder tests in MCAO rats were observed on postoperative day 28.
These data are consistent with the organization and integration of sensory, motor, and
cognitive pathways within the thalamus (Briggs and Usrey, 2008). Furthermore, the data
agree with the pharmacological evidence showing that drugs that prevent or mitigate
secondary pathology in the thalamus can improve behavioral performance in a delayed
manner (Hiltunen and Jolkkonen, in press).
In conclusion, this data highlight the close interplay between calcium and A pathology.
These findings emphasize the importance of therapeutic approaches targeted at preventing
calcium dyshomeostasis in diseases, such as AD. In this context, bepridil is a feasible
candidate worth further testing due to its multifunctional effects on both calcium- and
BACE1-related events.
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7 Methodological considerations related to studies I-IV
Study I: In this study, candidate genes were selected on the basis of the meta-analyses
performed in the AlzGene database. Altogether, 21 major risk gene polymorphisms, which
were not previously analyzed among the Finnish population, were selected for genotyping.
The AlzGene database assembles previously published risk gene polymorphism findings in
AD, which means that these genetic alterations have been already studied in at least one
ethnic sample cohort. Therefore, p-values obtained from different analyses in study I were
not corrected for multiple testing. This is a common procedure in the field of genetics
related to replication studies. In this context, however, it should be noted that
Bonferroni-corrected p-values were not statistically significant (p > 0.05) in study I.
Moreover, it is a well-established fact that sample size is a crucial determinant in genetic
association analyses, such as conducted in study I. Based on the previously conducted
power analyses with the case-control cohort used for study I, the population size was
shown to be large enough to detect a 1.5-fold risk effect with 80% probability. Conversely,
statistical power was lower among the CSF sample set owing to the smaller number of AD
patients. This may have thus affected the likelihood of detecting significant changes in the
biomarker levels. Collectively, the results obtained here with TNF and IL1B warrant further
genetic, epigenetic, and molecular studies in the context of AD.
Study II: This study concentrated on elucidating the molecular effects of seladin-1
down-regulation on pathways relevant for AD using cellular models. Commonly accepted
molecular, cellular, and biochemical approaches were used to assess the interplay between
seladin-1 and BACE1 in human SH-SY5Y neuroblastoma cells under apoptotic conditions.
In the individual experiments, different parameters, such as number of replicated samples,
condition of cells, transfection time, and transfection efficiency were carefully controlled in
each experiment to ensure reproducible and reliable results. As a proof of this,
GAPDH-normalized seladin-1 levels after siRNA transfections were similarly
down-regulated throughout the study. Importantly, the main findings e.g. related to the
effects of seladin-1 down-regulation on caspase-3 activity after the induction of apoptosis
were studied using two different biochemical assays (substrate-based activity- and Western
blot assays). The results from these two independent assays provided a similar outcome in
terms of caspase-3 activity. All the studied protein levels and A values were normalized to
the housekeeping protein (GAPDH) or total protein levels, respectively.
Study III: All the experiments conducted in cellular models, such as transfection time and
efficiency were carefully controlled in a similar way as in study II. The results obtained
with OR variants were studied in two different cell lines (HEK293 and SH-SY5Y), which
expressed either exogenous or endogenous APP. Results from the different cell lines in
terms of alter APP processing were similar, indicating that the observed key outcome
measures were reproducible and that they were not dependent on the expression status of
APP (over-expression vs. endogenous APP). In addition, over-expression and/or
maturation status of OR-Cys27 and OR-Phe27 variants were carefully assessed in the
biochemical and histological experiments. In the genetic part of the study, power analyses
with the case-control cohort revealed that the population size was large enough to detect a
1.5-fold risk effect with 80% probability (see also study I). Since only significance was
observed with the OR-Cys27 variant among the Finnish case-control cohort (p = 0.07), an
independent familial AD sample set from USA was used as a replication cohort to assess
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the risk effect of OR-Cys27 variant in a different ethnic population. Subsequently, meta-
analysis was performed using these two AD sample cohorts with regard to the OR-Cys27
risk effect. This is a commonly accepted protocol in genetic studies when possible risk gene
effects are being evaluated. Nevertheless, it should be pointed out that both of these sample
sets showed only a moderate risk effect and thus it is of the utmost importance to confirm
the observed findings in additional sample cohorts. The OPRD1 gene region has not shown
any significant association with AD in recent GWA studies after adjusting the p-values for
multiple comparisons
Study IV: Successful cerebral occlusion was controlled by performing behavioral tests in
MCAO rats. The number of MCAO rats was decreased by ~10% due to unsuccessful
operation or post-operational mortality. Commonly accepted molecular, cellular,
biochemical and functional approaches were applied to ensure reliable outcome measures.
In general, the sample size was sufficient for these analyzes (n = 5-7 animals/group).
However, it is evident that the preliminary results obtained in study IV should be
replicated in a larger sample set. Bepridil treatment at the 50 mg/kg/day dose was chosen
on the basis of previous studies conducted in bepridil-treated rodents. However, in the
subsequent experiments, it would be important to assess the outcome effects of different
doses of bepridil on the behavior and AD-related pathology as well as on the
bio-availability of the drug in the brain. Bepridil has been used as an anti-anginal drug in
humans, suggesting that it is a safe candidate for pre-clinical studies in animals. Related to
this, the weights of the rats were monitored during the entire treatment procedure to
ensure animal wellbeing. Although study IV concentrated on thalamic changes mimicking
some of the pathological changes seen in AD brain (accumulation of A and changes in
calcium), it should be recognized that there are also differences in terms of AD-related
pathogenic processes between AD and rat brain. It is also noteworthy that in the MCAO
model, the short term insult initiates rapid pathological changes, whereas AD is a slowly
progressing disease, in which the clinical symptoms are usually observed years after the
first pathological brain changes. Nevertheless, the MCAO rat model used in study IV is
already a well-established model to examine the molecular interplay between A and
calcium. Similar robust calcium changes are not typically detected in other animal models
of AD, which makes the MCAO rat model a good way to investigate the molecular
mechanisms underlying A and calcium pathology.
77
8 Summary and future perspectives
Several candidate gene-based association studies in various ethnic populations have
confirmed that common variants in different genes affect the risk of AD. These genetic
variations individually make only a minor contribution to AD risk, but in combination with
other genetic or environmental factors, they may have a significant impact on disease
pathogenesis over time. In complex diseases, such as in AD, the identification and
functional characterization of risk genes is an important task, because it may shed light on
the disease pathogenesis. Molecular studies related to these proteins and pathways enable
better understanding of the disease pathophysiology and may ultimately lead to the
identification of novel biomarkers and therapies. In AD, the molecular players behind the
formation of A-containing plaques and tau-containing tangles are fairly well known.
Therefore, the initial functional assessments of the candidate genes are often targeted to the
key pathological events, such as altered A production, secretases (e.g. BACE) or A
degrading enzymes, such as IDE, NEP, and LRP. This thesis focused on the functional
characterization of seladin-1; its down-regulation has been linked to neuronal degeneration
in AD. Another focus was on OR, which has been proposed to contribute to AD
pathogenesis by affecting A generation upon agonist stimulation. More specifically, this
thesis aimed to elucidate the effects of these factors on APP processing and intracellular
trafficking as well as on A and calcium pathology in various conditions, such as during
apoptosis, disrupted calcium homeostasis, and astrogliosis and inflammation in different in
vitro and in vivo models.
The results obtained in this thesis support the concept that alterations in the intracellular
trafficking of APP and BACE1 play an important role in AD pathogenesis. In addition,
seladin-1 acts as a neuroprotective factor, as demonstrated in different in vivo and in vitro
models as well as in AD brain. Genetic studies have provided further support for these
findings. One of the most important findings in this thesis was that seladin-1
down-regulation was closely connected to the increase in BACE1 levels and activity
especially under stress conditions, such as apoptosis (study II). It appears that the decrease
in seladin-1 levels could be an early indicator of neurodegeneration before the signs of
deleterious A accumulation are detectable. This hypothesis is supported by the findings in
the MCAO rat model, where increased seladin-1 mRNA levels correlated with decreased
insoluble A and calcium levels after bepridil treatment, suggesting that increased
seladin-1 expression could be an indication of improved neuronal survival (study IV). In
this study, MCAO was used to introduce secondary degeneration in the thalamus. A
similar kind of disruptive degeneration takes place in the brain after stroke and in many
neurodegenerative diseases, such AD. The general hallmarks of neurodegeneration include
astrogliosis (increased GFAP levels), enhanced A degradation (increased IDE levels), and
increased proinflammatory cytokine expression (increased TNF). TNF and IL1B genes
were also found to genetically affect the AD risk in the genetic screening of AlzGene based
risk genes in the Eastern Finnish population (study I). Similarly, a genetic association of
OPRD1 with AD was observed in study III, where the molecular and genetic aspects of the
OR-Cys27Phe variant were elucidated in cells expressing different OR variants. Study III
suggests that those AD patients carrying the heterozygous OR-Cys27Phe genotype may
respond differently to the OR antagonist treatment as compared to individuals, who are
homozygous for OR-Phe27 variant. These possibilities emphasize the importance of
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determining the genetic background of the OR-Phe27Cys variation on a case-by-case basis
in order to provide AD patients with the best possible treatment when evaluating potential
OR-related pharmacological approaches.
As genetic research gradually enters the post-genomic era, future research will focus on
epigenetic regulation of risk genes. Examples of such epigenetic modifications are DNA
methylation or histone acetylation, two processes which regulate gene expression. These
modifications are anticipated to play a central role also in AD pathogenesis and thus a
detailed epigenetic assessment of genetically identified risk genes is important in the
future. The AD-related genes and pathways studied in this thesis may also prove to be
potential molecular targets e.g. as novel biomarkers for risk assessment, early diagnosis,
and monitoring disease progression. Furthermore, the results obtained in this thesis may be
applicable for the development of novel intervention approaches to interrupt the
progression of AD. Finally, the genetic results emphasize the importance of mapping the
genetic profile of a person when introducing new potential pharmacological approaches in
the therapeutics of AD.
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Alzheimer’s disease (AD) is a complex 
disorder with a clear genetic back-
ground. Causative mutations explain 
less than 1% of all AD cases; the vast 
majority of cases are genetically het-
erogeneous. Several risk genes are 
known but their underlying biological 
mechanisms in AD pathogenesis re-
main generally unspecified. This thesis 
aims at exploring the molecular mech-
anisms of seladin-1 and δ-opioid recep-
tor that have been postulated to geneti-
cally and/or functionally play a role 
in AD. Genes and pathways studied in 
this thesis may prove to be potential 
targets as novel biomarkers in early 
diagnosis, and the results obtained may 
be applied for the development of novel 
therapeutic approaches in AD.
 
